

# Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

Andrew Rhodes, MB BS, MD(Res) (Co-chair)<sup>1</sup>; Laura E. Evans, MD, MSc, FCCM (Co-chair)<sup>2</sup>; Waleed Alhazzani, MD, MSc, FRCPC (methodology chair)<sup>3</sup>; Mitchell M. Levy, MD, MCCM<sup>4</sup>; Massimo Antonelli, MD<sup>5</sup>; Ricard Ferrer, MD, PhD<sup>6</sup>; Anand Kumar, MD, FCCM<sup>7</sup>; Jonathan E. Sevransky, MD, FCCM<sup>8</sup>; Charles L. Sprung, MD, JD, MCCM<sup>9</sup>; Mark E. Nunnally, MD, FCCM<sup>2</sup>; Bram Rochweg, MD, MSc (Epi)<sup>3</sup>; Gordon D. Rubenfeld, MD (conflict of interest chair)<sup>10</sup>; Derek C. Angus, MD, MPH, MCCM<sup>11</sup>; Djillali Annane, MD<sup>12</sup>; Richard J. Beale, MD, MB BS<sup>13</sup>; Geoffrey J. Bellinghan, MRCP<sup>14</sup>; Gordon R. Bernard, MD<sup>15</sup>; Jean-Daniel Chiche, MD<sup>16</sup>; Craig Coopersmith, MD, FACS, FCCM<sup>8</sup>; Daniel P. De Backer, MD, PhD<sup>17</sup>; Craig J. French, MB BS<sup>18</sup>; Seitaro Fujishima, MD<sup>19</sup>; Herwig Gerlach, MBA, MD, PhD<sup>20</sup>; Jorge Luis Hidalgo, MD, MACP, MCCM<sup>21</sup>; Steven M. Hollenberg, MD, FCCM<sup>22</sup>; Alan E. Jones, MD<sup>23</sup>; Dilip R. Karnad, MD, FACP<sup>24</sup>; Ruth M. Kleinpell, PhD, RN-CS, FCCM<sup>25</sup>; Younsuk Koh, MD, PhD, FCCM<sup>26</sup>; Thiago Costa Lisboa, MD<sup>27</sup>; Flavia R. Machado, MD, PhD<sup>28</sup>; John J. Marini, MD<sup>29</sup>; John C. Marshall, MD, FRCSC<sup>30</sup>; John E. Mazuski, MD, PhD, FCCM<sup>31</sup>; Lauralyn A. McIntyre, MD, MSc, FRCPC<sup>32</sup>; Anthony S. McLean, MB ChB, MD, FRACP, FJFICM<sup>33</sup>; Sangeeta Mehta, MD<sup>34</sup>; Rui P. Moreno, MD, PhD<sup>35</sup>; John Myburgh, MB ChB, MD, PhD, FANZCA, FCICM, FAICD<sup>36</sup>; Paolo Navalesi, MD<sup>37</sup>; Osamu Nishida, MD, PhD<sup>38</sup>; Tiffany M. Osborn, MD, MPH, FCCM<sup>31</sup>; Anders Perner, MD<sup>39</sup>; Colleen M. Plunkett<sup>25</sup>; Marco Ranieri, MD<sup>40</sup>; Christa A. Schorr, MSN, RN, FCCM<sup>22</sup>; Maureen A. Seckel, CCRN, CNS, MSN, FCCM<sup>41</sup>; Christopher W. Seymour, MD<sup>42</sup>; Lisa Shieh, MD, PhD<sup>43</sup>; Khalid A. Shukri, MD<sup>44</sup>; Steven Q. Simpson, MD<sup>45</sup>; Mervyn Singer, MD<sup>46</sup>; B. Taylor Thompson, MD<sup>47</sup>; Sean R. Townsend, MD<sup>48</sup>; Thomas Van der Poll, MD<sup>49</sup>; Jean-Louis Vincent, MD, PhD, FCCM<sup>50</sup>; W. Joost Wiersinga, MD, PhD<sup>51</sup>; Janice L. Zimmerman, MD, MACP, MCCM<sup>52</sup>; R. Phillip Dellinger, MD, MCCM<sup>22</sup>

<sup>1</sup>St. George's Hospital London, England, United Kingdom.

<sup>2</sup>New York University School of Medicine New York, NY.

<sup>3</sup>McMaster University Hamilton, Ontario, Canada.

<sup>4</sup>Brown University School of Medicine Providence, RI.

<sup>5</sup>Instituto di Anestesiologia e Rianimazione, Università Cattolica del Sacro Cuore, Rome, Italy.

<sup>6</sup>Vall d'Hebron University Hospital Barcelona, Spain.

<sup>7</sup>University of Manitoba Winnipeg, Manitoba, Canada.

<sup>8</sup>Emory University Hospital Atlanta, GA.

Copyright © 2017 by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine

DOI: 10.1097/CCM.0000000000002255

<sup>9</sup>Hadassah Hebrew University Medical Center Jerusalem, Israel.

<sup>10</sup>Sunnybrook Health Sciences Centre Toronto, Ontario, Canada.

<sup>11</sup>University of Pittsburgh Critical Care Medicine CRISMA Laboratory Pittsburgh, PA.

<sup>12</sup>Hospital Raymond Poincare Garches, France.

<sup>13</sup>Saint Thomas Hospital London, England, United Kingdom.

<sup>14</sup>University College London Hospitals London, England, United Kingdom.

<sup>15</sup>Vanderbilt University Medical Center Nashville, TN.

<sup>16</sup>Service de Reanimation Medicale Paris, France.

<sup>17</sup>CHIREC Hospitals Braine L'Alleud, Belgium.

<sup>18</sup>Western Hospital Victoria, Australia.

<sup>19</sup>Keio University School of Medicine, Tokyo, Japan.

- <sup>20</sup>Vivantes-Klinikum Neukölln, Berlin, Germany.
- <sup>21</sup>Karl Heusner Memorial Hospital Belize Healthcare Partners Belize City, Belize.
- <sup>22</sup>Cooper Health System Camden, NJ.
- <sup>23</sup>University of Mississippi Medical Center Jackson, MS.
- <sup>24</sup>Jupiter Hospital Thane, India.
- <sup>25</sup>Rush University Medical Center Chicago, IL.
- <sup>26</sup>ASAN Medical Center University of Ulsan College of Medicine Seoul, South Korea.
- <sup>27</sup>Hospital de Clinicas de Porto Alegre Porto Alegre, Brazil.
- <sup>28</sup>Federal University of Sao Paulo Sao Paulo, Brazil.
- <sup>29</sup>Regions Hospital St. Paul, MN.
- <sup>30</sup>Saint Michael's Hospital Toronto, Ontario, Canada.
- <sup>31</sup>Washington University School of Medicine St. Louis, MO.
- <sup>32</sup>Ottawa Hospital Ottawa, Ontario, Canada.
- <sup>33</sup>Nepean Hospital, University of Sydney Penrith, New South Wales, Australia.
- <sup>34</sup>Mount Sinai Hospital Toronto, Ontario, Canada.
- <sup>35</sup>UCINC, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.
- <sup>36</sup>University of New South Wales, Sydney, New South Wales, Australia.
- <sup>37</sup>Università della Magna Graecia Catanzaro, Italy.
- <sup>38</sup>Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
- <sup>39</sup>Rigshospitalet Copenhagen, Denmark.
- <sup>40</sup>Università Sapienza, Rome, Italy.
- <sup>41</sup>Christiana Care Health Services Newark, DE.
- <sup>42</sup>University of Pittsburgh School of Medicine Pittsburgh, PA.
- <sup>43</sup>Stanford University School of Medicine Stanford, CA.
- <sup>44</sup>Kaust Medical Services Thuwal, Saudi Arabia.
- <sup>45</sup>University of Kansas Medical Center Kansas City, KS.
- <sup>46</sup>Wolfson Institute of Biomedical Research London, England, United Kingdom.
- <sup>47</sup>Massachusetts General Hospital Boston, MA.
- <sup>48</sup>California Pacific Medical Center San Francisco, CA.
- <sup>49</sup>University of Amsterdam Amsterdam, Netherlands.
- <sup>50</sup>Erasmé University Hospital Brussels, Belgium.
- <sup>51</sup>University of Amsterdam, Amsterdam, Netherlands.
- <sup>52</sup>Houston Methodist Hospital, Houston, TX.

**Corresponding author:** Andrew Rhodes, St. George's Hospital, London, United Kingdom. Email: andrewrhodes@nhs.net

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this on the journal's Web site

This article is being simultaneously published in *Critical Care Medicine* and *Intensive Care Medicine*.

The following sponsoring organizations (with formal liaison appointees) endorse this guideline: American College of Chest Physicians, American College of Emergency Physicians, American Thoracic Society, Asia Pacific Association of Critical Care Medicine, Associação de Medicina Intensiva Brasileira, Australian and New Zealand Intensive Care Society, Consorcio Centroamericano y del Caribe de Terapia Intensiva, European Society of Clinical Microbiology and Infectious Diseases, German Sepsis Society, Indian Society of Critical Care Medicine, International Pan Arab Critical Care Medicine Society, Japanese Association for Acute Medicine, Japanese Society of Intensive Care Medicine, Latin American Sepsis Institute, Scandinavian Critical Care Trials Group, Society for Academic Emergency Medicine, Society of Hospital Medicine, Surgical Infection Society, World Federation of Critical Care Nurses, World Federation of Societies of Intensive and Critical Care Medicine.

The following non-sponsoring organizations (without formal liaison appointees) endorse this guideline: Academy of Medical Royal Colleges, Chinese Society of Critical Care Medicine, Asociación Colombiana de Medicina Crítica y Cuidado Intensivo, Emirates Intensive Care Society, European

Society of Paediatric and Neonatal Intensive Care, European Society for Emergency Medicine, Federación Panamericana e Ibérica de Medicina Crítica y Terapia Intensiva, Sociedad Peruana de Medicina Intensiva, Shock Society, Sociedad Argentina de Terapia Intensiva, World Federation of Pediatric Intensive and Critical Care Societies.

Dr. Rhodes is a past-president of the European Society of Intensive Care Medicine. Dr. Levy received consulting fees from ImmuneExpress. Dr. Antonelli received funding from Pfizer, MSD, Cubist, Maquet, Dräger, Toray, and Baxter; he participates in ESA and SIAARTI. Dr. Kumar received scientific consulting fees from Baxter, Isomark, and Opsonix on diagnostic technologies; he received grant funding from GSK in the area of influenza. Dr. Ferrer Roca received funding from Estor, MSD, Astra-Zeneca, and Grifols and participates in ESICM and SEMICYUC. Dr. Sevransky is an Associate Editor of *Critical Care Medicine*. Dr. Sprung received funding from Asahi Kasei Pharma America Corporation (consultant, Data Safety and Monitoring Committee) and LeukoDx Ltd. (consultant; PI, research study on biomarkers of sepsis). He participates in International Sepsis Forum (board member). Dr. Angus received funding Ferring Inc (consulting fees for serving on the Trial Steering Committee of a Phase 2/3 trial of selepressin for septic shock), and from Ibis and Genmark (both for consulting fees regarding diagnostic strategies in sepsis). He is a contributing editor for *JAMA*, has conducted committee membership work for the American Thoracic Society, and has contributed to an IOM workshop on regulatory science. Dr. Angus provided expert testimony in medical malpractice cases. Dr. Beale's institution received funding from Roche (consulting regarding sepsis diagnostics); he received funding from Quintiles (consulting on routes to license for a potential ARDS therapy); he participates in the UK National Institute for Clinical and Healthcare Excellence Sepsis Guideline Development Group; he has served as an expert witness, disclosing that he is approached from time to time regarding expert witness testimony for ICU cases, which may involve patients who have sepsis and the testimony relates to generally accepted current standards of care, and formal guidance, as it currently pertains within the UK. Dr. Bellingan received funding from Faron (research into interferon in lung injury) and Athersys (stem cells in lung injury). Dr. Chiche received funding for consulting activities and honoraria for lectures from GE Healthcare, monitoring and IT solutions; he received funding from Nestlé Healthsciences (consulting activities and honorarium), and from Abbott diagnostics (consulting activities). Dr. Coopersmith is on the fellowship committee of Surgical Infection Society. Dr. De Backer received funding from Edwards Healthcare, Fresenius Kabi, and Grifols. Dr. Dellinger provided expert testimony for alleged malpractice in critical care. Dr. French participates in Australian and New Zealand Intensive Care Society Clinical Trials Group (chair). Dr. Fujishima participates in the Japanese Association for Acute Medicine (board member, Japanese Guidelines for the management of sepsis) and Japanese Respiratory Society (board member, Japanese Guidelines for the management of ARDS); he received funding from Asahi Kasei Co (lecture). Dr. Hollenberg participates in the ACC/AHA PCI and Heart Failure guidelines, CHEST editorial board, ACCP-SEEK, and CHEST CV Network chair. Dr. Jones participates in ACEP and SAEM, and has served as an expert witness on various cases. Dr. Karnad received funding from Quintiles Cardiac Safety Services (consultant) and from Bharat Serum and Vaccines Ltd (consultant). He participates in the Indian Society of Critical Care Medicine and the Association of Physicians of India. Dr. Kleinpell participates in Critical Care Medicine American Board of Internal Medicine (board member), Institute of Medicine of Chicago (board member), and the Commission on Collegiate Nursing Education (board member). Dr. Koh participates in The Korean Society of Critical Care Medicine, The European Society of Intensive Care Medicine, and The Korean Society of Medical Ethics. Dr. Lisboa participates in ILAS, AMIB, and ESICM. Dr. Machado participates in the Latin America Sepsis Institution (CEO). Dr. Marshall received funding from Member Data Safety Monitoring Committee AKPA Pharma; he participates in International Forum for Acute Care Trialists (Chair) and World Federation of Societies of Intensive and Critical Care Medicine (Secretary-General). Dr. Mazuski received funding from Actavis (Allergan) (consultant), Astra-Zeneca (consultant), Bayer (consultant), and from Cubist (now part of Merck) (consultant); he received research grant funding from Astra-Zeneca, Bayer, and from Merck; and participates in Surgical Infection Society (President-elect and Chair of Task Force on Guidelines for the Management of Intra-abdominal Infection) and in the American College of Surgeons (speaker at Annual Congress, member of Trusted Medical Information Commission). Dr. Mehta participates in ATS activities. Dr. Moreno participates in the Portuguese and Brazilian Societies of Intensive Care Medicine. Dr. Myburgh's institution received unrestricted grant funding, logistical support and reimbursement from Fresenius Kabi for travel expenses to conduct a randomized controlled trial of fluid

resuscitation (CHEST study): 2008–2012: A\$7600000 (US\$ 5000000); an unrestricted grant for partial funding from Baxter Healthcare of an international observational study of patterns of fluid resuscitation (FLUID TRIPS study) in 2014: A\$70,000 (US\$ 50,000); honoraria and travel reimbursements from Baxter Healthcare for participation in Advisory Board meetings in Sydney (2013), Paris (2014) and China (2014); and an unrestricted grant for partial funding from CSL Bioplasma for an international observational study of patterns of fluid resuscitation (FLUID TRIPS study) in 2014: A\$10,000 (US\$ 7,500); he also participates as a council member in the World Federation of Societies of Intensive and Critical Care Medicine. Dr. Navalesi participates in the European Respiratory Society (Head of Assembly Respiratory Intensive Care), is a member of ESICM (European Society of Intensive Care Medicine) and ESA (European Society of Anaesthesiology), and is in the Scientific Committee of SIAARTI (the Italian Association of Anesthesia and Intensive Care). Dr. Nishida participates in The Japanese Society of Intensive Care Medicine (vice chairman of the executive boards), the Japanese Guidelines for the Management of Sepsis and Septic Shock 2016 (chairman), The Japanese Guidelines for Nutrition Support Therapy in the Adult and Pediatric Critically Ill Patients (board), The Japanese Guidelines for the Management of Acute Kidney Injury 2016 (board), The Expert Consensus of the Early Rehabilitation in Critical Care (board), The sepsis registry organization in Japan (member). Dr. Osborn received funding from Cheetah (speaker related to fluid resuscitation and use of NICOM); she participates in American College of Emergency Physicians (Representative to SCC), consultant for national database development, CDC sepsis task force, IHI consultant. Dr. Perner is the editor of ICM; his department received research funding from CSL Behring and Fresenius Kabi. Dr. Ranieri participates in ESICM. Dr. Seckel received funding from American Association of Critical-Care Nurses (AACN) (honorarium for speaker at 2016 annual conference; AACN Online Web based Essentials of Critical Care Orientation); she participates as a volunteer for AACN, and served as AACN liaison to the ATS/ESICM/SCCM CPG: Mechanical Ventilation in Adult Patients with ARDS. Dr. Shieh participates in Society of Hospital Medicine Faculty for Sepsis Workshop, SHM-SCCM Moore Foundation collaborative faculty. Dr. Shukri participates in the International Pan Arab Critical Care Society educational activities. Dr. Simpson participates in CHEST Regent at Large (board of directors), and is an ATS member. Dr. Singer received funding from Deltex Medical, Bayer, Biotest, and MSD; he participates in the UK Intensive Care Society research and Meeting committees; he has provided expert testimony, disclosing: I do medicolegal work (6 cases/year) as an independent expert, 80% on behalf of the defendant. Dr. Thompson received funding from serving on DSMBs trials sponsored by Ferring Pharmaceuticals, Farron Labs, and Roche Genentec; also received funding from Asahi Kasei Pharma America (consulting), UpToDate (wrote two chapters on pulmonary embolism diagnosis), and was a pro bono consultant for BioAegis; participates as a member of the American Thoracic Society committee to develop the ATS/ESICM/SCCM Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome. Dr. Vincent participates in World Federation of Societies of Intensive and Critical Care Societies (president) and Critical Care Foundation (president). Dr. Wiersinga is treasurer of both the ESCMID Study Group for Bloodstream Infections and Sepsis (ESGBIS) and the Dutch Working Party on Antibiotic Policy (SWAB), Academic Medical Center, University of Amsterdam (all non-profit). Dr. Zimmerman participates in ACCP, ACP, WFSICCM, and PAIF; she has provided expert testimony on loss of digits due to DIC, mesenteric ischemia. Dr. Nunnally participates in SOCCA (board), ASA (committee), NYSSA, IARS, and AUA. Dr. Rochweg participates as a methodologist for ATS, ESCIM, and Canadian Blood services. The remaining authors have disclosed that they do not have any potential conflicts of interest.

#### Governance of Surviving Sepsis Campaign Guidelines Committee

##### SSC Executive and Steering Committees

<http://www.survivingsepsis.org/About-SSC/Pages/Leadership.aspx>

##### SSC Guidelines Committee Oversight Group

Andrew Rhodes, Laura Evans, Mitchell M. Levy

##### SSC Guidelines Committee Group Heads

Massimo Antonelli (Hemodynamics), Ricard Ferrer (Adjunctive therapies), Anand Kumar (Infection), Jonathan E. Sevransky (Ventilation), Charles L. Sprung (Metabolic)

##### GRADE Methodology Group

Waleed Alhazzani (chair), Mark E. Nunnally, Bram Rochweg

For additional information regarding this article, email [andrewrhodes@nhs.net](mailto:andrewrhodes@nhs.net)

**Objective:** To provide an update to “Surviving Sepsis Campaign Guidelines for Management of Sepsis and Septic Shock: 2012.”

**Design:** A consensus committee of 55 international experts representing 25 international organizations was convened. Nominal groups were assembled at key international meetings (for those committee members attending the conference). A formal conflict-of-interest (COI) policy was developed at the onset of the process and enforced throughout. A stand-alone meeting was held for all panel members in December 2015. Teleconferences and electronic-based discussion among subgroups and among the entire committee served as an integral part of the development.

**Methods:** The panel consisted of five sections: hemodynamics, infection, adjunctive therapies, metabolic, and ventilation. Population, intervention, comparison, and outcomes (PICO) questions were reviewed and updated as needed, and evidence profiles were generated. Each subgroup generated a list of questions, searched for best available evidence, and then followed the principles of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system to assess the quality of evidence from high to very low, and to formulate recommendations as strong or weak, or best practice statement when applicable.

**Results:** The Surviving Sepsis Guideline panel provided 93 statements on early management and resuscitation of patients with sepsis or septic shock. Overall, 32 were strong recommendations, 39 were weak recommendations, and 18 were best-practice statements. No recommendation was provided for four questions.

**Conclusions:** Substantial agreement exists among a large cohort of international experts regarding many strong recommendations for the best care of patients with sepsis. Although a significant number of aspects of care have relatively weak support, evidence-based recommendations regarding the acute management of sepsis and septic shock are the foundation of improved outcomes for these critically ill patients with high mortality. (*Crit Care Med* 2017; 3:00–00)

**Key Words:** evidence-based medicine; Grading of Recommendations Assessment, Development, and Evaluation criteria; guidelines; infection; sepsis; sepsis bundles; sepsis syndrome; septic shock; Surviving Sepsis Campaign

## INTRODUCTION

Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection (1–3). Sepsis and septic shock are major healthcare problems, affecting millions of people around the world each year, and killing as many as one in four (and often more) (4–6). Similar to polytrauma, acute myocardial infarction, or stroke, early identification and appropriate management in the initial hours after sepsis develops improves outcomes.

The recommendations in this document are intended to provide guidance for the clinician caring for adult patients with sepsis or septic shock. Recommendations from these guidelines cannot replace the clinician’s decision-making capability when presented with a patient’s unique set of clinical variables. These guidelines are appropriate for the sepsis patient in a hospital setting. These guidelines are intended to be best practice

(the committee considers this a goal for clinical practice) and not created to represent standard of care.

## METHODOLOGY

Below is a summary of the important methodologic considerations for developing these guidelines.

### Definitions

As these guidelines were being developed, new definitions for sepsis and septic shock (Sepsis-3) were published. *Sepsis* is now defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. *Septic shock* is a subset of sepsis with circulatory and cellular/metabolic dysfunction associated with a higher risk of mortality (3). The Sepsis-3 definition also proposed clinical criteria to operationalize the new definitions; however, in the studies used to establish the evidence for these guidelines, patient populations were primarily characterized by the previous definition of sepsis, severe sepsis, and septic shock stated in the 1991 and 2001 consensus documents (7).

### History of the Guidelines

These clinical practice guidelines are a revision of the 2012 Surviving Sepsis Campaign (SSC) guidelines for the management of severe sepsis and septic shock (8, 9). The initial SSC guidelines were first published in 2004 (10), and revised in 2008 (11, 12) and 2012 (8, 9). The current iteration is based on updated literature searches incorporated into the evolving manuscript through July 2016. A summary of the 2016 guidelines appears in **Appendix 1**. A comparison of recommendations from 2012 to 2016 appears in **Appendix 2**. Unlike previous editions, the SSC pediatric guidelines will appear in a separate document, also to be published by the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM).

### Sponsorship

Funding for the development of these guidelines was provided by SCCM and ESICM. In addition, sponsoring organizations provided support for their members' involvement.

### Selection and Organization of Committee Members

The selection of committee members was based on expertise in specific aspects of sepsis. Co-chairs were appointed by the SCCM and ESICM governing bodies. Each sponsoring organization appointed a representative who had sepsis expertise. Additional committee members were appointed by the co-chairs and the SSC Guidelines Committee Oversight Group to balance continuity and provide new perspectives with the previous committees' membership as well as to address content needs. A patient representative was appointed by the co-chairs. Methodologic expertise was provided by the GRADE Methodology Group.

### Question Development

The scope of this guideline focused on early management of patients with sepsis or septic shock. The guideline panel was divided into five sections (hemodynamics, infection, adjunctive therapies, metabolic, and ventilation). The group designations

were the internal work structure of the guidelines committee. Topic selection was the responsibility of the co-chairs and group heads, with input from the guideline panel in each group. Prioritization of the topics was completed by discussion through e-mails, teleconferences, and face-to-face meetings. All guideline questions were structured in PICO format, which described the population, intervention, control, and outcomes.

Questions from the last version of the SSC guidelines were reviewed; those that were considered important and clinically relevant were retained. Questions that were considered less important or of low priority to clinicians were omitted, and new questions that were considered high priority were added. The decision regarding question inclusion was reached by discussion and consensus among the guideline panel leaders with input from panel members and the methodology team in each group.

GRADE methodology was applied in selecting only outcomes that were considered critical from a patient's perspective (13). All PICO questions with supporting evidence are presented in **Supplemental Digital Content 1** (<http://links.lww.com/CCM/C322>).

### Search Strategy

With the assistance of professional librarians, an independent literature search was performed for each defined question. The panel members worked with group heads, methodologists, and librarians to identify pertinent search terms that included, at a minimum, *sepsis*, *severe sepsis*, *septic shock*, *sepsis syndrome*, and *critical illness*, combined with appropriate key words specific to the question posed.

For questions addressed in the 2012 SSC guidelines, the search strategy was updated from the date of the last literature search. For each of the new questions, an electronic search was conducted of a minimum of two major databases (e.g., Cochrane Registry, MEDLINE, or EMBASE) to identify relevant systematic reviews and randomized clinical trials (RCTs).

### Grading of Recommendations

Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system principles guided assessment of quality of evidence from high to very low and were used to determine the strength of recommendations (**Tables 1 and 2**) (14). The GRADE methodology is based on assessment of evidence according to six categories: 1) risk of bias, 2) inconsistency, 3) indirectness, 4) imprecision, 5) publication bias, and 6) other criteria, followed by assessment of the balance between benefit and harm, patients' values and preferences, cost and resources, and feasibility and acceptability of the intervention. The final recommendations formulated by the guideline panel are based on the assessment of these factors. The GRADE assessment of the quality of evidence is presented in Table 1.

RCTs begin as high-quality evidence that could be downgraded due to limitations in any of the aforementioned categories. While observational (nonrandomized) studies begin as low-quality evidence, the quality level could be upgraded on the basis of a large magnitude of effect or other factors. The GRADE methodology classifies recommendations as strong

**TABLE 1. Determination of the Quality of Evidence**

<b>Underlying methodology</b>
1. High: RCTs
2. Moderate: Downgraded RCTs or upgraded observational studies
3. Low: Well-done observational studies with RCTs
4. Very Low: Downgraded controlled studies or expert opinion or other evidence
<b>Factors that may decrease the strength of evidence</b>
1. Methodologic features of available RCTs suggesting high likelihood of bias
2. Inconsistency of results, including problems with subgroup analyses
3. Indirectness of evidence (differing population, intervention, control, outcomes, comparison)
4. Imprecision of results
5. High likelihood of reporting bias
<b>Main factors that may increase the strength of evidence</b>
1. Large magnitude of effect (direct evidence, relative risk > 2 with no plausible confounders)
2. Very large magnitude of effect with relative risk > 5 and no threats to validity (by two levels)
3. Dose-response gradient

RCT = randomized clinical trial

or weak. The factors influencing this determination are presented in Table 2. The guideline committee assessed whether the desirable effects of adherence would outweigh the undesirable effects, and the strength of a recommendation reflects the group's degree of confidence in that balance assessment. Thus, a strong recommendation in favor of an intervention reflects the panel's opinion that the desirable effects of adherence to a

recommendation will clearly outweigh the undesirable effects. A weak recommendation in favor of an intervention indicates the judgment that the desirable effects of adherence to a recommendation probably will outweigh the undesirable effects, but the panel is not confident about these trade-offs—either because some of the evidence is low quality (and thus uncertainty remains regarding the benefits and risks) or the benefits and downsides are closely balanced. A strong recommendation is worded as “we recommend” and a weak recommendation as “we suggest.” An alphanumeric scheme was used in previous editions of the SSC guidelines. **Table 3** provides a comparison to the current grading system.

The implications of calling a recommendation strong are that most patients would accept that intervention and that most clinicians should use it in most situations. Circumstances may exist in which a strong recommendation cannot or should not be followed for an individual because of that patient's preferences or clinical characteristics that make the recommendation less applicable. These are described in **Table 4**. A strong recommendation does not imply standard of care.

A number of best practice statements (BPSs) appear throughout the document; these statements represent ungraded strong recommendations and are used under strict criteria. A BPS would be appropriate, for example, when the benefit or harm is unequivocal, but the evidence is hard to summarize or assess using GRADE methodology. The criteria suggested by the GRADE Working Group in **Table 5** were applied in issuing BPSs (15).

### Voting Process

Following formulation of statements through discussion in each group and deliberation among all panel members during face-to-face meetings at which the groups presented their draft statements, all panel members received links to polls created using SurveyMonkey, Inc. (Palo Alto, CA) to indicate agreement or disagreement with the statement, or abstention. Acceptance of a statement required votes from 75% of the panel members with an 80% agreement threshold. Voters could provide feedback for consideration in revising statements that did not receive consensus in up to three rounds of voting.

**TABLE 2. Factors Determining Strong vs. Weak Recommendation**

What Should Be Considered	Recommended Process
High or moderate evidence ( <i>Is there high- or moderate-quality evidence?</i> )	The higher the quality of evidence, the more likely a strong recommendation
Certainty about the balance of benefits vs. harms and burdens ( <i>Is there certainty?</i> )	The larger the difference between the desirable and undesirable consequences and the certainty around that difference, the more likely a strong recommendation. The smaller the net benefit and the lower the certainty for that benefit, the more likely a weak recommendation.
Certainty in, or similar, values ( <i>Is there certainty or similarity?</i> )	The more certainty or similarity in values and preferences, the more likely a strong recommendation.
Resource implications ( <i>Are resources worth expected benefits?</i> )	The lower the cost of an intervention compared to the alternative and other costs related to the decision (i.e., fewer resources consumed), the more likely a strong recommendation.

**TABLE 3. Comparison of 2016 Grading Terminology with Previous Alphanumeric Descriptors**

	2016 Descriptor	2012 Descriptor
Strength	Strong	1
	Weak	2
Quality	High	A
	Moderate	B
	Low	C
	Very Low	D
Ungraded strong recommendation	Best Practice Statement	Ungraded

**Conflict-of-Interest Policy**

No industry input into guidelines development occurred, and no industry representatives were present at any of the meetings. No member of the guidelines committee received honoraria for any role in the guidelines process.

The process relied solely on personal disclosure, and no attempt was made by the group to seek additional confirmation. The co-chairs, COI chair, and group heads adjudicated this to the best of their abilities.

On initial review, 31 financial COI disclosures and five non-financial disclosures were submitted by committee members; others reported no COI. Panelists could have both financial and nonfinancial COI. Declared COI disclosures from 11 members were determined by the COI subcommittee to be not relevant to the guidelines content process. Fifteen who were determined to have COI (financial and nonfinancial) were adjudicated by a management plan that required adherence to SSC COI policy limiting discussion or voting at any committee meetings during which content germane to their COI was discussed. Five were

judged as having conflicts that were managed through reassignment to another group as well as the described restrictions on voting on recommendations in areas of potential COI. One individual was asked to step down from the committee. All panelists with COI were required to work within their group with full disclosure when a topic for which they had relevant COI was discussed, and they were not allowed to serve as group head. At the time of final approval of the document, an update of the COI statement was required. No additional COI issues were reported that required further adjudication.

A summary of all statements determined by the guidelines panel appears in Appendix 1. All evidence summaries and evidence profiles that informed the recommendations and statements appear in **Supplemental Digital Content 2** (<http://links.lww.com/CCM/C323>). Links to specific tables and figures appear within the relevant text.

**A. INITIAL RESUSCITATION**

- 1. Sepsis and septic shock are medical emergencies, and we recommend that treatment and resuscitation begin immediately (BPS).**
- 2. We recommend that, in the resuscitation from sepsis-induced hypoperfusion, at least 30 mL/kg of IV crystalloid fluid be given within the first 3 hours (strong recommendation, low quality of evidence).**
- 3. We recommend that, following initial fluid resuscitation, additional fluids be guided by frequent reassessment of hemodynamic status (BPS).**

**Remarks:** Reassessment should include a thorough clinical examination and evaluation of available physiologic variables (heart rate, blood pressure, arterial oxygen saturation, respiratory rate, temperature, urine output, and others, as available) as well as other noninvasive or invasive monitoring, as available.

- 4. We recommend further hemodynamic assessment (such as assessing cardiac function) to determine the type of**

**TABLE 4. Implications of the Strength of Recommendation**

	Strong Recommendation	Weak Recommendation
<b>For patients</b>	Most individuals in this situation would want the recommended course of action, and only a small proportion would not.	The majority of individuals in this situation would want the suggested course of action, but many would not.
<b>For clinicians</b>	Most individuals should receive the recommended course of action. Adherence to this recommendation according to the guideline could be used as a quality criterion or performance indicator. Formal decision aids are not likely to be needed to help individuals make decisions consistent with their values and preferences.	Different choices are likely to be appropriate for different patients, and therapy should be tailored to the individual patient's circumstances. These circumstances may include the patient's or family's values and preferences.
<b>For policy makers</b>	The recommendation can be adapted as policy in most situations, including for use as performance indicators.	Policy-making will require substantial debates and involvement of many stakeholders. Policies are also more likely to vary between regions. Performance indicators would have to focus on the fact that adequate deliberation about the management options has taken place.

**TABLE 5. Criteria for Best Practice Statements**

Criteria for Best Practice Statements	
1	Is the statement clear and actionable?
2	Is the message necessary?
3	Is the net benefit (or harm) unequivocal?
4	Is the evidence difficult to collect and summarize?
5	Is the rationale explicit?
6	Is this better to be formally GRADEd?

GRADE = Grading of Recommendations Assessment, Development, and Evaluation

Modified from Guyatt et al (15).

**shock if the clinical examination does not lead to a clear diagnosis (BPS).**

5. **We suggest that dynamic over static variables be used to predict fluid responsiveness, where available (weak recommendation, low quality of evidence).**
6. **We recommend an initial target mean arterial pressure (MAP) of 65 mm Hg in patients with septic shock requiring vasopressors (strong recommendation, moderate quality of evidence).**
7. **We suggest guiding resuscitation to normalize lactate in patients with elevated lactate levels as a marker of tissue hypoperfusion (weak recommendation, low quality of evidence).**

**Rationale.** Early effective fluid resuscitation is crucial for stabilization of sepsis-induced tissue hypoperfusion or septic shock. Sepsis-induced hypoperfusion may be manifested by acute organ dysfunction and/or  $\pm$  decreased blood pressure and increased serum lactate. Previous iterations of these guidelines have recommended a protocolized quantitative resuscitation, otherwise known as early goal-directed therapy (EGDT), which was based on the protocol published by Rivers (16). This recommendation described the use of a series of “goals” that included central venous pressure (CVP) and central venous oxygen saturation ( $ScvO_2$ ). This approach has now been challenged following the failure to show a mortality reduction in three subsequent large multicenter RCTs (17–19). No harm was associated with the interventional strategies; thus, the use of the previous targets is still safe and may be considered. Of note, the more recent trials included less severely ill patients (lower baseline lactate levels,  $ScvO_2$  at or above the target value on admission, and lower mortality in the control group). Although this protocol cannot now be recommended from its evidence base, bedside clinicians still need guidance as to how to approach this group of patients who have significant mortality and morbidity. We recommend, therefore, that these patients be viewed as having a medical emergency that necessitates urgent assessment and treatment. As part of this, we recommend that initial fluid resuscitation begin with 30 mL/kg of crystalloid within the first 3 hours. This fixed volume of fluid enables clinicians to initiate resuscitation while obtaining more specific information about

the patient and while awaiting more precise measurements of hemodynamic status. Although little literature includes controlled data to support this volume of fluid, recent interventional studies have described this as usual practice in the early stages of resuscitation, and observational evidence supports the practice (20, 21). The average volume of fluid pre-randomization given in the PROCESS and ARISE trials was approximately 30 mL/kg, and approximately 2 liters in the PROMISE trial (17–19). Many patients will require more fluid than this, and for this group we advocate that further fluid be given in accordance with functional hemodynamic measurements.

One of the most important principles to understand in the management of these complex patients is the need for a detailed initial assessment and ongoing reevaluation of the response to treatment. This evaluation should start with a thorough clinical examination and evaluation of available physiologic variables that can describe the patient’s clinical state (heart rate, blood pressure, arterial oxygen saturation, respiratory rate, temperature, urine output, and others as available). Echocardiography in recent years has become available to many bedside clinicians and enables a more detailed assessment of the causes of the hemodynamic issues (22).

The use of CVP alone to guide fluid resuscitation can no longer be justified (22) because the ability to predict a response to a fluid challenge when the CVP is within a relatively normal range (8–12 mm Hg) is limited (23). The same holds true for other static measurements of right or left heart pressures or volumes. Dynamic measures of assessing whether a patient requires additional fluid have been proposed in an effort to improve fluid management and have demonstrated better diagnostic accuracy at predicting those patients who are likely to respond to a fluid challenge by increasing stroke volume. These techniques encompass passive leg raises, fluid challenges against stroke volume measurements, or the variations in systolic pressure, pulse pressure, or stroke volume to changes in intrathoracic pressure induced by mechanical ventilation (24). Our review of five studies of the use of pulse pressure variation to predict fluid responsiveness in patients with sepsis or septic shock demonstrated a sensitivity of 0.72 (95% CI, 0.61–0.81) and a specificity of 0.91 (95% CI, 0.83–0.95); the quality of evidence was low due to imprecision and risk of bias (**Supplemental Digital Content 3**, <http://links.lww.com/CCM/C324>) (24). A recent multicenter study demonstrated limited use of cardiac function monitors during fluid administration in the ICUs. Even though data on the use of these monitors in the emergency department are lacking, the availability of the devices and applicability of the parameters to all situations may influence the routine use of dynamic indices (22, 25).

MAP is the driving pressure of tissue perfusion. While perfusion of critical organs such as the brain or kidney may be protected from systemic hypotension by autoregulation of regional perfusion, below a threshold MAP, tissue perfusion becomes linearly dependent on arterial pressure. In a single-center trial (26), dose titration of norepinephrine from 65 to 75 and 85 mm Hg raised cardiac index (from  $4.7 \pm 0.5$  to  $5.5 \pm 0.6$  L/min/m<sup>2</sup>) but did not change urinary

flow, arterial lactate levels, oxygen delivery and consumption, gastric mucosal  $PCO_2$ , RBC velocity, or skin capillary flow. Another single-center (27) trial compared, in norepinephrine-treated septic shock, dose titration to maintain MAP at 65 mm Hg versus achieving 85 mm Hg. In this trial, targeting high MAP increased cardiac index from 4.8 (3.8–6.0) to 5.8 (4.3–6.9) L/min/m<sup>2</sup> but did not change renal function, arterial lactate levels, or oxygen consumption. A third single-center trial (28) found improved microcirculation, as assessed by sublingual vessel density and the ascending slope of the oxygen saturation after an occlusion test, by titrating norepinephrine to a MAP of 85 mm Hg compared to 65 mm Hg. Only one multicenter trial that compared norepinephrine dose titration to achieve a MAP of 65 mm Hg versus 85 mm Hg had mortality as a primary outcome (29). There was no significant difference in mortality at 28 days (36.6% in the high-target group and 34.0% in the low-target group) or 90 days (43.8% in the high-target group and 42.3% in the low-target group). Targeting a MAP of 85 mm Hg resulted in a significantly higher risk of arrhythmias, but the subgroup of patients with previously diagnosed chronic hypertension had a reduced need for renal replacement therapy (RRT) at this higher MAP. A recent pilot trial of 118 septic shock patients (30) suggested that, in the subgroup of patients older than 75 years, mortality was reduced when targeting a MAP of 60–65 mm Hg versus 75–80 mm Hg. The quality of evidence was moderate (**Supplemental Digital Content 4**, <http://links.lww.com/CCM/C325>) due to imprecise estimates (wide confidence intervals). As a result, the desirable consequences of targeting MAP of 65 mm Hg (lower risk of atrial fibrillation, lower doses of vasopressors, and similar mortality) led to a strong recommendation favoring an initial MAP target of 65 mm Hg over higher MAP targets. When a better understanding of any patient's condition is obtained, this target should be individualized to the pertaining circumstances.

Serum lactate is not a direct measure of tissue perfusion (31). Increases in the serum lactate level may represent tissue hypoxia, accelerated aerobic glycolysis driven by excess beta-adrenergic stimulation, or other causes (e.g., liver failure). Regardless of the source, increased lactate levels are associated with worse outcomes (32). Because lactate is a standard laboratory test with prescribed techniques for its measurement, it may serve as a more objective surrogate for tissue perfusion as compared with physical examination or urine output. Five randomized controlled trials (647 patients) have evaluated lactate-guided resuscitation of patients with septic shock (33–37). A significant reduction in mortality was seen in lactate-guided resuscitation compared to resuscitation without lactate monitoring (RR 0.67; 95% CI, 0.53–0.84; low quality). There was no evidence for difference in ICU length of stay (LOS) (mean difference –1.51 days; 95% CI, –3.65 to 0.62; low quality). Two other meta-analyses of the 647 patients who were enrolled in these trials demonstrate moderate evidence for reduction in mortality when an early lactate clearance strategy was used, compared with either usual care (nonspecified) or with a  $Scvo_2$  normalization strategy (38, 39).

## B.SCREENING FOR SEPSIS AND PERFORMANCE IMPROVEMENT

### 1. We recommend that hospitals and hospital systems have a performance improvement program for sepsis, including sepsis screening for acutely ill, high-risk patients (BPS).

**Rationale:** Performance improvement efforts for sepsis are associated with improved patient outcomes (40). Sepsis performance improvement programs should optimally have multiprofessional representation (physicians, nurses, affiliate providers, pharmacists, respiratory therapists, dietitians, administrators) with stakeholders from all key disciplines represented in their development and implementation. Successful programs should include protocol development and implementation, targeted metrics to be evaluated, data collection, and ongoing feedback to facilitate continuous performance improvement (41). In addition to traditional continuing education efforts to introduce guidelines into clinical practice, knowledge translation efforts can be valuable in promoting the use of high-quality evidence in changing behavior (42).

Sepsis performance improvement programs can be aimed at earlier recognition of sepsis via a formal screening effort and improved management of patients once they are identified as being septic. Because lack of recognition prevents timely therapy, sepsis screening is associated with earlier treatment (43, 44). Notably, sepsis screening has been associated with decreased mortality in several studies (20, 45). The implementation of a core set of recommendations (“bundle”) has been a cornerstone of sepsis performance improvement programs aimed at improving management (46). Note that the SSC bundles have been developed separately from the guidelines in conjunction with an educational and improvement partnership with the Institute for Healthcare Improvement (46). The SSC bundles that are based on previous guidelines have been adopted by the U.S.-based National Quality Forum and have also been adapted by the U.S. healthcare system's regulatory agencies for public reporting. To align with emerging evidence and U.S. national efforts, the SSC bundles were revised in 2015.

While specifics vary widely among different programs, a common theme is the drive toward improvement in compliance with sepsis bundles and practice guidelines such as SSC (8). A meta-analysis of 50 observational studies demonstrated that performance improvement programs were associated with a significant increase in compliance with the SSC bundles and a reduction in mortality (OR 0.66; 95% CI, 0.61–0.72) (47). The largest study to date examined the relationship between compliance with the SSC bundles (based on the 2004 guidelines) and mortality. A total of 29,470 patients in 218 hospitals in the United States, Europe, and South America were examined over a 7.5-year period (21). Lower mortality was observed in hospitals with higher compliance. Overall hospital mortality decreased 0.7% for every 3 months a hospital participated in the SSC, associated with a 4% decreased LOS for every 10% improvement in compliance with bundles. This benefit has also been shown across a wide geographic spectrum. A study of 1,794 patients from 62 countries with severe sepsis (now termed “sepsis”



after the Sepsis-3 definition (1) or septic shock demonstrated a 36%–40% reduction of the odds of dying in the hospital with compliance with either the 3- or 6-hour SSC bundles (48). This recommendation met the prespecified criteria for a BPS. The specifics of performance improvement methods varied markedly between studies; thus, no single approach to performance improvement could be recommended (**Supplemental Digital Content 5**, <http://links.lww.com/CCM/C326>).

## C. DIAGNOSIS

**1. We recommend that appropriate routine microbiologic cultures (including blood) be obtained before starting antimicrobial therapy in patients with suspected sepsis or septic shock if doing so results in no substantial delay in the start of antimicrobials (BPS).**

**Remarks: Appropriate routine microbiologic cultures always include at least two sets of blood cultures (aerobic and anaerobic).**

**Rationale:** Sterilization of cultures can occur within minutes to hours after the first dose of an appropriate antimicrobial (49, 50). Obtaining cultures prior to the administration of antimicrobials significantly increases the yield of cultures, making identification of a pathogen more likely. Isolation of an infecting organism(s) allows for de-escalation of antimicrobial therapy first at the point of identification and then again when susceptibilities are obtained. De-escalation of antimicrobial therapy is a mainstay of antibiotic stewardship programs and is associated with less resistant microorganisms, fewer side effects, and lower costs (51). Several retrospective studies have suggested that obtaining cultures prior to antimicrobial therapy is associated with improved outcome (52, 53). Similarly, de-escalation has also been associated with improved survival in several observational studies (54, 55). The desire to obtain cultures prior to initiating antimicrobial therapy must be balanced against the mortality risk of delaying a key therapy in critically ill patients with suspected sepsis or septic shock who are at significant risk of death (56, 57).

We recommend that blood cultures be obtained prior to initiating antimicrobial therapy if cultures can be obtained in a timely manner. However, the risk/benefit ratio favors rapid administration of antimicrobials if it is not logistically possible to obtain cultures promptly. Therefore, in patients with suspected sepsis or septic shock, appropriate routine microbiologic cultures should be obtained before initiation of antimicrobial therapy from all sites considered to be potential sources of infection if it results in no substantial delay in the start of antimicrobials. This may include blood, cerebrospinal fluid, urine, wounds, respiratory secretions, and other body fluids, but does not normally include samples that require an invasive procedure such as bronchoscopy or open surgery. The decision regarding which sites to culture requires careful consideration from the treatment team. “Pan culture” of all sites that could potentially be cultured should be discouraged (unless the source of sepsis is not clinically apparent), because this practice can lead to inappropriate antimicrobial use (58). If history or

clinical examination clearly indicates a specific anatomic site of infection, cultures of other sites (apart from blood) are generally unnecessary. We suggest 45 minutes as an example of what may be considered to be no substantial delay in the initiation of antimicrobial therapy while cultures are being obtained.

Two or more sets (aerobic and anaerobic) of blood cultures are recommended before initiation of any new antimicrobial in all patients with suspected sepsis (59). All necessary blood cultures may be drawn together on the same occasion. Blood culture yield has not been shown to be improved with sequential draws or timing to temperature spikes (60, 61). Details on appropriate methods to draw and transport blood culture samples are enumerated in other guidelines (61, 62).

In potentially septic patients with an intravascular catheter (in place > 48 hours) in whom a site of infection is not clinically apparent or a suspicion of intravascular catheter-associated infection exists, at least one blood culture set should be obtained from the catheter (along with simultaneous peripheral blood cultures). This is done to assist in the diagnosis of a potential catheter-related bloodstream infection. Data are inconsistent regarding the utility of differential time to blood culture positivity (i.e., equivalent volume blood culture from the vascular access device positive more than 2 hours before the peripheral blood culture) in suggesting that the vascular access device is the source of the infection (63–65). It is important to note that drawing blood cultures from an intravascular catheter in case of possible infection of the device does not eliminate the option of removing the catheter (particular non-tunneled catheters) immediately afterward.

In patients without a suspicion of catheter-associated infection and in whom another clinical infection site is suspected, at least one blood culture (of the two or more that are required) should be obtained peripherally. However, no recommendation can be made as to where additional blood cultures should be drawn. Options include: a) all cultures drawn peripherally via venipuncture, b) cultures drawn through each separate intravascular device but not through multiple lumens of the same intravascular catheter, or c) cultures drawn through multiple lumens in an intravascular device (66–70).

In the near future, molecular diagnostic methods may offer the potential to diagnose infections more quickly and more accurately than current techniques. However, varying technologies have been described, clinical experience remains limited, and additional validation is needed before recommending these methods as an adjunct to or replacement for standard blood culture techniques (71–73). In addition, susceptibility testing is likely to require isolation and direct testing of viable pathogens for the foreseeable future.

## D. ANTIMICROBIAL THERAPY

**1. We recommend that administration of IV antimicrobials be initiated as soon as possible after recognition and within one hour for both sepsis and septic shock (strong recommendation, moderate quality of evidence; grade applies to both conditions).**

**Rationale:** The rapidity of administration is central to the beneficial effect of appropriate antimicrobials. In the presence of sepsis or septic shock, each hour delay in administration of appropriate antimicrobials is associated with a measurable increase in mortality (57, 74). Further, several studies show an adverse effect on secondary end points (e.g., LOS (75), acute kidney injury (76), acute lung injury (77), and organ injury assessed by Sepsis-Related Organ Assessment score (78) with increasing delays. Despite a meta-analysis of mostly poor-quality studies that failed to demonstrate a benefit of rapid antimicrobial therapy, the largest and highest-quality studies support giving appropriate antimicrobials as soon as possible in patients with sepsis with or without septic shock (57, 74, 79–81). The majority of studies within the meta-analysis were of low quality due to a number of deficiencies, including small study size, using an initial index time of an arbitrary time point such as emergency department arrival, and indexing of outcome to delay in time to the first antimicrobial (regardless of activity against the putative pathogen) (82, 83). Other negative studies not included in this meta-analysis are compromised by equating bacteremia with sepsis (as currently defined to include organ failure) and septic shock (84–87). Many of these studies are also compromised by indexing delays to easily accessible but non-physiologic variables such as time of initial blood culture draw (an event likely to be highly variable in timing occurrence).

While available data suggest that the earliest possible administration of appropriate IV antimicrobials following recognition of sepsis or septic shock yields optimal outcomes, one hour is recommended as a reasonable minimal target. The feasibility of achieving this target consistently, however, has not been adequately assessed. Practical considerations, for example, challenges with clinicians' early identification of patients or operational complexities in the drug delivery chain, represent poorly studied variables that may affect achieving this goal. A number of patient and organizational factors appear to influence antimicrobial delays (88).

Accelerating appropriate antimicrobial delivery institutionally starts with an assessment of causes of delays (89). These can include an unacceptably high frequency of failure to recognize the potential existence of sepsis or septic shock and of inappropriate empiric antimicrobial initiation (e.g., as a consequence of lack of appreciation of the potential for microbial resistance or recent previous antimicrobial use in a given patient). In addition, unrecognized or underappreciated administrative or logistic factors (often easily remedied) may be found. Possible solutions to delays in antimicrobial initiation include use of "stat" orders or including a minimal time element in antimicrobial orders, addressing delays in obtaining blood and site cultures pending antimicrobial administration, and sequencing antimicrobial delivery optimally or using simultaneous delivery of key antimicrobials, as well as improving supply chain deficiencies. Improving communication among medical, pharmacy, and nursing staff can also be highly beneficial.

Most issues can be addressed by quality improvement initiatives, including defined order sets. If antimicrobial agents

cannot be mixed and delivered promptly from the pharmacy, establishing a supply of premixed drugs for urgent situations is an appropriate strategy for ensuring prompt administration. Many antimicrobials will not remain stable if premixed in a solution. This issue must be taken into consideration in institutions that rely on premixed solutions for rapid antimicrobial availability. In choosing the antimicrobial regimen, clinicians should be aware that some antimicrobial agents (notably  $\beta$ -lactams) have the advantage of being able to be safely administered as a bolus or rapid infusion, while others require a lengthy infusion. If vascular access is limited and many different agents must be infused, drugs that can be administered as a bolus or rapid infusion may offer an advantage for rapid achievement of therapeutic levels for the initial dose.

While establishing vascular access and initiating aggressive fluid resuscitation are very important when managing patients with sepsis or septic shock, prompt IV infusion of antimicrobial agents is also a priority. This may require additional vascular access ports. Intraosseous access, which can be quickly and reliably established (even in adults), can be used to rapidly administer the initial doses of any antimicrobial (90, 91). In addition, intramuscular preparations are approved and available for several first-line  $\beta$ -lactams, including imipenem/cilastatin, cefepime, ceftriaxone, and ertapenem. Several additional first-line  $\beta$ -lactams can also be effectively administered intramuscularly in emergency situations if vascular and intraosseous access is unavailable, although regulatory approval for intramuscular administration for these drugs is lacking (92–94). Intramuscular absorption and distribution of some of these agents in severe illness has not been studied; intramuscular administration should be considered only if timely establishment of vascular access is not possible.

2. We recommend empiric broad-spectrum therapy with one or more antimicrobials for patients presenting with sepsis or septic shock to cover all likely pathogens (including bacterial and potentially fungal or viral coverage) (strong recommendation, moderate quality of evidence).
3. We recommend that empiric antimicrobial therapy be narrowed once pathogen identification and sensitivities are established and/or adequate clinical improvement is noted (BPS).

**Rationale:** The initiation of appropriate antimicrobial therapy (i.e., with activity against the causative pathogen or pathogens) is one of the most important facets of effective management of life-threatening infections causing sepsis and septic shock. Failure to initiate appropriate empiric therapy in patients with sepsis and septic shock is associated with a substantial increase in morbidity and mortality (79, 95–97). In addition, the probability of progression from gram-negative bacteremic infection to septic shock is increased (98). Accordingly, the initial selection of antimicrobial therapy must be broad enough to cover all likely pathogens. The choice of empiric antimicrobial therapy depends on complex issues related to the patient's history, clinical status, and local epidemiologic factors. Key patient factors include the nature of the clinical syndrome/site of infection,

concomitant underlying diseases, chronic organ failures, medications, indwelling devices, the presence of immunosuppression or other form of immunocompromise, recent known infection or colonization with specific pathogens, and the receipt of antimicrobials within the previous three months. In addition, the patient's location at the time of infection acquisition (i.e., community, chronic care institution, acute care hospital), local pathogen prevalence, and the susceptibility patterns of those common local pathogens in both the community and hospital must be factored into the choice of therapy. Potential drug intolerances and toxicity must also be considered.

The most common pathogens that cause septic shock are gram-negative bacteria, gram-positive, and mixed bacterial microorganisms. Invasive candidiasis, toxic shock syndromes, and an array of uncommon pathogens should be considered in selected patients. Certain specific conditions put patients at risk for atypical or resistant pathogens. For example, neutropenic patients are at risk for an especially wide range of potential pathogens, including resistant gram-negative bacilli and *Candida* species. Patients with nosocomial acquisition of infection are prone to sepsis with methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococci*.

Historically, critically ill patients with overwhelming infection have not been considered a unique subgroup comparable to neutropenic patients for purposes of selection of antimicrobial therapy. Nonetheless, critically ill patients with severe and septic shock are, like neutropenic patients, characterized by distinct differences from the typical infected patient that impact on the optimal antimicrobial management strategy. Primary among these differences are a predisposition to infection with resistant organisms and a marked increase in frequency of death and other adverse outcomes if there is a failure of rapid initiation of effective antimicrobial therapy.

Selection of an optimal empiric antimicrobial regimen in sepsis and septic shock is one of the central determinants of outcome. Survival may decrease as much as fivefold for septic shock treated with an empiric regimen that fails to cover the offending pathogen (95). Because of the high mortality associated with inappropriate initial therapy, empiric regimens should err on the side of over-inclusiveness. However, the choice of empiric antimicrobial regimens in patients with sepsis and septic shock is complex and cannot be reduced to a simple table. Several factors must be assessed and used in determining the appropriate antimicrobial regimen at each medical center and for each patient. These include:

- a) The anatomic site of infection with respect to the typical pathogen profile and to the properties of individual antimicrobials to penetrate that site
- b) Prevalent pathogens within the community, hospital, and even hospital ward
- c) The resistance patterns of those prevalent pathogens
- d) The presence of specific immune defects such as neutropenia, splenectomy, poorly controlled HIV infection and acquired or congenital defects of immunoglobulin, complement or leukocyte function or production

- e) Age and patient comorbidities including chronic illness (e.g., diabetes) and chronic organ dysfunction (e.g., liver or renal failure), the presence of invasive devices (e.g., central venous lines or urinary catheter) that compromise the defense to infection.

In addition, the clinician must assess risk factors for infection with multidrug-resistant pathogens including prolonged hospital/chronic facility stay, recent antimicrobial use, prior hospitalization, and prior colonization or infection with multidrug-resistant organisms. The occurrence of more severe illness (e.g., septic shock) may be intrinsically associated with a higher probability of resistant isolates due to selection in failure to respond to earlier antimicrobials.

Given the range of variables that must be assessed, the recommendation of any specific regimen for sepsis and septic shock is not possible. The reader is directed to guidelines that provide potential regimens based on anatomic site of infection or specific immune defects (67, 99–109).

However, general suggestions can be provided. Since the vast majority of patients with severe sepsis and septic shock have one or more forms of immunocompromise, the initial empiric regimen should be broad enough to cover most pathogens isolated in healthcare-associated infections. Most often, a broad-spectrum carbapenem (e.g., meropenem, imipenem/cilastatin or doripenem) or extended-range penicillin/ $\beta$ -lactamase inhibitor combination (e.g., piperacillin/tazobactam or ticarcillin/clavulanate) is used. However, several third- or higher-generation cephalosporins can also be used, especially as part of a multidrug regimen. Of course, the specific regimen can and should be modified by the anatomic site of infection if it is apparent and by knowledge of local microbiologic flora.

Multidrug therapy is often required to ensure a sufficiently broad spectrum of empiric coverage initially. Clinicians should be cognizant of the risk of resistance to broad-spectrum  $\beta$ -lactams and carbapenems among gram-negative bacilli in some communities and healthcare settings. The addition of a supplemental gram-negative agent to the empiric regimen is recommended for critically ill septic patients at high risk of infection with such multidrug-resistant pathogens (e.g., *Pseudomonas*, *Acinetobacter*, etc.) to increase the probability of at least one active agent being administered (110). Similarly, in situations of a more-than-trivial risk for other resistant or atypical pathogens, the addition of a pathogen-specific agent to broaden coverage is warranted. Vancomycin, teicoplanin, or another anti-MRSA agent can be used when risk factors for MRSA exist. A significant risk of infection with *Legionella* species mandates the addition of a macrolide or fluoroquinolone.

Clinicians should also consider whether *Candida* species are likely pathogens when choosing initial therapy. Risk factors for invasive *Candida* infections include immunocompromised status (neutropenia, chemotherapy, transplant, diabetes mellitus, chronic liver failure, chronic renal failure), prolonged invasive vascular devices (hemodialysis catheters, central venous catheters), total parenteral nutrition, necrotizing pancreatitis, recent major surgery (particularly abdominal),

prolonged administration of broad-spectrum antibiotics, prolonged hospital/ICU admission, recent fungal infection, and multisite colonization (111, 112). If the risk of *Candida* sepsis is sufficient to justify empiric antifungal therapy, the selection of the specific agent should be tailored to the severity of illness, the local pattern of the most prevalent *Candida* species, and any recent exposure to antifungal drugs. Empiric use of an echinocandin (anidulafungin, micafungin, or caspofungin) is preferred in most patients with severe illness, especially in those patients with septic shock, who have recently been treated with other antifungal agents, or if *Candida glabrata* or *Candida krusei* infection is suspected from earlier culture data (100, 105). Triazoles are acceptable in hemodynamically stable, less ill patients who have not had previous triazole exposure and are not known to be colonized with azole-resistant species. Liposomal formulations of amphotericin B are a reasonable alternative to echinocandins in patients with echinocandin intolerance or toxicity (100, 105). Knowledge of local resistance patterns to antifungal agents should guide drug selection until fungal susceptibility test results, if available, are received. Rapid diagnostic testing using  $\beta$ -D-glucan or rapid polymerase chain reaction assays to minimize inappropriate anti-*Candida* therapy may have an evolving supportive role. However, the negative predictive value of such tests is not high enough to justify dependence on these tests for primary decision-making.

Superior empiric coverage can be obtained using local and unit-specific antibiograms (113, 114) or an infectious diseases consultation (115–117). Where uncertainty regarding appropriate patient-specific antimicrobial therapy exists, infectious diseases consultation is warranted. Early involvement of infectious diseases specialists can improve outcome in some circumstances (e.g., *S aureus* bacteremia) (113–115).

Although restriction of antimicrobials is an important strategy to reduce both the development of pathogen resistance and cost, it is not an appropriate strategy in the initial therapy for this patient population. Patients with sepsis or septic shock generally warrant empiric broad-spectrum therapy until the causative organism and its antimicrobial susceptibilities are defined. At that point, the spectrum of coverage should be narrowed by eliminating unneeded antimicrobials and replacing broad-spectrum agents with more specific agents (118). However, if relevant cultures are negative, empiric narrowing of coverage based on a good clinical response is appropriate. Collaboration with antimicrobial stewardship programs is encouraged to ensure appropriate choices and rapid availability of effective antimicrobials for treating septic patients.

In situations in which a pathogen is identified, de-escalation to the narrowest effective agent should be implemented for most serious infections. However, approximately one third of patients with sepsis do not have a causative pathogen identified (95, 119). In some cases, this may be because guidelines do not recommend obtaining cultures (e.g., community-acquired abdominal sepsis with bowel perforation) (108). In others, cultures may have followed antimicrobial therapy. Further, almost half of patients with suspected sepsis in one study have been adjudicated in post hoc analysis to lack infection or represent

only “possible” sepsis (120). Given the adverse societal and individual risks to continued unnecessary antimicrobial therapy, we recommend thoughtful de-escalation of antimicrobials based on adequate clinical improvement even if cultures are negative. When infection is found not to be present, antimicrobial therapy should be stopped promptly to minimize the likelihood that the patient will become infected with an antimicrobial-resistant pathogen or develop a drug-related adverse effect. Thus, the decisions to continue, narrow, or stop antimicrobial therapy must be made on the basis of clinician judgment and clinical information.

**4. We recommend against sustained systemic antimicrobial prophylaxis in patients with severe inflammatory states of noninfectious origin (e.g., severe pancreatitis, burn injury) (BPS).**

**Rationale:** A systemic inflammatory response without infection does not mandate antimicrobial therapy. Examples of conditions that may exhibit acute inflammatory signs without infection include severe pancreatitis and extensive burn injury. Sustained systemic antimicrobial therapy in the absence of suspected infection should be avoided in these situations to minimize the likelihood that the patient will become infected with an antimicrobial-resistant pathogen or will develop a drug-related adverse effect.

Although the prophylactic use of systemic antimicrobials for severe necrotizing pancreatitis has been recommended in the past, recent guidelines have favored avoidance of this approach (121). The current position is supported by meta-analyses that demonstrate no clinical advantage of prophylactic antibiotics that would outweigh their long-term adverse effects (122). Similarly, prolonged systemic antimicrobial prophylaxis has been used in the past for patients with severe burns. However, recent meta-analyses suggest questionable clinical benefit with this approach (123, 124). Current guidelines for burn management do not support sustained antimicrobial prophylaxis (101). Summarizing the evidence is challenging due to the diversity of the population. The quality of evidence was low for mortality in pancreatitis (122) and low for burns; therefore, we believe this recommendation is better addressed as a BPS, in which the alternative of administering antibiotics without indicators of infection is implausible (122–124). Despite our recommendation against sustained systemic antimicrobial prophylaxis generally, brief antibiotic prophylaxis for specific invasive procedures may be appropriate. In addition, if there is a strong suspicion of concurrent sepsis or septic shock in patients with a severe inflammatory state of noninfectious origin (despite overlapping clinical presentations), antimicrobial therapy is indicated.

**5. We recommend that dosing strategies of antimicrobials be optimized based on accepted pharmacokinetic/pharmacodynamic principles and specific drug properties in patients with sepsis or septic shock (BPS).**

**Rationale:** Early optimization of antimicrobial pharmacokinetics can improve the outcome of patients with severe

infection. Several considerations should be made when determining optimal dosing for critically ill patients with sepsis and septic shock. These patients have distinct differences from the typical infected patient that affect the optimal antimicrobial management strategy. These differences include an increased frequency of hepatic and renal dysfunction, a high prevalence of unrecognized immune dysfunction, and a predisposition to infection with resistant organisms. Perhaps most importantly with respect to initial empiric antimicrobial dosing is an increased volume of distribution for most antimicrobials, in part due to the rapid expansion of extracellular volume as a consequence of aggressive fluid resuscitation. This results in an unexpectedly high frequency of suboptimal drug levels with a variety of antimicrobials in patients with sepsis and septic shock (125–128). Early attention to appropriate antimicrobial dosing is central to improving outcome given the marked increase in mortality and other adverse outcomes if there is a failure of rapid initiation of effective therapy. Antimicrobial therapy in these patients should always be initiated with a full, high end-loading dose of each agent used.

Different antimicrobials have different required plasma targets for optimal outcomes. Failure to achieve peak plasma targets on initial dosing has been associated with clinical failure with aminoglycosides (129). Similarly, inadequate early vancomycin trough plasma concentrations (in relation to pathogen minimum inhibitory concentration [MIC]) have been associated with clinical failure for serious MRSA infections (130) (including nosocomial pneumonia (131) and septic shock (132)). The clinical success rate for treatment of serious infections correlates with higher peak blood levels (in relation to pathogen MIC) of fluoroquinolones (nosocomial pneumonia and other serious infections) (133–135) and aminoglycosides (gram-negative bacteremia, nosocomial pneumonia, and other serious infections) (129, 136). For  $\beta$ -lactams, superior clinical and microbiologic cures appear to be associated with a longer duration of plasma concentration above the pathogen MIC, particularly in critically ill patients (137–140).

The optimal dosing strategy for aminoglycosides and fluoroquinolones involves optimizing peak drug plasma concentrations. For aminoglycosides, this can most easily be attained with once daily dosing (5–7 mg/kg daily gentamicin equivalent). Once-daily dosing yields at least comparable clinical efficacy with possibly decreased renal toxicity compared to multiple daily dosing regimens (141, 142). Once-daily dosing of aminoglycosides is used for patients with preserved renal function. Patients with chronically mildly impaired renal function should still receive a once-daily-equivalent dose but would normally have an extended period (up to 3 days) before the next dose. This dosing regimen should not be used in patients with severe renal function in whom the aminoglycoside is not expected to clear within several days. Therapeutic drug monitoring of aminoglycosides in this context is primarily meant to ensure that trough concentrations are sufficiently low to minimize the potential for renal toxicity. For fluoroquinolones, an approach that optimizes the dose within a nontoxic range (e.g., ciprofloxacin, 600 mg every 12 hours, or levofloxacin, 750 mg

every 24 hours, assuming preserved renal function) should provide the highest probability of a favorable microbiologic and clinical response (127, 143, 144).

Vancomycin is another antibiotic whose efficacy is at least partially concentration-dependent. Dosing to a trough target of 15–20 mg/L is recommended by several authorities to maximize the probability of achieving appropriate pharmacodynamic targets, improve tissue penetration, and optimize clinical outcomes (145–147). Pre-dose monitoring of trough concentrations is recommended. For sepsis and septic shock, an IV loading dose of 25–30 mg/kg (based on actual body weight) is suggested to rapidly achieve the target trough drug concentration. A loading dose of 1 gram of vancomycin will fail to achieve early therapeutic levels for a significant subset of patients. In fact, loading doses of antimicrobials with low volumes of distribution (teicoplanin, vancomycin, colistin) are warranted in critically ill patients to more rapidly achieve therapeutic drug levels due to their expanded extracellular volume related to volume expansion following fluid resuscitation (148–152). Loading doses are also recommended for  $\beta$ -lactams administered as continuous or extended infusions to accelerate accumulation of drug to therapeutic levels (153). Notably, the required loading dose of any antimicrobial is not affected by alterations of renal function, although this may affect frequency of administration and/or total daily dose.

For  $\beta$ -lactams, the key pharmacodynamics correlate to microbiologic and clinical response is the time that the plasma concentration of the drug is above the pathogen MIC relative to the dosing interval ( $T > MIC$ ). A minimum  $T > MIC$  of 60% is generally sufficient to allow a good clinical response in mild to moderate illness. However, optimal response in severe infections, including sepsis, may be achieved with a  $T > MIC$  of 100% (139). The simplest way to increase  $T > MIC$  is to use increased frequency of dosing (given an identical total daily dose). For example, piperacillin/tazobactam can be dosed at either 4.5 g every 8 hours or 3.375 g every 6 hours for serious infections; all things being equal, the latter would achieve a higher  $T > MIC$ . We suggested earlier that initial doses of  $\beta$ -lactams can be given as a bolus or rapid infusion to rapidly achieve therapeutic blood levels. However, following the initial dose, an extended infusion of drug over several hours (which increases  $T > MIC$ ) rather than the standard 30 minutes has been recommended by some authorities (154, 155). In addition, some meta-analyses suggest that extended/continuous infusion of  $\beta$ -lactams may be more effective than intermittent rapid infusion, particularly for relatively resistant organisms and in critically ill patients with sepsis (140, 156–158). A recent individual patient data meta-analysis of randomized controlled trials comparing continuous versus intermittent infusion of  $\beta$ -lactam antibiotics in critically ill patients with severe sepsis demonstrated an independent protective effect of continuous therapy after adjustment for other correlates of outcome (140).

While the weight of evidence supports pharmacokinetically optimized antimicrobial dosing strategies in critically ill patients with sepsis and septic shock, this is difficult to

achieve on an individual level without a broader range of rapid therapeutic drug monitoring options than currently available (i.e., vancomycin, teicoplanin and aminoglycosides). The target group of critically ill, septic patients exhibit a variety of physiologic perturbations that dramatically alter antimicrobial pharmacokinetics. These include unstable hemodynamics, increased cardiac output, increased extracellular volume (markedly increasing volume of distribution), variable kidney and hepatic perfusion (affecting drug clearance) and altered drug binding due to reduced serum albumin (159). In addition, augmented renal clearance is a recently described phenomenon that may lead to decreased serum antimicrobial levels in the early phase of sepsis (160–162). These factors make individual assessment of optimal drug dosing difficult in critically ill patients. Based on studies with therapeutic drug monitoring, under-dosing (particularly in the early phase of treatment) is common in critically ill, septic patients, but drug toxicity such as central nervous system irritation with  $\beta$ -lactams and renal injury with colistin is also seen (163–166). These problems mandate efforts to expand access to therapeutic drug monitoring for multiple antimicrobials for critically ill patients with sepsis.

**6. We suggest empiric combination therapy (using at least two antibiotics of different antimicrobial classes) aimed at the most likely bacterial pathogen(s) for the initial management of septic shock (weak recommendation, low quality of evidence).**

**Remarks:** Readers should review Table 6 for definitions of empiric, targeted/definitive, broad-spectrum, combination, and multidrug therapy before reading this section.

**7. We suggest that combination therapy not be routinely used for ongoing treatment of most other serious infections, including bacteremia and sepsis without shock (weak recommendation, low quality of evidence).**

**Remarks:** This does not preclude the use of multidrug therapy to broaden antimicrobial activity.

**8. We recommend against combination therapy for the routine treatment of neutropenic sepsis/bacteremia (strong recommendation, moderate quality of evidence).**

**Remarks:** This does not preclude the use of multidrug therapy to broaden antimicrobial activity.

**9. If combination therapy is initially used for septic shock, we recommend de-escalation with discontinuation of combination therapy within the first few days in response to clinical improvement and/or evidence of infection resolution. This applies to both targeted (for culture-positive infections) and empiric (for culture-negative infections) combination therapy (BPS).**

**Rationale:** In light of the increasing frequency of pathogen resistance to antimicrobial agents in many parts of the world, the initial use of multidrug therapy is often required to ensure an appropriately broad-spectrum range of coverage for initial

empiric treatment. The use of multidrug therapy for this purpose in severe infections is well understood.

The phrase “combination therapy” in the context of this guideline connotes the use of two different classes of antibiotics (usually a  $\beta$ -lactam with a fluoroquinolone, aminoglycoside, or macrolide) for a single putative pathogen expected to be sensitive to both, particularly for purposes of accelerating pathogen clearance. The term is not used where the purpose of a multidrug strategy is to strictly broaden the range of antimicrobial activity (e.g., vancomycin added to ceftazidime, meropenem added to an aminoglycoside or an echinocandin added to a  $\beta$ -lactam).

A propensity-matched analysis and a meta-analysis/meta-regression analysis have demonstrated that combination therapy produces higher survival in severely ill septic patients with a high risk of death, particularly in those with septic shock (167, 168). A meta-regression study (167) suggested benefit with combination therapy in patients with a mortality risk greater than 25%. Several observational studies have similarly shown a survival benefit in very ill patients (169–172). However, the aforementioned meta-regression analysis also suggested the possibility of increased mortality risk with combination therapy in low-risk (< 15% mortality risk) patients without septic shock (167). One controlled trial suggested that, when using a carbapenem as empiric therapy in a population at low risk for infection with resistant microorganisms, the addition of a fluoroquinolone does not improve patients’ outcomes (173). A close examination of the results, however, demonstrates findings consistent with the previously mentioned meta-regression (trend to benefit in septic shock with an absence of benefit in sepsis without shock). Despite the overall favorable evidence for combination therapy in septic shock, direct evidence from adequately powered RCTs is not available to validate this approach definitively. Nonetheless, in clinical scenarios of severe clinical illness (particularly septic shock), several days of combination therapy is biologically plausible and is likely to be clinically useful (152, 167, 168) even if evidence has not definitively demonstrated improved clinical outcome in bacteremia and sepsis without shock (174, 175). Thus, we issue a weak recommendation based on low quality of evidence.

A number of other recent observational studies and some small, prospective trials also support initial combination therapy for selected patients with specific pathogens (e.g., severe pneumococcal infection, multidrug-resistant gram-negative pathogens) (172, 176–182). Unfortunately, in most cases and pending the development of rapid bedside pathogen detection techniques, the offending pathogen is not known at the time of presentation. Therefore, specifying combination therapy to specific identified pathogens is useful only if more prolonged, targeted combination therapy is contemplated. In addition, with respect to multidrug-resistant pathogens, both individual studies and meta-analyses yield variable results depending on the pathogen and the clinical scenario (179–184). Infectious diseases consultation may be advisable if multidrug-resistant pathogens are suspected. One area of broad consensus on the use of a specific form of combination therapy is for

**TABLE 6. Important Terminology for Antimicrobial Recommendations**

<i>Empiric therapy</i>	Initial therapy started in the absence of definitive microbiologic pathogen identification. Empiric therapy may be mono-, combination, or broad-spectrum, and/or multidrug in nature.
<i>Targeted/definitive therapy</i>	Therapy targeted to a specific pathogen (usually after microbiologic identification). Targeted/definitive therapy may be mono- or combination, but is not intended to be broad-spectrum.
<i>Broad-spectrum therapy</i>	The use of one or more antimicrobial agents with the specific intent of broadening the range of potential pathogens covered, usually during empiric therapy (e.g., piperacillin/tazobactam, vancomycin, and anidulafungin; each is used to cover a different group of pathogens). Broad-spectrum therapy is typically empiric since the usual purpose is to ensure antimicrobial coverage with at least one drug when there is uncertainty about the possible pathogen. On occasion, broad-spectrum therapy may be continued into the targeted/definitive therapy phase if multiple pathogens are isolated.
<i>Multidrug therapy</i>	Therapy with multiple antimicrobials to deliver broad-spectrum therapy (i.e., to broaden coverage) for empiric therapy (i.e., where pathogen is unknown) or to potentially accelerate pathogen clearance (combination therapy) with respect to a specific pathogen(s) where the pathogen(s) is known or suspected (i.e., for both targeted or empiric therapy). This term therefore includes combination therapy.
<i>Combination therapy</i>	The use of multiple antibiotics (usually of different mechanistic classes) with the specific intent of covering the known or suspected pathogen(s) with more than one antibiotic (e.g., piperacillin/tazobactam and an aminoglycoside or fluoroquinolone for gram-negative pathogens) to accelerate pathogen clearance rather than to broaden antimicrobial coverage. Other proposed applications of combination therapy include inhibition of bacterial toxin production (e.g., clindamycin with $\beta$ -lactams for streptococcal toxic shock) or potential immune modulatory effects (macrolides with a $\beta$ -lactam for pneumococcal pneumonia).

streptococcal toxic shock syndrome, for which animal models and uncontrolled, clinical experience demonstrate a survival advantage with penicillin and clindamycin, the latter as a transcriptional inhibitor to pyrogenic exotoxin superantigens (109, 185, 186).

Despite evidence suggesting benefit of combination therapy in septic shock, this approach has not been shown to be effective for ongoing treatment of most other serious infections, including bacteremia and sepsis without shock (168, 174, 175). The term “ongoing treatment” includes extended empiric therapy for culture-negative infections and extended definitive/targeted therapy where a pathogen is identified. In the case of neutropenia in the absence of septic shock, studies using modern broad-spectrum antibiotics consistently suggest that, while multidrug therapy to broaden pathogen coverage (e.g., to include *Candida* species) may be useful, combination therapy using a  $\beta$ -lactam and an aminoglycoside for purposes of accelerating pathogen clearance is not beneficial for less severely ill “low-risk” patients (187). Combination therapy of this sort for even “high-risk” neutropenic patients (inclusive of hemodynamic instability and organ failure) with sepsis is inconsistently supported by several international expert groups (106, 188). This position against combination therapy for a single pathogen in any form of neutropenic infection emphatically does not preclude the use of multidrug therapy for the purpose of broadening the spectrum of antimicrobial treatment.

High-quality data on clinically driven de-escalation of antimicrobial therapy for severe infections are limited (189). Early de-escalation of antimicrobial therapy in the context of combination therapy as described here has not been studied. However, observational studies have shown

that early de-escalation of multidrug therapy is associated with equivalent or superior clinical outcomes in sepsis and septic shock (54, 190–192); despite this, at least one study has indicated an increased frequency of superinfection and longer ICU stay (192). In addition to institutional benefit with respect to limiting a driver of antimicrobial resistance, early de-escalation can also benefit the individual patient (193–195). Although the data are not entirely consistent, on balance, an approach that emphasizes early de-escalation is favored when using combination therapy.

While substantial consensus on the need for early de-escalation of combination therapy exists, agreement is lacking on precise criteria for triggering de-escalation. Among approaches used by panel members are de-escalation based on: a) clinical progress (shock resolution, decrease in vasopressor requirement, etc.), b) infection resolution as indicated by biomarkers (especially procalcitonin), and c) a relatively fixed duration of combination therapy. This lack of consensus on de-escalation criteria for combination therapy reflects the lack of solid data addressing this issue (notwithstanding procalcitonin data relating to general de-escalation)

**10. We suggest that an antimicrobial treatment duration of 7 to 10 days is adequate for most serious infections associated with sepsis and septic shock (weak recommendation, low quality of evidence).**

**11. We suggest that longer courses are appropriate in patients who have a slow clinical response, undrainable foci of infection, bacteremia with *S aureus*, some fungal and viral infections, or immunologic deficiencies, including neutropenia. (weak recommendation, low quality of evidence).**

- 12. We suggest that shorter courses are appropriate in some patients, particularly those with rapid clinical resolution following effective source control of intra-abdominal or urinary sepsis and those with anatomically uncomplicated pyelonephritis (weak recommendation, low quality of evidence).**
- 13. We recommend daily assessment for de-escalation of antimicrobial therapy in patients with sepsis and septic shock (BPS).**

**Rationale.** Unnecessarily prolonged administration of antimicrobials is detrimental to society and to the individual patient. For society, excessive antimicrobial use drives antimicrobial resistance development and dissemination (196). For individual patients, prolonged antibiotic therapy is associated with specific illnesses such as *Clostridium difficile* colitis (195) and, more broadly, an increased mortality risk (54). The basis of the increased mortality with unnecessarily prolonged and broad antimicrobial therapy has not been convincingly demonstrated, although cumulative antimicrobial toxicity; the occurrence of antimicrobial-associated secondary infections (e.g., *C difficile* colitis); and selection of, and superinfection with, multidrug-resistant pathogens are all potential contributors.

Although patient factors will influence the length of antibiotic therapy, a treatment duration of 7 to 10 days (in the absence of source control issues) is generally adequate for most serious infections (103, 197–199). Current guidelines recommend a 7-day course of therapy for nosocomial pneumonia (both hospital-acquired and ventilator-associated pneumonia [VAP]) (103). Recent data suggest that some serious infections may be treated with shorter courses especially if there is a need for and successful provision of source control (200, 201). Subgroup analysis of the most critically ill subjects (Acute Physiologic and Chronic Health Evaluation [APACHE] II score greater than either 15 or 20) in the short course of antimicrobials in the intra-abdominal sepsis study of Sawyer et al demonstrated no difference in outcome based on the duration of therapy (as with the overall group) (200, 202). A treatment duration of 3 to 5 days or fewer was as effective as a duration of up to 10 days. Similarly, studies have shown that a treatment duration of < 7 days is as effective as longer durations in the management of acute pyelonephritis with or without bacteremia (201), uncomplicated cellulitis (203), and spontaneous bacterial peritonitis (204). Some conditions are generally thought to require more prolonged antimicrobial therapy. These include situations in which there is a slow clinical response, undrainable foci of infection, bacteremia with *S aureus* (particularly MRSA) (67, 104), candidemia/invasive candidiasis (105) and other fungal infections, some viral infections (e.g., herpes, cytomegalovirus), and immunologic deficiencies, including neutropenia (188).

Assessment of the required duration of therapy in critically ill patients should include host factors, particularly immune status. For example, patients with neutropenic infection and sepsis usually require therapy for at least the duration of their neutropenia.

The nature of the infecting pathogen also plays a role. In particular, uncomplicated *S aureus* bacteremia requires at least 14 days of therapy, while complicated bacteremia requires treatment as an endovascular infection with 6 weeks of therapy. Uncomplicated bacteremia has been defined as: 1) exclusion of endocarditis, 2) no implanted prostheses, 3) negative results of follow-up blood cultures drawn 2 to 4 days after the initial set, 4) defervescence within 72 hours after the initiation of effective antibiotic therapy, and 5) no evidence of metastatic infection (104). Patients with candidemia (whether or not catheter-associated) and deep *Candida* infections, whether or not associated with sepsis, require more prolonged therapy (105, 205). Highly resistant gram-negative pathogens with marginal sensitivity to utilized antimicrobials may be slow to clear and represent another example. The nature and site of infection may also affect duration of therapy. Larger abscesses and osteomyelitis have limited drug penetration and require longer therapy. Although it is well known that endocarditis requires prolonged antimicrobial therapy, severe disease more typically presents as cardiac failure/cardiogenic shock and emboli rather than as sepsis or septic shock (206, 207). A variety of other factors may play a role in determining the optimal duration of therapy, particularly in critically ill infected patients. If the clinician is uncertain, infectious diseases consultation should be sought.

Few of the studies noted focused on patients with septic shock, sepsis with organ failure, or even critical illness. To an extent, standard recommendations on duration of therapy in this document depend on inferences from less ill cohorts. Therefore, decisions to narrow or stop antimicrobial therapy must ultimately be made on the basis of sound clinical judgment.

There are many reasons for unnecessarily prolonged antimicrobial therapy. For complicated, critically ill patients admitted with serious infections, noninfectious concurrent illness and medical interventions may produce signs and symptoms consistent with active infection (even following control of infection). For example, pulmonary infiltrates and shortness of breath may be caused by pulmonary edema in addition to pneumonia; an elevated white cell count may occur as a consequence of corticosteroid administration or physiologic stress; fever may be associated with certain drugs, including  $\beta$ -lactams and phenytoin. In addition, there is a natural tendency to want to continue a therapy that is often seen as benign long enough to be confident of cure. However, as discussed, antimicrobials are not an entirely benign therapy. In low-risk patients, the adverse effects can outweigh any benefit.

Given the potential harm associated with unnecessarily prolonged antimicrobial therapy, daily assessment for de-escalation of antimicrobial therapy is recommended in patients with sepsis and septic shock. Studies have shown that daily prompting on the question of antimicrobial de-escalation is effective and may be associated with improved mortality rates (55, 208).

- 14. We suggest that measurement of procalcitonin levels can be used to support shortening the duration of antimicrobial therapy in sepsis patients (weak recommendation, low quality of evidence).**



15. We suggest that procalcitonin levels can be used to support the discontinuation of empiric antibiotics in patients who initially appeared to have sepsis, but subsequently have limited clinical evidence of infection (weak recommendation, low quality of evidence).

**Rationale.** During the past decade, the role of biomarkers to assist in the diagnosis and management of infections has been extensively explored. The use of galactomannan and  $\beta$ -D-glucan to assist in the assessment of invasive aspergillus (and a broad range of fungal pathogens) has become well accepted (209, 210). Similarly, measurement of serum procalcitonin is commonly used in many parts of the world to assist in the diagnosis of acute infection and to help define the duration of antimicrobial therapy. Various procalcitonin-based algorithms have been used to direct de-escalation of antimicrobial therapy in severe infections and sepsis (211–216). However, it is not clear that any particular algorithm provides a clinical advantage over another. A large body of literature suggests that use of such algorithms can speed safe antimicrobial de-escalation compared to standard clinical approaches with reduced antimicrobial consumption without an adverse effect on mortality. Recently, a large randomized trial on procalcitonin use in critically ill patients with presumed bacterial infection demonstrated evidence of a reduction in duration of treatment and daily defined doses of antimicrobials (217). However, given the design of the study, the reduction could have been related to a prompting effect as seen in other studies (55, 218). In addition, the procalcitonin group showed a significant reduction in mortality. This finding is congruent with studies demonstrating an association between early antimicrobial de-escalation and survival in observational studies of sepsis and septic shock (54, 55). This benefit is uncertain, though, because another meta-analysis of randomized controlled studies of de-escalation failed to demonstrate a similar survival advantage (219). Meta-analyses also suggest that procalcitonin can also be used to assist in differentiating infectious and noninfectious conditions at presentation (211, 214, 216). The strongest evidence appears to relate to bacterial pneumonia versus noninfectious pulmonary pathology (216, 220), where meta-analysis suggests that procalcitonin may assist in predicting the presence of bacteremia, particularly in ICU patients (221).

No evidence to date demonstrates that the use of procalcitonin reduces the risk of antibiotic-related diarrhea from *C difficile*. However, the occurrence of *C difficile* colitis is known to be associated with cumulative antibiotic exposure in individual patients (195), so such a benefit is likely. In addition, although prevalence of antimicrobial resistance has not been shown to be reduced by the use of procalcitonin, the emergence of antimicrobial resistance is known to be associated with total antimicrobial consumption in large regions (196).

It is important to note that procalcitonin and all other biomarkers can provide only supportive and supplemental data to clinical assessment. Decisions on initiating, altering, or discontinuing antimicrobial therapy should never be made solely on the basis of changes in any biomarker, including procalcitonin.

## E. SOURCE CONTROL

1. We recommend that a specific anatomic diagnosis of infection requiring emergent source control be identified or excluded as rapidly as possible in patients with sepsis or septic shock, and that any required source control intervention be implemented as soon as medically and logistically practical after the diagnosis is made (BPS).
2. We recommend prompt removal of intravascular access devices that are a possible source of sepsis or septic shock after other vascular access has been established (BPS).

**Rationale.** The principles of source control in the management of sepsis and septic shock include rapid diagnosis of the specific site of infection and determination of whether that infection site is amenable to source control measures (specifically the drainage of an abscess, debridement of infected necrotic tissue, removal of a potentially infected device, and definitive control of a source of ongoing microbial contamination) (222). Foci of infection readily amenable to source control include intra-abdominal abscesses, gastrointestinal perforation, ischemic bowel or volvulus, cholangitis, cholecystitis, pyelonephritis associated with obstruction or abscess, necrotizing soft tissue infection, other deep space infection (e.g., empyema or septic arthritis), and implanted device infections.

Infectious foci suspected to cause septic shock should be controlled as soon as possible following successful initial resuscitation (223, 224). A target of no more than 6 to 12 hours after diagnosis appears to be sufficient for most cases (223–229). Observational studies generally show reduced survival beyond that point. The failure to show benefit with even earlier source control implementation may be a consequence of the limited number of patients in these studies. Therefore, any required source control intervention in sepsis and septic shock should ideally be implemented as soon as medically and logistically practical after the diagnosis is made.

Clinical experience suggests that, without adequate source control, some more severe presentations will not stabilize or improve despite rapid resuscitation and provision of appropriate antimicrobials. In view of this fact, prolonged efforts at medical stabilization prior to source control for severely ill patients, particularly those with septic shock, are generally not warranted (108).

The selection of optimal source control methods must weigh the benefits and risks of the specific intervention, risks of transfer for the procedure, potential delays associated with a specific procedure, and the probability of the procedure's success. Source control interventions may cause further complications, such as bleeding, fistulas, or inadvertent organ injury. In general, the least invasive effective option for source control should be pursued. Open surgical intervention should be considered when other interventional approaches are inadequate or cannot be provided in a timely fashion. Surgical exploration may also be indicated when diagnostic uncertainty persists despite radiologic evaluation or when the probability of success with a percutaneous procedure is uncertain and the mortality risk as a consequence of a failed procedure causing delays

is high. Specific clinical situations require consideration of available choices, the patient's preferences, and the clinician's expertise. Logistic factors unique to each institution, such as surgical or interventional staff availability, may also play a role in the decision.

Intravascular devices such as central venous catheters can be the source of sepsis or septic shock. An intravascular device suspected to be a source of sepsis should generally be removed promptly after establishing another site for vascular access. In the absence of both septic shock and fungemia, some implanted, tunneled catheter infections may be able to be treated effectively with prolonged antimicrobial therapy if removal of the catheter is not practical (67). However, catheter removal (with antimicrobial therapy) is definitive and is preferred where possible.

## F. FLUID THERAPY

1. We recommend that a fluid challenge technique be applied where fluid administration is continued as long as hemodynamic factors continue to improve (BPS).
2. We recommend crystalloids as the fluid of choice for initial resuscitation and subsequent intravascular volume replacement in patients with sepsis and septic shock (strong recommendation, moderate quality of evidence).
3. We suggest using either balanced crystalloids or saline for fluid resuscitation of patients with sepsis or septic shock (weak recommendation, low quality of evidence).
4. We suggest using albumin in addition to crystalloids for initial resuscitation and subsequent intravascular volume replacement in patients with sepsis and septic shock when patients require substantial amounts of crystalloids (weak recommendation, low quality of evidence).
5. We recommend against using hydroxyethyl starches (HESs) for intravascular volume replacement in patients with sepsis or septic shock (strong recommendation, high quality of evidence).
6. We suggest using crystalloids over gelatins when resuscitating patients with sepsis or septic shock (weak recommendation, low quality of evidence).

**Rationale.** The use of IV fluids in the resuscitation of patients is a cornerstone of modern therapy. Despite this, there is little available evidence from RCTs to support its practice; this is an area in which research is urgently needed. One trial of children (mostly with malaria) in Africa, in a setting where escalation to mechanical ventilation and other organ support was limited, questioned this practice (230). We believe that the extrapolation of these data to patients in better-resourced settings is not valid and thus recommend that clinicians restore euvoemia with IV fluids, more urgently initially, and then more cautiously as the patient stabilizes. There is some evidence that a sustained positive fluid balance during ICU stay is harmful (231–235). We do not recommend, therefore, that fluid be given beyond initial resuscitation without some estimate of the likelihood that the patient will respond positively.

The absence of any clear benefit following the administration of colloid compared to crystalloid solutions in the combined subgroups of sepsis, in conjunction with the expense of albumin, supports a strong recommendation for the use of crystalloid solutions in the initial resuscitation of patients with sepsis and septic shock.

We were unable to recommend one crystalloid solution over another because no direct comparisons have been made between isotonic saline and balanced salt solutions in patients with sepsis. One before-after study in all ICU patients suggested increased rates of acute kidney injury and RRT in patients managed with a chloride-liberal strategy compared to a chloride-restrictive strategy (236). There is indirect low-quality evidence from a network meta-analysis suggesting improved outcome with balanced salt solutions as compared to saline in patients with sepsis (237) (**Supplemental Digital Content 6**, <http://links.lww.com/CCM/C327>). In addition, the neutral result of the SPLIT cluster RCT in ICU patients (mainly surgical patients) in four New Zealand ICUs lowered our confidence in recommending one solution over the other (238). No cost-effectiveness studies compare balanced and unbalanced crystalloid solutions. Therefore, we considered the desirable and undesirable consequences to be comparable for both solutions, and issued a weak recommendation to use either solution. Hyperchloremia should be avoided, however, and thus close scrutiny of serum chloride levels is advised, whichever fluid solutions are used.

The SAFE study indicated that albumin administration was safe and equally effective as 0.9% saline in ICU patients requiring fluid administration (239). A meta-analysis aggregated data from 17 randomized trials ( $n = 1,977$ ) of albumin versus other fluid solutions in patients with sepsis or septic shock (240); 279 deaths occurred among 961 albumin-treated patients (29%) versus 343 deaths among 1,016 patients (34%) treated with other fluids, favoring albumin (OR, 0.82; 95% CI, 0.67–1.00). When albumin-treated patients were compared with those receiving crystalloids (seven trials,  $n = 144$ ), the odds ratio of dying was significantly reduced for albumin-treated patients (OR, 0.78; 95% CI, 0.62–0.99).

Since the 2012 SSC guideline publication, six systematic reviews/meta-analyses (237, 241–245) were published assessing the use of albumin solutions in the management of patients with sepsis or septic shock. Each meta-analysis included different populations (adult/child, septic/nonseptic, and acute resuscitation/maintenance), different comparators and different duration of exposure to the intervention (hours, days), which made combining data challenging (**Supplemental Digital Content 7**, <http://links.lww.com/CCM/C328>).

Xu et al (242) evaluated albumin compared to crystalloid as a resuscitation fluid. Five studies, encompassing 3,658 sepsis and 2,180 septic shock patients, were included. Albumin use resulted in reduced septic shock 90-day mortality (OR, 0.81; 95% CI, 0.67–0.97) and trended toward reduced 90-day mortality in sepsis (OR, 0.88; 95% CI, 0.76–1.01;  $p = 0.08$ ). Jiang et al (245) evaluated albumin in a mixed population of sepsis severity including adults and children. Three septic shock

studies, encompassing 1,931 patients, were included. Albumin use resulted in decreased mortality (OR, 0.89; 95% CI, 0.80–0.99) with low heterogeneity ( $I^2 = 0\%$ ). A mortality reduction trend was reported for albumin administration compared to crystalloids when given less than 6 hours from identification (11 studies;  $n = 5515$ ; OR, 0.94; 95% CI, 0.86–1.03).

Patel et al (244) evaluated mixed populations, including resuscitation and maintenance. Additionally, a series of studies excluded from other meta-analyses due to accuracy concerns was included in this evaluation (246–248). When comparing crystalloid and albumin, the authors report a combined mortality benefit of albumin as compared to crystalloid (7 studies,  $n = 3,878$ ; OR, 0.93; 95% CI, 0.86–1.00), but it was not consistent across individual severity subgroups. Use of albumin in septic shock trended toward mortality benefit (4 studies;  $n = 1,949$ ; OR, 0.91; 95% CI, 0.82–1.01;  $p = 0.06$ ), and the use of albumin in sepsis was not significant (4 studies;  $n = 1,929$ ; OR, 0.96; 95% CI, 0.83–1.10). Evaluation of treatment within 24 hours also trended toward mortality benefit (4 studies;  $n = 3,832$ ; RR, 0.93; 95% CI, 0.86–1.01). Rochwerg 2014 et al (237) evaluated resuscitative fluid use in a network meta-analysis of 14 trials, encompassing 18,916 patients. When comparing albumin to crystalloid, there was no significant reduction in mortality with moderate quality of evidence in both the four- and six-node analyses (four-node: OR, 0.83; credible interval [CrI] 0.65–1.04; six-node OR 0.82; CrI 0.65–1.04).

The ALBIOS trial (249) showed no mortality benefit of albumin in combination with crystalloids compared to crystalloids alone in patients with sepsis or septic shock (RR, 0.94; 95% CI, 0.85–1.05); a subgroup analysis suggested that the albumin group was associated with lower 90-day mortality in patients with septic shock (RR, 0.87; 95% CI, 0.77–0.99). Fluid administration continued for 28 days or until discharge and was not targeted for acute resuscitation. In addition, the amount of 20% albumin was guided by serum albumin level with the ultimate goal of achieving levels  $> 30$  g/L. These results are limited by significant indirectness and imprecision, resulting in low quality of evidence.

HESs are colloids for which there are safety concerns in patients with sepsis. A meta-analysis of nine trials (3,456 patients) comparing 6% HES 130/0.38–0.45 solutions to crystalloids or albumin in patients with sepsis showed no difference in all-cause mortality (RR, 1.04; 95% CI, 0.89–1.22) (250). However, when low risk of bias trials were analyzed separately, HES use resulted in higher risk of death compared to other fluids (RR, 1.11; 95% CI, 1.01–1.22; high-quality evidence), which translates to 34 more deaths per 1,000 patients. Furthermore, HES use led to a higher risk of RRT (RR, 1.36; 95% CI, 1.08–1.72; high-quality evidence) (250). A subsequent network meta-analysis focused on acute resuscitation of patients with sepsis or septic shock and found that HES resulted in higher risk of death (10 RCTs; OR, 1.13; CrI, 0.99–1.30; high-quality evidence) and need for RRT (7 RCTs; OR, 1.39; CrI, 1.17–1.66; high-quality evidence) compared to crystalloids. When comparing albumin to HES, albumin resulted in lower risk of death (OR, 0.73; CrI, 0.56–0.93; moderate-quality evidence) and a

trend toward less need for RRT (OR, 0.74; CrI, 0.53–1.04; low-quality evidence) (237). Overall, the undesirable consequences of using HES (increased risk of death and need for RRT) along with moderate to high quality of available evidence resulted in a strong recommendation against the use of HES in resuscitation of patients with sepsis or septic shock.

Gelatin is another synthetic colloid that can be used for fluid resuscitation; however, high-quality studies comparing gelatins to other fluids in patients with sepsis or septic shock are lacking. Trials conducted in critically ill patients were summarized in a recent meta-analysis (251). Gelatin use in critically ill adult patients did not increase mortality (RR, 1.10; 95% CI, 0.85–1.43; low-quality evidence) or acute kidney injury (RR, 1.35; 95% CI, 0.58–3.14; very low-quality evidence) compared to albumin or crystalloid. These results are limited by indirectness, since the studies did not focus on critically ill patients. The aforementioned network meta-analysis by Rochwerg et al did not identify any RCTs comparing gelatins to crystalloids or albumin; therefore, the generated estimates were imprecise and were based on indirect comparisons (237). Given the low quality of the available data and the cost associated with gelatin use, we issued a weak recommendation favoring the use of crystalloids over gelatins.

## G. VASOACTIVE MEDICATIONS

1. We recommend norepinephrine as the first-choice vasopressor (strong recommendation, moderate quality of evidence).
2. We suggest adding either vasopressin (up to 0.03 U/min) (weak recommendation, moderate quality of evidence) or epinephrine (weak recommendation, low quality of evidence) to norepinephrine with the intent of raising MAP to target, or adding vasopressin (up to 0.03 U/min) (weak recommendation, moderate quality of evidence) to decrease norepinephrine dosage.
3. We suggest using dopamine as an alternative vasopressor agent to norepinephrine only in highly selected patients (e.g., patients with low risk of tachyarrhythmias and absolute or relative bradycardia) (weak recommendation, low quality of evidence).
4. We recommend against using low-dose dopamine for renal protection (strong recommendation, high quality of evidence).
5. We suggest using dobutamine in patients who show evidence of persistent hypoperfusion despite adequate fluid loading and the use of vasopressor agents (weak recommendation, low quality of evidence).

**Remarks:** If initiated, vasopressor dosing should be titrated to an end point reflecting perfusion, and the agent reduced or discontinued in the face of worsening hypotension or arrhythmias.

**Rationale.** The physiologic effects of vasopressors and combined inotrope/vasopressor selection in septic shock are outlined in an extensive number of literature reviews (252–261).

Norepinephrine increases MAP due to its vasoconstrictive effects, with little change in heart rate and less increase in stroke volume compared with dopamine. Dopamine increases MAP and cardiac output, primarily due to an increase in stroke volume and heart rate. Norepinephrine is more potent than dopamine and may be more effective at reversing hypotension in patients with septic shock. Dopamine may be particularly useful in patients with compromised systolic function but causes more tachycardia and may be more arrhythmogenic than norepinephrine (262). It may also influence the endocrine response via the hypothalamic pituitary axis and may have immunosuppressive effects (263). However, a recent systematic review and meta-analysis that included 11 randomized trials ( $n = 1,710$ ) comparing norepinephrine to dopamine does not support the routine use of dopamine in the management of septic shock (264). Indeed, norepinephrine use resulted in lower mortality (RR, 0.89; 95% CI, 0.81–0.98, high-quality evidence) and lower risk of arrhythmias (RR, 0.48; 95% CI, 0.40–0.58; high-quality evidence) compared with dopamine (**Supplemental Digital Content 8**, <http://links.lww.com/CCM/C329>).

Human and animal studies suggest that the infusion of epinephrine may have deleterious effects on the splanchnic circulation and produces hyperlactatemia. However, clinical trials do not demonstrate worsening of clinical outcomes. One RCT comparing norepinephrine to epinephrine demonstrated no difference in mortality but an increase in adverse drug-related events with epinephrine (265). Similarly, a meta-analysis of four randomized trials ( $n = 540$ ) comparing norepinephrine to epinephrine found no significant difference in mortality (RR, 0.96; CI, 0.77–1.21; low-quality evidence) (**Supplemental Digital Content 9**, <http://links.lww.com/CCM/C330>) (264). Epinephrine may increase aerobic lactate production via stimulation of skeletal muscle  $\beta_2$ -adrenergic receptors and thus may preclude the use of lactate clearance to guide resuscitation.

Vasopressin levels in septic shock have been reported to be lower than anticipated for a shock state (266). Low doses of vasopressin may be effective in raising blood pressure in patients refractory to other vasopressors and may have other potential physiologic benefits (266–271). Terlipressin has similar effects, but is long-acting (272). Studies show that vasopressin concentrations are elevated in early septic shock, but decrease to normal range in the majority of patients between 24 and 48 hours as shock continues (273). This finding has been called *relative vasopressin deficiency* because, in the presence of hypotension, vasopressin would be expected to be elevated. The significance of this finding is unknown. The VASST trial, an RCT comparing norepinephrine alone to norepinephrine plus vasopressin at 0.03 U/min, showed no difference in outcome in the intent-to-treat population (274). An a priori defined subgroup analysis demonstrated improved survival among patients receiving  $<15 \mu\text{g}/\text{min}$  norepinephrine at randomization with the addition of vasopressin; however, the pretrial rationale for this stratification was based on exploring potential benefit in the population requiring  $\geq 15 \mu\text{g}/\text{min}$  norepinephrine. Higher doses of vasopressin have been

associated with cardiac, digital, and splanchnic ischemia and should be reserved for situations in which alternative vasopressors have failed (275). In the VANISH trial, 409 patients with septic shock were randomized in a factorial ( $2 \times 2$ ) design to receive vasopressin with placebo or hydrocortisone, or norepinephrine with placebo or hydrocortisone. There was no significant difference in kidney failure-free days or death; however, the vasopressin group had less use of RRT (276). We conducted an updated meta-analysis to include the results of the VANISH trial. Data from nine trials ( $n = 1,324$  patients with septic shock), comparing norepinephrine with vasopressin (or terlipressin) demonstrated no significant difference in mortality (RR, 0.89; 95% CI, 0.79–1.00; moderate-quality evidence) (**Supplemental Digital Content 10**, <http://links.lww.com/CCM/C331>) (268, 271, 272, 277–279). Results were similar after excluding trials that used a combination of norepinephrine and vasopressin in the intervention arm (RR, 0.89; 95% CI, 0.77–1.02). Large studies comparing vasopressin to other vasopressors in septic shock are lacking; most of the data regarding vasopressin support a sparing effect on norepinephrine dose, and there is uncertainty about the effect of vasopressin on mortality. Norepinephrine, therefore, remains the first-choice vasopressor to treat patients with septic shock. We do not recommend the use of vasopressin as a first-line vasopressor for the support of MAP and would advocate caution when using it in patients who are not euvolemic or at doses higher than 0.03 U/min.

Phenylephrine is a pure  $\alpha$ -adrenergic agonist. Clinical trial data in sepsis are limited. Phenylephrine has the potential to produce splanchnic vasoconstriction (280). A network meta-analysis resulted in imprecise estimates (wide confidence intervals) when phenylephrine was compared to other vasopressors (281). Therefore, the impact on clinical outcomes is uncertain, and phenylephrine use should be limited until more research is available.

A large randomized trial and meta-analysis comparing low-dose dopamine to placebo found no difference in need for RRT, urine output, time to renal recovery, survival, ICU stay, hospital stay, or arrhythmias (282, 283). Thus, the available data do not support administration of low doses of dopamine solely to maintain renal function.

Myocardial dysfunction consequent to infection occurs in a subset of patients with septic shock, but cardiac output is usually preserved by ventricular dilation, tachycardia, and reduced vascular resistance (284). Some portion of these patients may have diminished cardiac reserve, and may not be able to achieve a cardiac output adequate to support oxygen delivery. Recognition of such reduced cardiac reserve can be challenging; imaging studies that show decreased ejection fraction may not necessarily indicate inadequate cardiac output. Concomitant measurement of cardiac output along with a measure of the adequacy of perfusion is preferable.

Routinely increasing cardiac output to predetermined “supranormal” levels in all patients clearly does not improve outcomes, as shown by two large prospective clinical trials of critically ill ICU patients with sepsis treated with dobutamine (285–287).

Some patients, however, may have improved tissue perfusion with inotropic therapy aimed at increasing oxygen delivery. In this situation, dobutamine is the first-choice inotrope for patients with measured or suspected low cardiac output in the presence of adequate left ventricular filling pressure (or clinical assessment of adequate fluid resuscitation) and adequate MAP. Monitoring the response of indices of perfusion to measured increases in cardiac output is the best way to target such a therapy (287).

The data supporting dobutamine are primarily physiologic, with improved hemodynamics and some improvement in indices of perfusion, which may include clinical improvement, decreasing lactate levels, and improvement in  $ScvO_2$ . No randomized controlled trials have compared the effects of dobutamine versus placebo on clinical outcomes. Mortality in patients randomized to dobutamine added to norepinephrine was no different compared to epinephrine (287), although the trial may have been underpowered. Dobutamine was used as the first-line inotrope as part of standard care in clinical trials of EGDT (16, 19, 288, 289), and adverse effects on mortality were not detected with its use.

Although there are only a few studies, alternative inotropic agents might be used to increase cardiac output in specific situations. Phosphodiesterase inhibitors increase intracellular cyclic AMP and thus have inotropic effects independent of  $\beta$ -adrenergic receptors. The phosphodiesterase inhibitor milrinone was shown to increase cardiac output in one small randomized trial of 12 pediatric patients, but the trial was underpowered for assessment of outcomes (290). Levosimendan increases cardiac myocyte calcium responsiveness and also opens ATP-dependent potassium channels, giving the drug both inotropic and vasodilatory properties. Given the potential role for abnormal calcium handling in sepsis-induced myocardial depression, the use of levosimendan has been proposed in septic shock as well. In a trial of 35 patients with septic shock and acute respiratory distress syndrome (ARDS) randomized to levosimendan or placebo, levosimendan improved right ventricular performance and mixed venous oxygen saturation compared to placebo (291). Trials comparing levosimendan with dobutamine are limited but show no clear advantage for levosimendan (292). Levosimendan is more expensive than dobutamine and is not available in many parts of the world. Six small RCTs (116 patients in total) compared levosimendan to dobutamine; pooled estimates showed no significant effect on mortality (RR, 0.83; 95% CI, 0.66–1.05; low quality) (**Supplemental Digital Content 11**, <http://links.lww.com/CCM/C332>). Given the low-quality evidence available and the higher cost associated with levosimendan, dobutamine remains the preferred choice in this population. An RCT enrolled 516 patients with septic shock who were randomized to receive either levosimendan or placebo; there was no difference in mortality. However, levosimendan led to significantly higher risk of supraventricular tachyarrhythmia than placebo (absolute difference, 2.7%; 95% CI, 0.1%–5.3%) (293). The results of this trial question the systematic use of this agent in patients with septic shock. Of note, cardiac function was not

evaluated in that trial, and inotropic stimulation may be of benefit in patients with a low cardiac output due to impaired cardiac function.

- 6. We suggest that all patients requiring vasopressors have an arterial catheter placed as soon as practical if resources are available (weak recommendation, very low quality of evidence).**

**Rationale.** In shock states, estimation of blood pressure using a cuff, especially an automated measurement system, may be inaccurate. Use of an arterial cannula provides a more accurate and reproducible measurement of arterial pressure (287, 294) and also allows beat-to-beat analysis so that decisions regarding therapy can be based on immediate and reproducible blood pressure information (295). Insertion of radial arterial catheters is generally safe; a systematic review of observational studies showed an incidence of limb ischemia and bleeding to be less than 1%, with the most common complication being localized hematoma (14%) (296). Complication rates may be lower if an ultrasound-guided technique is used (297). A recent systematic review showed higher risk of infections when femoral arterial catheters were used compared to radial artery catheters (RR, 1.93; 95% CI, 1.32–2.84), and the overall pooled incidence of bloodstream infection was 3.4 per 1,000 catheters (298). Large randomized trials that compare arterial blood pressure monitoring versus noninvasive methods are lacking.

In view of the low complication rate and likely better estimation of blood pressure but potentially limited resources in some countries, and the lack of high quality studies, the benefits of arterial catheters probably outweigh the risks. Therefore, we issued a weak recommendation in favor of arterial catheter placement. Arterial catheters should be removed as soon as continuous hemodynamic monitoring is not required to minimize the risk of complications.

## H. CORTICOSTEROIDS

- 1. We suggest against using IV hydrocortisone to treat septic shock patients if adequate fluid resuscitation and vasopressor therapy are able to restore hemodynamic stability. If this is not achievable, we suggest IV hydrocortisone at a dose of 200 mg per day (weak recommendation, low quality of evidence).**

**Rationale.** The response of septic shock patients to fluid and vasopressor therapy seems to be an important factor in selection of patients for optional hydrocortisone therapy. One French multicenter RCT of patients in vasopressor-unresponsive septic shock (systolic blood pressure < 90 mm Hg despite fluid resuscitation and vasopressors for more than one hour) showed significant shock reversal and reduction of mortality rate in patients with relative adrenal insufficiency (defined as a maximal post-adrenocorticotrophic hormone [ACTH] cortisol increase  $\leq 9$   $\mu$ g/dL) (299). Two smaller RCTs also showed significant effects on shock reversal with steroid therapy (300, 301). In contrast, a large, European multicenter trial (CORTICUS)

that enrolled patients with systolic blood pressure of < 90 mm Hg despite adequate fluid replacement or need for vasopressors had a lower risk of death than the French trial and failed to show a mortality benefit with steroid therapy (302). There was no difference in mortality in groups stratified by ACTH response.

Several systematic reviews have examined the use of low-dose hydrocortisone in septic shock with contradictory results. Annane et al (299) analyzed the results of 12 studies and calculated a significant reduction in 28-day mortality with prolonged low-dose steroid treatment in adult septic shock patients (RR, 0.84; 95% CI, 0.72–0.97;  $p = 0.02$ ). In parallel, Sligl et al (303) used a similar technique, but identified only eight studies for their meta-analysis, six of which had a high-level RCT design with low risk of bias. In contrast to the aforementioned review, this analysis revealed no statistically significant difference in mortality (RR, 1.00; 95% CI, 0.84–1.18). Both reviews, however, confirmed the improved shock reversal by using low-dose hydrocortisone. More recently, Annane et al included 33 eligible trials ( $n = 4,268$ ) in a new systematic review (304). Of these 33 trials, 23 were at low risk of selection bias; 22 were at low risk of performance and detection bias; 27 were at low risk of attrition bias; and 14 were at low risk of selective reporting. Corticosteroids reduced 28-day mortality (27 trials;  $n = 3,176$ ; RR, 0.87; 95% CI, 0.76–1.00). Treatment with a long course of low-dose corticosteroids significantly reduced 28-day mortality (22 trials; RR, 0.87; 95% CI, 0.78–0.97). Corticosteroids also reduced ICU mortality (13 trials; RR, 0.82; 95% CI, 0.68–1.00) and in hospital mortality (17 trials; RR, 0.85; 95% CI, 0.73–0.98). Corticosteroids increased the proportion of shock reversal by day 7 (12 trials; RR, 1.31; 95% CI, 1.14–1.51) and by day 28 (seven trials;  $n = 1,013$ ; RR, 1.11; 95% CI, 1.02–1.21). Finally, an additional systematic review by Volbeda et al including a total of 35 trials randomizing 4,682 patients has been published (all but two trials had high risk of bias) (305). Conversely, in this review, no statistically significant effect on mortality was found for any dose of steroids versus placebo or for no intervention at maximal follow-up. The two trials with low risk of bias also showed no statistically significant difference (random-effects model RR, 0.38; 95% CI, 0.06–2.42). Similar results were obtained in subgroups of trials stratified according to hydrocortisone (or equivalent) at high (> 500 mg) or low ( $\leq 500$  mg) doses (RR, 0.87; trial sequential analysis [TSA]-adjusted CI, 0.38–1.99; and RR, 0.90; TSA-adjusted CI, 0.49–1.67, respectively). No statistically significant effects on serious adverse events other than mortality were reported (RR, 1.02; TSA-adjusted CI, 0.7–1.48). In the absence of convincing evidence of benefit, we issue a weak recommendation against the use of corticosteroids to treat septic shock patients if adequate fluid resuscitation and vasopressor therapy are able to restore hemodynamic stability.

In one study, the observation of a potential interaction between steroid use and ACTH test was not statistically significant (306). Furthermore, no evidence of this distinction was observed between responders and nonresponders in a recent multicenter trial (302). Random cortisol levels may

still be useful for absolute adrenal insufficiency; however, for septic shock patients who have relative adrenal insufficiency (no adequate stress response), random cortisol levels have not been demonstrated to be useful. Cortisol immunoassays may over- or underestimate the actual cortisol level, affecting the assignment of patients to responders or non-responders (307). Although the clinical significance is not clear, it is now recognized that etomidate, when used for induction for intubation, will suppress the hypothalamic-pituitary-adrenal axis (308, 309). Moreover, a subanalysis of the CORTICUS trial revealed that the use of etomidate before application of low-dose steroids was associated with an increased 28-day mortality rate (302).

There has been no comparative study between a fixed-duration and clinically guided regimen or between tapering and abrupt cessation of steroids. Three RCTs used a fixed-duration protocol for treatment (300, 302, 306), and therapy was decreased after shock resolution in two RCTs (301, 310). In four studies, steroids were tapered over several days (300–302, 310) and steroids were withdrawn abruptly in two RCTs (306, 311). One crossover study showed hemodynamic and immunologic rebound effects after abrupt cessation of corticosteroids (312). Further, one study revealed no difference in outcome of septic shock patients if low-dose hydrocortisone is used for 3 or 7 days; hence, we suggest tapering steroids when vasopressors are no longer needed (313).

Steroids may be indicated when there is a history of steroid therapy or adrenal dysfunction, but whether low-dose steroids have a preventive potency in reducing the incidence of sepsis and septic shock in critically ill patients cannot be answered. A recent large multicenter RCT demonstrated no reduction in the development of septic shock in septic patients treated with hydrocortisone versus placebo (314); steroids should not be used in septic patients to prevent septic shock. Additional studies are underway that may provide additional information to inform clinical practice.

Several randomized trials on the use of low-dose hydrocortisone in septic shock patients revealed a significant increase of hyperglycemia and hyponatremia (306) as side effects. A small prospective study demonstrated that repetitive bolus application of hydrocortisone leads to a significant increase in blood glucose; this peak effect was not detectable during continuous infusion. Further, considerable inter-individual variability was seen in this blood glucose peak after the hydrocortisone bolus (315). Although an association of hyperglycemia and hyponatremia with patient outcome measures could not be shown, good practice includes strategies for avoidance and/or detection of these side effects.

## I. BLOOD PRODUCTS

1. We recommend that RBC transfusion occur only when hemoglobin concentration decreases to < 7.0g/dL in adults in the absence of extenuating circumstances, such as myocardial ischemia, severe hypoxemia, or acute hemorrhage (strong recommendation, high quality of evidence).

**Rationale.** Two clinical trials in septic patients evaluated specific blood transfusion thresholds. The Transfusion Requirements In Septic Shock (TRISS) trial addressed a transfusion threshold of 7 g/dL versus 9 g/dL in septic shock patients after admission to the ICU (316). Results showed similar 90-day mortality, ischemic events, and use of life support in the two treatment groups with fewer transfusions in the lower-threshold group. The hemoglobin targets in two of the three treatment arms in the Protocol-Based Care for Early Septic Shock (ProCESS) trial were a subpart of a more comprehensive sepsis management strategy (18). The EGDT group received transfusion at a hematocrit < 30% (hemoglobin 10 g/dL) when the  $ScvO_2$  was < 70% after initial resuscitation interventions compared to the protocol-based standard care group that received blood transfusion only when the hemoglobin was < 7.5 g/dL. No significant differences were found between the two groups for 60-day in-hospital mortality or 90-day mortality. Although the ProCESS trial is a less direct assessment of blood transfusion therapy, it does provide important information in regard to transfusion in the acute resuscitative phase of sepsis. We judge the evidence to be high certainty that there is little difference in mortality, and, if there is, that it would favor lower hemoglobin thresholds.

**2. We recommend against the use of erythropoietin for treatment of anemia associated with sepsis (strong recommendation, moderate quality of evidence).**

**Rationale.** No specific information regarding erythropoietin use in septic patients is available, and clinical trials of erythropoietin administration in critically ill patients show a small decrease in red cell transfusion requirement with no effect on mortality (317, 318). The effect of erythropoietin in sepsis and septic shock would not be expected to be more beneficial than in other critical conditions. Erythropoietin administration may be associated with an increased incidence of thrombotic events in the critically ill. Patients with sepsis and septic shock may have coexisting conditions that meet indications for the use of erythropoietin or similar agents.

**3. We suggest against the use of fresh frozen plasma to correct clotting abnormalities in the absence of bleeding or planned invasive procedures (weak recommendation, very low quality of evidence).**

**Rationale.** No RCTs exist related to prophylactic fresh frozen plasma transfusion in septic or critically ill patients with coagulation abnormalities. Current recommendations are based primarily on expert opinion that fresh frozen plasma be transfused when there is a documented deficiency of coagulation factors (increased prothrombin time, international normalized ratio, or partial thromboplastin time) and the presence of active bleeding or before surgical or invasive procedures (319). In addition, transfusion of fresh frozen plasma usually fails to correct the prothrombin time in nonbleeding patients with mild abnormalities. No studies suggest that correction of more severe coagulation abnormalities benefits patients who are not bleeding.

**4. We suggest prophylactic platelet transfusion when counts are < 10,000/mm<sup>3</sup> ( $10 \times 10^9/L$ ) in the absence of apparent bleeding and when counts are < 20,000/mm<sup>3</sup> ( $20 \times 10^9/L$ ) if the patient has a significant risk of bleeding. Higher platelet counts ( $\geq 50,000/mm^3$  [ $50 \times 10^9/L$ ]) are advised for active bleeding, surgery, or invasive procedures (weak recommendation, very low quality of evidence).**

**Rationale.** No RCTs of prophylactic platelet transfusion in septic or critically ill patients exist. Current recommendations and guidelines for platelet transfusion are based on clinical trials of prophylactic platelet transfusion in patients with therapy-induced thrombocytopenia (usually leukemia and stem cell transplant) (320–327). Thrombocytopenia in sepsis is likely due to a different pathophysiology of impaired platelet production and increased platelet consumption. Factors that may increase the bleeding risk and indicate the need for a higher platelet count are frequently present in patients with sepsis.

## J. IMMUNOGLOBULINS

**1. We suggest against the use of IV immunoglobulins in patients with sepsis or septic shock (weak recommendation, low quality of evidence).**

**Rationale.** There were no new studies informing this guideline recommendation. One larger multicenter RCT (n = 624) (328) in adult patients found no benefit for IV immunoglobulin (IVIg). The most recent Cochrane meta-analysis (329) differentiates between standard polyclonal IV immunoglobulins (IVIgG) and immunoglobulin M-enriched polyclonal Ig (IVIgGM). In 10 studies with IVIgG (1,430 patients), mortality between 28 and 180 days was 29.6% in the IVIgG group and 36.5% in the placebo-group (RR, 0.81; 95% CI, 0.70–0.93), and for the seven studies with IVIgGM (528 patients), mortality between 28 and 60 days was 24.7% in the IVIgGM group and 37.5% in the placebo-group (RR, 0.66; 95% CI, 0.51–0.85). The certainty of the studies was rated as low for the IVIgG trials, based on risk of bias and heterogeneity, and as moderate for the IVIgGM trials, based on risk of bias. Comparable results were found in other meta-analyses (330). However, after excluding low-quality trials, the recent Cochrane analysis (329) revealed no survival benefit.

These findings are in accordance with those of two older meta-analyses (331, 332) from other Cochrane authors. One systematic review (332) included a total of 21 trials and showed a reduction in death with immunoglobulin treatment (RR, 0.77; 95% CI, 0.68–0.88); however, the results of only high-quality trials (total of 763 patients) did not show a statistically significant difference (RR, 1.02; 95% CI, 0.84–1.24). Similarly, Laupland et al (331) found a significant reduction in mortality with the use of IVIg treatment (OR, 0.66; 95% CI, 0.53–0.83;  $p < 0.005$ ). When only high-quality studies were pooled, the results were no longer statistically significant (OR, 0.96); OR for mortality was 0.96 (95% CI, 0.71–1.3;  $p = 0.78$ ). Two meta-analyses that used less strict criteria to identify sources of bias

or did not state their criteria for the assessment of study quality found significant improvement in patient mortality with IVIg treatment (333–335). Finally, there are no cutoffs for plasma IgG levels in septic patients, for which substitution with IVIgG improves outcome data (334).

Most IVIg studies are small, and some have a high risk of bias; the only large study ( $n = 624$ ) showed no effect (328). Subgroup effects between IgM-enriched and non-enriched formulations reveal significant heterogeneity. Indirectness and publication bias were considered, but not invoked in grading this recommendation. The low certainty of evidence led to the grading as a weak recommendation. The statistical information that comes from the high-quality trials does not support a beneficial effect of polyclonal IVIg. We encourage conduct of large multicenter studies to further evaluate the effectiveness of other IV polyclonal immunoglobulin preparations in patients with sepsis.

## K. BLOOD PURIFICATION

### 1. We make no recommendation regarding the use of blood purification techniques.

**Rationale.** Blood purification includes various techniques, such as high-volume hemofiltration and hemoabsorption (or hemoperfusion), where sorbents, removing either endotoxin or cytokines, are placed in contact with blood; plasma exchange or plasma filtration, through which plasma is separated from whole blood, removed, and replaced with normal saline, albumin, or fresh frozen plasma; and the hybrid system: coupled plasma filtration adsorption (CPFA), which combines plasma filtration and adsorption by a resin cartridge that removes cytokines.

When these modalities of blood purification are considered versus conventional treatment, the available trials are, overall, small, unblinded, and with high risk of bias. Patient selection was unclear and differed with the various techniques. Hemoabsorption is the technique most largely investigated, in particular with polymyxin B-immobilized polystyrene-derived fibers to remove endotoxin from the blood. A recent meta-analysis demonstrated a favorable effect on overall mortality with this technique (336). The composite effect, however, depends on a series of studies performed in a single country (Japan), predominantly by one group of investigators. A recent large RCT performed on patients with peritonitis related to organ perforation within 12 hours after emergency surgery found no benefit of polymyxin B hemoperfusion on mortality and organ failure, as compared to standard treatment (337). Illness severity of the study patients, however, was low overall, which makes these findings questionable. A multicenter blinded RCT is ongoing, which should provide stronger evidence regarding this technique (338).

Few RCTs evaluated plasma filtration, alone or combined with adsorption for cytokine removal (CPFA). A recent RCT comparing CPFA with standard treatment was stopped for futility (339). About half of the patients randomized to CPFA

were undertreated, primarily because of clotting of the circuit, which raises doubts about CPFA feasibility.

In consideration of all these limitations, our confidence in the evidence is very low either in favor of or against blood purification techniques; therefore, we do not provide a recommendation. Further research is needed to clarify the clinical benefit of blood purification techniques.

## L. ANTICOAGULANTS

### 1. We recommend against the use of antithrombin for the treatment of sepsis and septic shock (strong recommendation, moderate quality of evidence).

**Rationale.** Antithrombin is the most abundant anticoagulant circulating in plasma. The decrease of its plasma activity at onset of sepsis correlates with disseminated intravascular coagulation (DIC) and lethal outcome. However, a phase III clinical trial of high-dose antithrombin for adults with sepsis and septic shock as well as systematic reviews of antithrombin for critically ill patients did not demonstrate any beneficial effect on overall mortality. Antithrombin was associated with an increased risk of bleeding (340, 341). Although post hoc subgroup analyses of patients with sepsis associated with DIC showed better survival in patients receiving antithrombin, this agent cannot be recommended until further clinical trials are performed.

### 2. We make no recommendation regarding the use of thrombomodulin or heparin for the treatment of sepsis or septic shock.

**Rationale:** Most RCTs of recombinant soluble thrombomodulin have been targeted for sepsis associated with DIC, and a systematic review suggested a beneficial effect on survival without an increase of bleeding risk (342, 343). A phase III RCT is ongoing for sepsis associated with DIC. The guideline panel has elected to make no recommendation pending these new results. Two systematic reviews showed a potential survival benefit of heparin in patients with sepsis without an increase in major bleeding (344). However, overall impact remains uncertain, and heparin cannot be recommended until further RCTs are performed.

Recombinant activated protein C, which was originally recommended in the 2004 and 2008 SSC guidelines, was not shown to be effective for adult patients with septic shock by the PROWESS-SHOCK trial, and was withdrawn from the market (345).

## M. MECHANICAL VENTILATION

### 1. We recommend using a target tidal volume of 6 mL/kg predicted body weight (PBW) compared with 12 mL/kg in adult patients with sepsis-induced ARDS (strong recommendation, high quality of evidence).

### 2. We recommend using an upper limit goal for plateau pressures of 30 cm H<sub>2</sub>O over higher plateau pressures in adult patients with sepsis-induced severe ARDS (strong recommendation, moderate quality of evidence).



**Rationale.** This recommendation is unchanged from the previous guidelines. Of note, the studies that guide the recommendations in this section enrolled patients using criteria from the American-European Consensus Criteria Definition for Acute Lung Injury and ARDS (346). For the current document, we used the 2012 Berlin definition and the terms *mild*, *moderate*, and *severe ARDS* ( $\text{PaO}_2/\text{FiO}_2 \leq 300$ ,  $\leq 200$ , and  $\leq 100$  mm Hg, respectively) (347). Several multicenter randomized trials have been performed in patients with established ARDS to evaluate the effects of limiting inspiratory pressure through moderation of tidal volume (348–351). These studies showed differing results, which may have been caused by differences in airway pressures in the treatment and control groups (347, 350, 352). Several meta-analyses suggest decreased mortality in patients with a pressure- and volume-limited strategy for established ARDS (353, 354).

The largest trial of a volume- and pressure-limited strategy showed 9% absolute decrease in mortality in ARDS patients ventilated with tidal volumes of 6 mL/kg compared with 12 mL/kg PBW, and aiming for plateau pressure  $\leq 30$  cm H<sub>2</sub>O (350). The use of lung-protective strategies for patients with ARDS is supported by clinical trials and has been widely accepted; however, the precise tidal volume for an individual ARDS patient requires adjustment for factors such as the plateau pressure, the selected positive end-expiratory pressure (PEEP), thoracoabdominal compliance, and the patient's breathing effort. Patients with profound metabolic acidosis, high minute ventilation, or short stature may require additional manipulation of tidal volumes. Some clinicians believe it may be safe to ventilate with tidal volumes  $> 6$  mL/kg PBW as long as plateau pressure can be maintained  $\leq 30$  cm H<sub>2</sub>O (355, 356). The validity of this ceiling value will depend on the patient's effort, because those who are actively breathing generate higher transpulmonary pressures for a given plateau pressure than patients who are passively inflated. Conversely, patients with very stiff chest/abdominal walls and high pleural pressures may tolerate plateau pressures  $> 30$  cm H<sub>2</sub>O because transpulmonary pressures will be lower. A retrospective study suggested that tidal volumes should be lowered even with plateau pressures  $\leq 30$  cm H<sub>2</sub>O (357) because lower plateau pressures were associated with reduced hospital mortality (358). A recent patient-level mediation analysis suggested that a tidal volume that results in a driving pressure (plateau pressure minus set PEEP) below 12–15 cm H<sub>2</sub>O may be advantageous in patients without spontaneous breathing efforts (359). Prospective validation of tidal volume titration by driving pressure is needed before this approach can be recommended.

High tidal volumes coupled with high plateau pressures should be avoided in ARDS. Clinicians should use as a starting point the objective of reducing tidal volume over 1 to 2 hours from its initial value toward the goal of a “low” tidal volume ( $\approx 6$  mL/kg PBW) achieved in conjunction with an end-inspiratory plateau pressure  $\leq 30$  cm H<sub>2</sub>O. If plateau pressure remains  $> 30$  cm H<sub>2</sub>O after reduction of tidal volume to 6 mL/kg PBW, tidal volume may be further reduced to as low as 4 mL/kg PBW. Respiratory rate should be increased to a

maximum of 35 breaths/minute during tidal volume reduction to maintain minute ventilation. Volume- and pressure-limited ventilation may lead to hypercapnia even with these maximum tolerated set respiratory rates; this appears to be tolerated and safe in the absence of contraindications (e.g., high intracranial pressure, sickle cell crisis).

No single mode of ventilation (pressure control, volume control) has consistently been shown to be advantageous when compared with any other that respects the same principles of lung protection.

### 3. We suggest using higher PEEP over lower PEEP in adult patients with sepsis-induced moderate to severe ARDS (weak recommendation, moderate quality of evidence).

**Rationale.** Raising PEEP in ARDS may open lung units to participate in gas exchange. This may increase  $\text{PaO}_2$  when PEEP is applied through either an endotracheal tube or a face mask (360–362). In animal experiments, avoidance of end-expiratory alveolar collapse helps minimize ventilator-induced lung injury when relatively high plateau pressures are in use. Three large multicenter trials and a pilot trial using higher versus lower levels of PEEP in conjunction with low tidal volumes did not show benefit or harm (363–366). A patient-level meta-analysis showed no benefit in all patients with ARDS; however, patients with moderate or severe ARDS ( $\text{PaO}_2/\text{FiO}_2 \leq 200$  mm Hg) had decreased mortality with the use of higher PEEP, whereas those with mild ARDS did not (367). A patient-level analysis of two of the randomized PEEP trials suggested a survival benefit if  $\text{PaO}_2/\text{FiO}_2$  increased with higher PEEP and harm if  $\text{PaO}_2/\text{FiO}_2$  fell (368). A small randomized trial suggested that adjusting PEEP to obtain a positive transpulmonary pressure as estimated by esophageal manometry improved outcomes; a confirmatory trial is underway (369). An analysis of nearly all the randomized trials of lung-protective ventilation suggested a benefit of higher PEEP if driving pressure fell with increased PEEP, presumably indicating increased lung compliance from opening of lung units (359).

While moderate-quality evidence suggests that higher PEEP improves outcomes in moderate to severe ARDS, the optimal method for selecting a higher PEEP level is unclear. One option is to titrate PEEP according to bedside measurements of thoracopulmonary compliance with the objective of obtaining the best compliance or lowest driving pressure, reflecting a favorable balance of lung recruitment and overdistension (370). The second option is to titrate PEEP upward on a tidal volume of 6 mL/kg PBW until the plateau airway pressure is 28 cm H<sub>2</sub>O (365). A third option is to use a PEEP/ $\text{FiO}_2$  titration table that titrates PEEP based on the combination of  $\text{FiO}_2$  and PEEP required to maintain adequate oxygenation (350, 363–365, 368). A PEEP  $> 5$  cm H<sub>2</sub>O is usually required to avoid lung collapse (371).

### 4. We suggest using recruitment maneuvers in adult patients with sepsis-induced, severe ARDS (weak recommendation, moderate quality of evidence).

**Rationale.** Many strategies exist for treating refractory hypoxemia in patients with severe ARDS (372). Temporarily raising

transpulmonary pressure may facilitate opening atelectatic alveoli to permit gas exchange (371), but could also overdistend aerated lung units, leading to ventilator-induced lung injury and transient hypotension. The application of sustained continuous positive airway pressure (CPAP) appears to improve survival (RR, 0.84; 95% CI, 0.74–0.95) and reduce the occurrence of severe hypoxia requiring rescue therapy (RR, 0.76; 95% CI, 0.41–1.40) in patients with ARDS. Although the effects of recruitment maneuvers improve oxygenation initially, the effects can be transient (373). Selected patients with severe hypoxemia may benefit from recruitment maneuvers in conjunction with higher levels of PEEP, but little evidence supports the routine use in all ARDS patients (373). Any patient receiving this therapy should be monitored closely and recruitment maneuvers discontinued if deterioration in clinical variables is observed.

**5. We recommend using prone over supine position in adult patients with sepsis-induced ARDS and a  $P_{aO_2}/F_{iO_2}$  ratio < 150 (strong recommendation, moderate quality of evidence).**

**Rationale:** In patients with ARDS and a  $P_{aO_2}/F_{iO_2}$  ratio < 150, the use of prone compared with supine position within the first 36 hours of intubation, when performed for > 16 hours a day, showed improved survival (374). Meta-analysis including this study demonstrated reduced mortality in patients treated with prone compared with supine position (RR, 0.85; 95% CI, 0.71–1.01) as well as improved oxygenation as measured by change in  $P_{aO_2}/F_{iO_2}$  ratio (median 24.03 higher, 95% CI, 13.3–34.7 higher) (375). Most patients respond to the prone position with improved oxygenation and may also have improved lung compliance (374, 376–379). While prone position may be associated with potentially life-threatening complications including accidental removal of the endotracheal tube, this was not evident in pooled analysis (RR, 1.09; 95% CI, 0.85–1.39). However, prone position was associated with an increase in pressure sores (RR, 1.37; 95% CI, 1.05–1.79) (375), and some patients have contraindications to the prone position (374).

In patients with refractory hypoxia, alternative strategies, including airway pressure release ventilation and extracorporeal membrane oxygenation, may be considered as rescue therapies in experienced centers (372, 380–383).

**6. We recommend against using high-frequency oscillatory ventilation (HFOV) in adult patients with sepsis-induced ARDS (strong recommendation, moderate quality of evidence).**

**Rationale:** HFOV has theoretical advantages that make it an attractive ventilator mode for patients with ARDS. Two large RCTs evaluating routine HFOV in moderate-severe ARDS have been recently published (384, 385). One trial was stopped early because the mortality was higher in patients randomized to HFOV (384). Including these recent studies, a total of five RCTs (1,580 patients) have examined the role of HFOV in ARDS. Pooled analysis demonstrates no effect on mortality (RR, 1.04; 95% CI, 0.83–1.31) and an increased duration of

mechanical ventilation (MD, 1.1 days higher; 95% CI, 0.03–2.16) in patients randomized to HFOV. An increase in barotrauma was seen in patients receiving HFOV (RR, 1.19; 95% CI, 0.83–1.72); however, this was based on very low-quality evidence.

The role of HFOV as a rescue technique for refractory ARDS remains unclear; however, we recommend against its early use in moderate-severe ARDS given the lack of demonstrated benefit and a potential signal for harm.

**7. We make no recommendation regarding the use of noninvasive ventilation (NIV) for patients with sepsis-induced ARDS.**

**Rationale.** NIV may have theoretical benefits in patients with sepsis-induced respiratory failure, such as better communication abilities, reduced need for sedation, and avoidance of intubation. However, NIV may preclude the use of low tidal volume ventilation or achieving adequate levels of PEEP, two ventilation strategies that have shown benefit even in mild-moderate ARDS (365, 386). Also, in contrast to indications such as cardiogenic pulmonary edema or chronic obstructive pulmonary disease exacerbation where NIV use is brief, ARDS often takes days or weeks to improve, and prolonged NIV use may lead to complications such as facial skin breakdown, inadequate nutritional intake, and failure to rest respiratory muscles.

A few small RCTs have shown benefit with NIV for early or mild ARDS or de novo hypoxic respiratory failure; however, these were in highly selected patient populations (387, 388). More recently, a larger RCT in patients with hypoxemic respiratory failure compared NIV to traditional oxygen therapy or high-flow nasal cannula (389). This study demonstrated improved 90-day survival with high-flow oxygen compared with standard therapy or NIV; however, the NIV technique was not standardized and the experience of the centers varied. Although high-flow oxygen has not been addressed here, it is possible that this technique may play a more prominent role in the treatment of hypoxic respiratory failure and ARDS moving forward.

Given the uncertainty regarding whether clinicians can identify ARDS patients in whom NIV might be beneficial, we have not made a recommendation for or against this intervention. If NIV is used for patients with ARDS, we suggest close monitoring of tidal volumes

**8. We suggest using neuromuscular blocking agents (NMBAs) for ≤ 48 hours in adult patients with sepsis-induced ARDS and a  $P_{aO_2}/F_{iO_2}$  ratio < 150 mm Hg (weak recommendation, moderate quality of evidence).**

**Rationale:** The most common indication for NMBA use in the ICU is to facilitate mechanical ventilation (390). When appropriately used, these agents may improve chest wall compliance, prevent respiratory dyssynchrony, and reduce peak airway pressures (391). Muscle paralysis may also reduce oxygen consumption by decreasing the work of breathing and respiratory muscle blood flow (392). However, a placebo-controlled RCT

in patients with severe sepsis demonstrated that oxygen delivery, oxygen consumption, and gastric intramucosal pH were not improved during deep neuromuscular blockade (393).

An RCT of continuous infusions of cisatracurium in patients with early ARDS and a  $\text{PaO}_2/\text{FiO}_2 < 150$  mm Hg showed improved adjusted survival rates and more organ failure-free days without an increased risk in ICU-acquired weakness compared with placebo-treated patients (394). The investigators used a high fixed dose of cisatracurium without train-of-four monitoring; half of the patients in the placebo group received at least a single NMBA dose. Of note, groups in both the intervention and control groups were ventilated with volume-cycled and pressure-limited mechanical ventilation. Although many of the patients in this trial appeared to meet sepsis criteria, it is not clear whether similar results would occur in sepsis patients or in patients ventilated with alternate modes. Pooled analysis including three trials that examined the role of NMBAs in ARDS, including the one above, showed improved survival (RR, 0.72; 95% CI, 0.58–0.91) and a decreased frequency of barotrauma (RR, 0.43; 95% CI, 0.20–0.90) in those receiving NMBAs (395).

An association between NMBA use and myopathies and neuropathies has been suggested by case studies and prospective observational studies in the critical care population (391, 396–399), but the mechanisms by which NMBAs produce or contribute to myopathies and neuropathies in these patients are unknown. Pooled analysis of the RCT data did not show an increase in neuromuscular weakness in those who received NMBAs (RR, 1.08; 95% CI, 0.83–1.41); however, this was based on very low quality of evidence (395). Given the uncertainty that still exists pertaining to these important outcomes and the balance between benefits and potential harms, the panel decided that a weak recommendation was most suitable. If NMBAs are used, clinicians must ensure adequate patient sedation and analgesia (400, 401); recently updated clinical practice guidelines are available for specific guidance (402).

**9. We recommend a conservative fluid strategy for patients with established sepsis-induced ARDS who do not have evidence of tissue hypoperfusion (strong recommendation, moderate quality of evidence).**

**Rationale:** Mechanisms for the development of pulmonary edema in patients with ARDS include increased capillary permeability, increased hydrostatic pressure, and decreased oncotic pressure (403). Small prospective studies in patients with critical illness and ARDS have suggested that low weight gain is associated with improved oxygenation (404) and fewer days of mechanical ventilation (405, 406). A fluid-conservative strategy to minimize fluid infusion and weight gain in patients with ARDS, based on either a CVP or a pulmonary artery (PA) catheter (PA wedge pressure) measurement, along with clinical variables to guide treatment, led to fewer days of mechanical ventilation and reduced ICU LOS without altering the incidence of renal failure or mortality rates (407). This strategy was only used in patients with established ARDS, some of whom had shock during their ICU stay, and active attempts to reduce fluid volume were conducted only outside periods of shock.

**10. We recommend against the use of  $\beta$ -2 agonists for the treatment of patients with sepsis-induced ARDS without bronchospasm (strong recommendation, moderate quality of evidence).**

**Rationale:** Patients with sepsis-induced ARDS often develop increased vascular permeability; preclinical data suggest that  $\beta$ -adrenergic agonists may hasten resorption of alveolar edema (408). Three RCTs (646 patients) evaluated  $\beta$ -agonists in patients with ARDS (408–410). In two of these trials, salbutamol (15  $\mu\text{g}/\text{kg}$  of ideal body weight) delivered intravenously (408, 409) was compared with placebo, while the third trial compared inhaled albuterol versus placebo (410). Group allocation was blinded in all three trials, and two trials were stopped early for futility or harm (409, 411). More than half of the patients enrolled in all three trials had pulmonary or non-pulmonary sepsis as the cause of ARDS.

Pooled analysis suggests  $\beta$ -agonists may reduce survival to hospital discharge in ARDS patients (RR, 1.22; 95% CI, 0.95–1.56) while significantly decreasing the number of ventilator-free days (MD,  $-2.19$ ; 95% CI,  $-3.68$  to  $-0.71$ ) (412).  $\beta$ -agonist use also led to more arrhythmias (RR, 1.97; 95% CI, 0.70–5.54) and more tachycardia (RR, 3.95; 95% CI, 1.41–11.06).

$\beta$ -2 agonists may have specific indications in the critically ill, such as the treatment of bronchospasm and hyperkalemia. In the absence of these conditions, we recommend against the use of  $\beta$ -agonists, either in IV or aerosolized form, for the treatment of patients with sepsis-induced ARDS.

**11. We recommend against the routine use of the PA catheter for patients with sepsis-induced ARDS (strong recommendation, high quality of evidence).**

**Rationale:** This recommendation is unchanged from the previous guidelines. Although insertion of a PA catheter may provide useful information regarding volume status and cardiac function, these benefits may be confounded by differences in interpretation of the results (413, 414), poor correlation of PA occlusion pressures with clinical response (415), and lack of a PA catheter-based strategy demonstrated to improve patient outcomes (416). Pooled analysis of two multicenter randomized trials, one with 676 patients with shock or ARDS (417) and another with 1,000 patients with ARDS (418), failed to show any benefit associated with PA catheter use on mortality (RR, 1.02; 95% CI, 0.96–1.09) or ICU LOS (mean difference 0.15 days longer; 95% CI, 0.74 days fewer – 1.03 days longer) (407, 419–421). This lack of demonstrated benefit must be considered in the context of the increased resources required. Notwithstanding, selected sepsis patients may be candidates for PA catheter insertion if management decisions depend on information solely obtainable from PA catheter measurements.

**12. We suggest using lower tidal volumes over higher tidal volumes in adult patients with sepsis-induced respiratory failure without ARDS (weak recommendation, low quality of evidence).**

**Rationale:** Low tidal volume ventilation (4–6 mL/kg) has been shown to be beneficial in patients with established ARDS (422) by limiting ventilator-induced lung injury. However, the effect of volume- and pressure-limited ventilation is less clear in patients with sepsis who do not have ARDS. Meta-analysis demonstrates the benefits of low tidal volume ventilation in patients without ARDS, including a decrease in the duration of mechanical ventilation (MD, 0.64 days fewer; 95% CI, 0.49–0.79) and the decreased development of ARDS (RR, 0.30; 95% CI, 0.16–0.57) with no impact on mortality (RR, 0.95; 95% CI, 0.64–1.41). Importantly, the certainty in this data is limited by indirectness because the included studies varied significantly in terms of populations enrolled, mostly examining perioperative patients and very few focusing on ICU patients. The use of low tidal volumes in patients who undergo abdominal surgery, which may include sepsis patients, has been shown to decrease the incidence of respiratory failure, shorten LOS, and result in fewer postoperative episodes of sepsis (423). Subgroup analysis of only the studies that enrolled critically ill patients (424) suggests similar benefits of low tidal volume ventilation on duration of mechanical ventilation and development of ARDS, but is further limited by imprecision given the small number of studies included. Despite these methodologic concerns, the benefits of low tidal volume ventilation in patients without ARDS are thought to outweigh any potential harm. Planned RCTs may inform future practice.

**13. We recommend that mechanically ventilated sepsis patients be maintained with the head of the bed elevated between 30 and 45 degrees to limit aspiration risk and to prevent the development of VAP (strong recommendation, low quality of evidence).**

**Rationale:** The semi-recumbent position has been demonstrated to decrease the incidence of VAP (425). Enteral feeding increased the risk of developing VAP; 50% of the patients who were fed enterally in the supine position developed VAP, compared with 9% of those fed in the semi-recumbent position (425). However, the bed position was monitored only once a day, and patients who did not achieve the desired bed elevation were not included in the analysis (425). One study did not show a difference in incidence of VAP between patients maintained in supine and semi-recumbent positions (426); patients assigned to the semi-recumbent group did not consistently achieve the desired head-of-bed elevation, and the head-of-bed elevation in the supine group approached that of the semi-recumbent group by day 7 (426). When necessary, patients may be laid flat when indicated for procedures, hemodynamic measurements, and during episodes of hypotension. Patients should not be fed enterally while supine. There were no new published studies since the last guidelines that would inform a change in the strength of the recommendation for the current iteration. The evidence profile for this recommendation demonstrated low quality of evidence. The lack of new evidence, along with the low harms of head-of-bed and high feasibility of implementation given the frequency of the practice resulted in the strong recommendation. There is a small subgroup of patients, such

as trauma patients with a spine injury, for whom this recommendation would not apply.

**14. We recommend using spontaneous breathing trials in mechanically ventilated patients with sepsis who are ready for weaning (strong recommendation, high quality of evidence).**

**Rationale:** Spontaneous breathing trial options include a low level of pressure support, CPAP ( $\approx 5$  cm H<sub>2</sub>O), or use of a T-piece. A recently published clinical practice guideline suggests the use of inspiratory pressure augmentation rather than T-piece or CPAP for an initial spontaneous breathing trial for acutely hospitalized adults on mechanical ventilation for more than 24 hours (427). Daily spontaneous breathing trials in appropriately selected patients reduce the duration of mechanical ventilation and weaning duration both in individual trials as well as with pooled analysis of the individual trials (428–430). These breathing trials should be conducted in conjunction with a spontaneous awakening trial (431). Successful completion of spontaneous breathing trials leads to a high likelihood of successful early discontinuation of mechanical ventilation with minimal demonstrated harm.

**15. We recommend using a weaning protocol in mechanically ventilated patients with sepsis-induced respiratory failure who can tolerate weaning (strong recommendation, moderate quality of evidence).**

**Rationale.** Protocols allow for standardization of clinical pathways to facilitate desired treatment (432). These protocols may include both spontaneous breathing trials, gradual reduction of support, and computer-generated weaning. Pooled analysis demonstrates that patients treated with protocolized weaning compared with usual care experienced shorter weaning duration (–39 hours; 95% CI, –67 hours to –11 hours), and shorter ICU LOS (–9 hours; 95% CI, –15 to –2). There was no difference between groups in ICU mortality (OR, 0.93; 95% CI, 0.58–1.48) or need for reintubation (OR, 0.74; 95% CI, 0.44–1.23) (428).

## **N. SEDATION AND ANALGESIA**

**1. We recommend that continuous or intermittent sedation be minimized in mechanically ventilated sepsis patients, targeting specific titration end points (BPS).**

**Rationale.** Limiting the use of sedation in critically ill ventilated patients reduces the duration of mechanical ventilation and ICU and hospital LOS, and allows earlier mobilization (433, 434). While these data arise from studies performed in a wide range of critically ill patients, there is little reason to believe that septic patients will not derive the same benefits from sedation minimization.

Several strategies have been shown to reduce sedative use and the duration of mechanical ventilation. Nurse-directed protocols that incorporate a sedation scale likely result in improved outcomes; however, the benefit depends on the

existing local culture and practice (435, 436). Another option for systematically limiting the use of sedation is the administration of intermittent rather than continuous sedation (437, 438). Daily sedation interruption (DSI) was associated with improved outcomes in a single-center randomized trial compared with usual care (430); however, in a multicenter RCT there was no advantage to DSI when patients were managed with a sedation protocol, and nurses perceived a higher workload (439). A recent Cochrane meta-analysis did not find strong evidence that DSI alters the duration of mechanical ventilation, mortality, ICU or hospital LOS, adverse event rates, or drug consumption for critically ill adults receiving mechanical ventilation compared to sedation strategies that do not include DSI; however, interpretation of the results is limited by imprecision and clinical heterogeneity (440). Another strategy is the primary use of opioids alone and avoidance of sedatives, which was shown to be feasible in the majority of ventilated patients in a single-center trial, and was associated with more rapid liberation from mechanical ventilation (441). Finally, the use of short-acting drugs such as propofol and dexmedetomidine may result in better outcomes than the use of benzodiazepines (442–444). Recent pain, agitation, and delirium guidelines provide additional detail on implementation of sedation management, including nonpharmacologic approaches for the management of pain, agitation, and delirium (445).

Regardless of approach, a large body of indirect evidence is available demonstrating the benefit of limiting sedation in those requiring mechanical ventilation and without contraindication. As such, this should be best practice for any critically ill patient, including those with sepsis.

## O. GLUCOSE CONTROL

1. We recommend a protocolized approach to blood glucose management in ICU patients with sepsis, commencing insulin dosing when two consecutive blood glucose levels are  $> 180$  mg/dL. This approach should target an upper blood glucose level  $\leq 180$  mg/dL rather than an upper target blood glucose level  $\leq 110$  mg/dL (strong recommendation, high quality of evidence).
2. We recommend that blood glucose values be monitored every 1 to 2 hours until glucose values and insulin infusion rates are stable, then every 4 hours thereafter in patients receiving insulin infusions (BPS).
3. We recommend that glucose levels obtained with point-of-care testing of capillary blood be interpreted with caution because such measurements may not accurately estimate arterial blood or plasma glucose values (BPS).
4. We suggest the use of arterial blood rather than capillary blood for point-of-care testing using glucose meters if patients have arterial catheters (weak recommendation, low quality of evidence).

**Rationale:** A large single-center RCT in 2001 demonstrated a reduction in ICU mortality with intensive IV insulin (Leuven protocol) targeting blood glucose to 80–110 mg/dL (446). A

second randomized trial of intensive insulin therapy using the Leuven protocol enrolled medical ICU patients with an anticipated ICU LOS of more than three days in three medical ICUs; overall mortality was not reduced (447).

Since these studies (446, 447) appeared, several RCTs (448–455) and meta-analyses (456–462) of intensive insulin therapy have been performed. The RCTs studied mixed populations of surgical and medical ICU patients and found that intensive insulin therapy did not significantly decrease mortality, whereas the NICE-SUGAR trial demonstrated an increased mortality (451). All studies reported a much higher incidence of severe hypoglycemia (glucose  $\leq 40$  mg/dL) (6%–29%) with intensive insulin therapy. Several meta-analyses confirmed that intensive insulin therapy was not associated with a mortality benefit in surgical, medical, or mixed ICU patients. The meta-analysis by Song et al (462) evaluated only septic patients and found that intensive insulin therapy did not change 28-day or 90-day mortality, but was associated with a higher incidence of hypoglycemia. The trigger to start an insulin protocol for blood glucose levels  $> 180$  mg/dL with an upper target blood glucose level  $< 180$  mg/dL derives from the NICE-SUGAR trial, which used these values for initiating and stopping therapy. The NICE-SUGAR trial is the largest, most compelling study to date on glucose control in ICU patients given its inclusion of multiple ICUs and hospitals and a general patient population. Several medical organizations, including the American Association of Clinical Endocrinologists, American Diabetes Association, American Heart Association, American College of Physicians, and Society of Critical Care Medicine, have published consensus statements for glycemic control of hospitalized patients (463, 464). These statements usually targeted glucose levels between 140 and 180 mg/dL. Because there is no evidence that targets between 140 and 180 mg/dL are different from targets of 110 to 140 mg/dL, the present recommendations use an upper target blood glucose  $\leq 180$  mg/dL without a lower target other than hypoglycemia. Stricter ranges, such as 110–140 mg/dL, may be appropriate for selected patients if this can be achieved without significant hypoglycemia (463, 465). Treatment should avoid hyperglycemia ( $> 180$  mg/dL), hypoglycemia, and wide swings in glucose levels that have been associated with higher mortality (466–471). The continuation of insulin infusions, especially with the cessation of nutrition, has been identified as a risk factor for hypoglycemia (454). Balanced nutrition may be associated with a reduced risk of hypoglycemia (472). Hyperglycemia and glucose variability seem to be unassociated with increased mortality rates in diabetic patients compared to nondiabetic patients (473–475). Patients with diabetes and chronic hyperglycemia, end-stage renal failure, or medical versus surgical ICU patients may require higher blood glucose ranges (476, 477).

Several factors may affect the accuracy and reproducibility of point-of-care testing of blood capillary blood glucose, including the type and model of the device used, user expertise, and patient factors, including hematocrit (false elevation with anemia),  $\text{PaO}_2$ , and drugs (478). Plasma glucose values by capillary point-of-care testing have been found to be potentially

inaccurate, with frequent false elevations (479–481) over the range of glucose levels, but especially in the hypoglycemic and hyperglycemic ranges (482) and in shock patients (receiving vasopressors) (478, 480). A review of studies found the accuracy of glucose measurements by arterial blood gas analyzers and glucose meters by using arterial blood significantly higher than measurements with glucose meters using capillary blood (480). The U.S. Food and Drug Administration has stated that “critically ill patients should not be tested with a glucose meter because results may be inaccurate,” and Centers for Medicare and Medicaid Services have plans to enforce the prohibition of off-label use of point-of-care capillary blood glucose monitor testing in critically ill patients (483). Several medical experts have stated the need for a moratorium on this plan (484). Despite the attempt to protect patients from harm because of inaccurate capillary blood testing, a prohibition might cause more harm because a central laboratory test may take significantly longer to provide results than point-of-care glucometer testing.

A review of 12 published insulin infusion protocols for critically ill patients showed wide variability in dose recommendations and variable glucose control (485). This lack of consensus about optimal dosing of IV insulin may reflect variability in patient factors (severity of illness, surgical versus medical settings), or practice patterns (e.g., approaches to feeding, IV dextrose) in the environments in which these protocols were developed and tested. Alternatively, some protocols may be more effective than others, a conclusion supported by the wide variability in hypoglycemia rates reported with protocols. Thus, the use of established insulin protocols is important not only for clinical care, but also for the conduct of clinical trials to avoid hypoglycemia, adverse events, and premature termination of trials before the efficacy signal, if any, can be determined. Several studies have suggested that computer-based algorithms result in tighter glycemic control with a reduced risk of hypoglycemia (486, 487). Computerized decision support systems and fully automated closed-loop systems for glucose control are feasible, but not yet standard care. Further study of validated, safe, and effective protocols and closed-loop systems for controlling blood glucose concentrations and variability in the sepsis population is needed.

## P. RENAL REPLACEMENT THERAPY

1. We suggest that either continuous RRT (CRRT) or intermittent RRT be used in patients with sepsis and acute kidney injury (weak recommendation, moderate quality of evidence).
2. We suggest using CRRT to facilitate management of fluid balance in hemodynamically unstable septic patients (weak recommendation, very low quality of evidence).
3. We suggest against the use of RRT in patients with sepsis and acute kidney injury for increase in creatinine or oliguria without other definitive indications for dialysis (weak recommendation, low quality of evidence).

**Rationale:** Although numerous nonrandomized studies have reported a nonsignificant trend toward improved survival using continuous methods (488–494), two meta-analyses (495, 496) reported the absence of significant differences in hospital mortality between patients who receive CRRT and intermittent RRT. This absence of apparent benefit of one modality over the other persists even when the analysis is restricted to RCTs (496). To date, five prospective RCTs have been published (497–501); four found no significant difference in mortality (497, 498, 500, 501), whereas one found significantly higher mortality in the continuous treatment group (499); but imbalanced randomization had led to a higher baseline severity of illness in this group. When a multivariable model was used to adjust for severity of illness, no difference in mortality was apparent between the groups. Most studies comparing modes of RRT in the critically ill have included a small number of outcomes and had a high risk of bias (e.g., randomization failure, modifications of therapeutic protocol during the study period, combination of different types of CRRT, small number of heterogeneous groups of enrollees). The most recent and largest RCT (501) enrolled 360 patients and found no significant difference in survival between the continuous and intermittent groups. We judged the overall certainty of the evidence to be moderate and not in support of continuous therapies in sepsis independent of renal replacement needs.

For this revision of the guidelines, no additional RCTs evaluating the hemodynamic tolerance of continuous versus intermittent RRT were identified. Accordingly, the limited and inconsistent evidence persists. Two prospective trials (497, 502) have reported a better hemodynamic tolerance with continuous treatment, with no improvement in regional perfusion (502) and no survival benefit (497). Four other studies did not find any significant difference in MAP or drop in systolic pressure between the two methods (498, 500, 501, 503). Two studies reported a significant improvement in goal achievement with continuous methods (497, 499) regarding fluid balance management.

Two additional RCTs reporting the effect of dose of CRRT on outcomes in patients with acute renal failure were identified in the current literature review (504, 505). Both studies enrolled patients with sepsis and acute kidney injury and did not demonstrate any difference in mortality associated with a higher dose of RRT. Two large, multicenter, randomized trials comparing the dose of renal replacement (Acute Renal Failure Trial Network in the United States and RENAL Study in Australia and New Zealand) also failed to show benefit of more aggressive renal replacement dosing (506, 507). A meta-analysis of the sepsis patients included in all relevant RCTs ( $n = 1,505$ ) did not demonstrate any significant relationship between dose and mortality; the point estimate, however, favors CRRT doses  $> 30$  mL/kg/hr. Because of risk of bias, inconsistency, and imprecision, confidence in the estimate is very low; further research is indicated. A typical dose for CRRT would be 20–25 mL/kg/hr of effluent generation.

One small trial from 2002 (504) evaluated early versus “late” or “delayed” initiation of RRT; it included only four patients with sepsis and did not show any benefit of early CRRT.

Since then, two relevant RCTs (508, 509) were published in 2016. Results suggest the possibility of either benefit (509) or harm (508) for mortality, increased use of dialysis, and increased central line infections with early RRT. Enrollment criteria and timing of initiation of RRT differed in the two trials. Results were judged to be of low certainty based on indirectness (many nonseptic patients) and imprecision for mortality. The possibility of harm (e.g., central line infections) pushes the balance of risk and benefit against early initiation of RRT. Meanwhile, the undesirable effects and costs appear to outweigh the desirable consequences; therefore, we suggest not using RRT in patients with sepsis and acute kidney injury for increase in creatinine or oliguria without other definitive indications for dialysis.

## Q. BICARBONATE THERAPY

1. **We suggest against the use of sodium bicarbonate therapy to improve hemodynamics or to reduce vasopressor requirements in patients with hypoperfusion-induced lactic acidemia with pH  $\geq$  7.15 (weak recommendation, moderate quality of evidence).**

**Rationale:** Although sodium bicarbonate therapy may be useful in limiting tidal volume in ARDS in some situations of permissive hypercapnia, no evidence supports the use of sodium bicarbonate therapy in the treatment of hypoperfusion-induced lactic acidemia associated with sepsis. Two blinded, crossover RCTs that compared equimolar saline and sodium bicarbonate in patients with lactic acidosis failed to reveal any difference in hemodynamic variables or vasopressor requirements (510, 511). The number of patients with  $<$  7.15 pH in these studies was small, and we downgraded the certainty of evidence for serious imprecision; further, patients did not have exclusively septic shock, but also had other diseases, such as mesenteric ischemia. Bicarbonate administration has been associated with sodium and fluid overload, an increase in lactate and  $\text{PaCO}_2$ , and a decrease in serum ionized calcium, but the directness of these variables to outcome is uncertain. The effect of sodium bicarbonate administration on hemodynamics and vasopressor requirements at lower pH, as well as the effect on clinical outcomes at any pH level, is unknown. No studies have examined the effect of bicarbonate administration on outcomes. This recommendation is unchanged from the 2012 guidelines.

## R. VENOUS THROMBOEMBOLISM PROPHYLAXIS

1. **We recommend pharmacologic prophylaxis (unfractionated heparin [UFH] or low-molecular-weight heparin [LMWH]) against venous thromboembolism (VTE) in the absence of contraindications to the use of these agents (strong recommendation, moderate quality of evidence).**
2. **We recommend LMWH rather than UFH for VTE prophylaxis in the absence of contraindications to the use of LMWH (strong recommendation, moderate quality of evidence).**

3. **We suggest combination pharmacologic VTE prophylaxis and mechanical prophylaxis, whenever possible (weak recommendation, low quality of evidence).**
4. **We suggest mechanical VTE prophylaxis when pharmacologic VTE is contraindicated (weak recommendation, low quality of evidence).**

**Rationale:** ICU patients are at risk for deep vein thrombosis (DVT) as well as pulmonary embolism (PE). The incidence of DVT acquired in the ICU may be as high as 10% (512); the incidence of acquired PE may be 2%–4% (513, 514). Patients with sepsis and septic shock are likely at increased risk for this complication. Vasopressor use, which is frequent in these patients, has been found to be an independent risk factor for ICU-acquired DVT.

A meta-analysis of pharmacologic prophylaxis with UFH or LMWH in critically ill patients showed significant reductions in both DVT and PE, with no significant increase in bleeding complications. Mortality was lower in the patients receiving prophylaxis, although this did not reach statistical significance (514). All studies included in the meta-analysis were cited in the 2012 guideline, which recommended pharmacologic prophylaxis. No additional prospective randomized controlled trials related to this topic have been identified since the meta-analysis and the previous guideline were published (**Supplemental Digital Content 12**, <http://links.lww.com/CCM/C333>). Data in support of pharmacologic prophylaxis are considered somewhat indirect. Except for a large prospective randomized controlled trial comparing VTE in septic patients treated with drotrecogin alfa who were randomized to receive placebo versus UFH versus LWMH (515), all studies have been in an undifferentiated population of critically ill patients. Overall, we made a strong recommendation in favor of pharmacologic prophylaxis against VTE in critically ill patients based on the overall efficacy of this intervention, although the evidence was downgraded to moderate because of indirectness of the populations studied.

A number of studies have also compared use of LMWH to UFH for prevention of VTE prophylaxis in critically ill patients. Four trials were included in the meta-analysis of Alhazzani et al (514). We did not identify any new trials since then. In this meta-analysis, the overall rate of DVT was lower in patients receiving LWMH compared to UFH, and overall mortality was reduced by 7%; however, these differences did not reach statistical significance. In those trials evaluating PE, the rates were significantly lower in patients receiving LWMH. As with all studies of pharmacologic VTE prophylaxis, only one trial (515) was restricted to septic patients, and that trial utilized drotrecogin alfa in all patients. An additional meta-analysis found that LWMH was more effective than UFH in reducing the incidence of DVT and PE in critically ill patients (516). However, the authors of this meta-analysis included studies of critically ill trauma patients.

All studies of LMWH have compared these agents against UFH administered twice daily. No high-quality studies in critically ill patients have directly compared LWMH against

UFH administered thrice daily. An indirect comparison meta-analysis published in 2011 failed to identify a significant difference in efficacy between twice-daily and thrice-daily heparin in medical patients (517). However, another review and meta-analysis (also using indirect comparison) suggested greater efficacy but higher rates of bleeding with thrice-daily UFH (518). A Cochrane review demonstrated a substantial decrease in the incidence of HIT in postoperative patients receiving LMWH compared to UFH (519), although the studies were not specific to either septic or critically ill patients. Finally, a cost-effectiveness analysis based on one trial of LMWH versus UFH (520) suggested that use of LMWH resulted in an overall decrease in costs of care, despite the higher acquisition cost of the pharmaceutical agent (521). Overall, the desirable consequences (i.e., reduction in PE, HIT, cost savings, and ease of administration) of using LMWH clearly outweigh the undesirable consequences; therefore, we made a strong recommendation in favor of LMWH instead of UFH, whenever feasible. However, the evidence for this was considered only of moderate quality because of indirectness, both with respect to the populations studied and also because LMWH has only been systematically compared to UFH administered twice daily, and not thrice daily.

Precautions are generally suggested regarding use of LMWH in patients with renal dysfunction. In a preliminary trial, no accumulation of anti-Xa levels was demonstrated with dalteparin in patients with a calculated creatinine clearance < 30 mL/min (522). Thus, these patients were included in the PROTECT study (520). In the actual trial, 118 patients with renal failure were analyzed, 60 of whom were randomized to dalteparin and 58 to UFH. There was no evidence of untoward reactions in patients receiving dalteparin compared to UFH. However, dalteparin was not more efficacious than UFH in this small number of patients. These investigators speculated that other types of LMWH might be safe to use in patients with renal failure, but acknowledged no other high-quality data to support this theory. Thus, use of LMWH in septic patients with renal dysfunction might be an option, but data in support of that remain quite limited.

Combined pharmacologic prophylaxis and mechanical prophylaxis with intermittent pneumatic compression (IPC) and/or graduated compression stockings (GCS) is a potential option in critically ill patients with sepsis and septic shock. No high-quality studies of this approach in septic patients, or even critically ill patients in general, exist; however, further research is ongoing (523). A Cochrane review (524) of 11 studies in surgical patients suggested that combined prophylaxis was more effective than either modality used alone. However, the quality of evidence was low due to indirectness of population and imprecision of estimates. Therefore, we can make only a weak recommendation for combined modality therapy for VTE prophylaxis in critically ill patients with sepsis or septic shock. Recent American College of Chest Physicians guidelines made no recommendation regarding the use of combined modality in critically ill patients, but do suggest use of combined mechanical and pharmacologic prophylaxis in high-risk surgical patients (525, 526).

A significant number of septic patients may have relative contraindications to the use of pharmacologic prophylaxis. These patients may be candidates for mechanical prophylaxis using IPC and/or GCS. However, relatively little data exist regarding this approach in critically ill patients. Two meta-analyses have been published comparing use of mechanical prophylaxis with no prophylaxis in combined patient groups, primarily those undergoing orthopedic surgery (527, 528). The former meta-analysis focused on use of GCS and the latter on use of IPC. In these analyses, both modalities appeared more effective than no mechanical prophylaxis, but variable numbers of patients received pharmacologic prophylaxis in both arms, making this evidence indirect. A cohort study of 798 patients using propensity scores for risk adjustment concluded that IPC was the only effective means for mechanical VTE prophylaxis in critically ill patients; however, there was heavy use of pharmacologic prophylaxis in all groups (529). Overall, based on these data, we made a weak recommendation for using mechanical prophylaxis in critically ill septic patients with contraindications to use of pharmacologic prophylaxis. Very limited evidence indicates that IPC may be more effective than GCS alone in critically ill patients, making it the preferred modality for mechanical prophylaxis.

## S. STRESS ULCER PROPHYLAXIS

1. **We recommend that stress ulcer prophylaxis be given to patients with sepsis or septic shock who have risk factors for gastrointestinal (GI) bleeding (strong recommendation, low quality of evidence).**
2. **We suggest using either proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs) when stress ulcer prophylaxis is indicated (weak recommendation, low quality of evidence).**
3. **We recommend against stress ulcer prophylaxis in patients without risk factors for GI bleeding (BPS).**

**Rationale:** Stress ulcers develop in the GI tract of critically ill patients and can be associated with significant morbidity and mortality (530). The exact mechanism is not completely understood, but is believed to be related to disruption of protective mechanisms against gastric acid, gastric mucosal hypoperfusion, increased acid production, and oxidative injury to the digestive track (531). The strongest clinical predictors of GI bleeding risk in critically ill patients are mechanical ventilation for > 48 hours and coagulopathy (532). A recent international cohort study showed that preexisting liver disease, need for RRT, and higher organ failure scores were independent predictors of GI bleeding risk (533). A multicenter prospective cohort study found the incidence of clinically important GI bleeding to be 2.6% (95% CI, 1.6%–3.6%) in critically ill patients (533); however, other observational studies showed lower rates of GI bleeding (534–537).

A recent systematic review and meta-analysis of 20 RCTs examined the efficacy and safety of stress ulcer prophylaxis (538).



Moderate quality of evidence showed that prophylaxis with either H2RAs or PPIs reduced the risk of GI bleeding compared to no prophylaxis (RR, 0.44; 95% CI, 0.28–0.68; low quality of evidence showed a nonsignificant increase in pneumonia risk (RR, 1.23; 95% CI, 0.86–1.78) (538). Recently, a large, retrospective cohort study examined the effect of stress ulcer prophylaxis in patients with sepsis and found no significant difference in the risk of *C difficile* infection compared to no prophylaxis (539) (**Supplemental Digital Content 13**, <http://links.lww.com/CCM/C334>). The choice of prophylactic agent should depend on patients' characteristics, patients' values and preferences, and the local incidence of *C difficile* infections and pneumonia.

Although published RCTs did not exclusively include septic patients, risk factors for GI bleeding are frequently present in patients with sepsis and septic shock (532); therefore, using the results to inform our recommendations is acceptable. Based on the available evidence, the desirable consequences of stress ulcer prophylaxis outweigh the undesirable consequences; therefore, we made a strong recommendation in favor of using stress ulcer prophylaxis in patients with risk factors. Patients without risk factors are unlikely to develop clinically important GI bleeding during their ICU stay (532); therefore, stress ulcer prophylaxis should only be used when risk factors are present, and patients should be periodically evaluated for the continued need for prophylaxis.

While there is variation in practice worldwide, several surveys showed that PPIs are the most frequently used agents in North America, Australia, and Europe, followed by H2RAs (540–544). A recent meta-analysis including 19 RCTs ( $n = 2,177$ ) showed that PPIs were more effective than H2RAs in preventing clinically important GI bleeding (RR, 0.39; 95% CI, 0.21–0.71;  $p = 0.002$ ; moderate quality), but led to a nonsignificant increase in pneumonia risk (RR, 1.17; 95% CI, 0.88–1.56;  $p = 0.28$ ; low quality) (544) prior meta-analyses reached a similar conclusion (545, 546). None of the RCTs reported the risk of *C difficile* infection; nonetheless, a large retrospective cohort study demonstrated a small increase in the risk of *C difficile* infection with PPIs compared to H2RAs (2.2% vs. 3.8%;  $p < 0.001$ ; very low-quality evidence). Studies reporting patients' values and preferences concerning the efficacy and safety of these agents are essentially lacking. Furthermore, cost-effectiveness analyses reached different conclusions (547, 548).

Consequently, the benefit of preventing GI bleeding (moderate-quality evidence) must be weighed against the potential increase in infectious complications (very low- to low-quality evidence). The choice of prophylactic agent will largely depend on individual patients' characteristics; patients' values; and the local prevalence of GI bleeding, pneumonia, and *C difficile* infection. Because of the uncertainties, we did not recommend one agent over the other. Ongoing trials aim to investigate the benefit and harm of withholding stress ulcer prophylaxis (clinicaltrials.gov registration NCT02290327, NCT02467621). The results of these trials will inform future recommendations.

## T. NUTRITION

1. **We recommend against the administration of early parenteral nutrition alone or parenteral nutrition in combination with enteral feedings (but rather initiate early enteral nutrition) in critically ill patients with sepsis or septic shock who can be fed enterally (strong recommendation, moderate quality of evidence).**

**Rationale:** Parenteral nutrition delivery can secure the intended amount of calories. This may represent an advantage over enteral nutrition, especially when patients may be underfed due to GI intolerance, which may be pertinent over the first days of care in the ICU. However, parenteral delivery is more invasive and has been associated with complications, including an increased risk of infections. Further, purported physiologic benefits are associated with enteral feeding, which make this strategy the mainstay of care (549). To address the question of the superiority of parenteral nutrition for patients with sepsis and septic shock, we evaluated the evidence for patients who could be fed enterally early versus those for whom early enteral feeding was not feasible.

Our first systematic review examined the impact of an early parenteral feeding strategy alone or in combination with enteral feeding versus enteral feeding alone on mortality in patients who could be fed enterally. We identified a total of 10 trials with 2,888 patients that were conducted in heterogeneous critically ill and surgical patients, trauma and traumatic brain injury, and those with severe acute pancreatitis (550–559). No evidence showed that early parenteral nutrition reduced mortality (RR 0.97; 95% CI, 0.87–1.08;  $n = 2,745$ ) or infection risk (RR, 1.52; 95% CI, 0.88–2.62;  $n = 2,526$ ), but ICU LOS was increased (MD, 0.90; 95% CI, 0.38–1.42;  $n = 46$ ). The quality of the evidence was graded as moderate to very low. In the largest randomized trial that addressed this study question (CALORIES,  $n = 2,400$ ), there were fewer episodes of hypoglycemia and vomiting in the early parenteral group, but no differences in death between the study groups (553, 560). Due to the lack of mortality benefit, the added cost of parenteral nutrition in absence of clinical benefit (550, 551, 555, 560), and the potential physiologic benefits of enteral feeding (549, 561, 562), we recommend early enteral nutrition as the preferred route of administration in patients with sepsis or septic shock who can be fed enterally.

2. **We recommend against the administration of parenteral nutrition alone or in combination with enteral feeds (but rather to initiate IV glucose and advance enteral feeds as tolerated) over the first 7 days in critically ill patients with sepsis or septic shock for whom early enteral feeding is not feasible (strong recommendation, moderate quality of evidence).**

**Rationale:** In some patients with sepsis or septic shock, feeding enterally early may not be feasible because of contraindications related to surgery or feeding intolerance. These patients represent another subgroup of critically ill patients for whom the clinician may question whether to start parenteral

nutrition early with or without some enteral feeding to meet nutritional goals, versus trophic/hypocaloric enteral feeding alone, or nothing except the addition of IV glucose/dextrose for the provision of some calories. To address this question, we conducted a systematic review, which included a total of four trials and 6,087 patients (563–566). Two of the included trials accounted for 98.5% of the patients included in the review and, of these trials, more than 65% of the patients were surgical critically ill patients (564, 567). Seven (20%) of the patients from these two trials were considered septic and patients with malnourishment were either excluded or represented a very small fraction ( $n = 46$ , 3.3%) of the included patients. In three of the included trials, parenteral nutrition was initiated if enteral feeding was not tolerated after the first 7 days of care (564, 566, 567). Our review found that early parenteral nutrition with or without supplementation of enteral nutrition was not associated with reduced mortality (RR, 0.96; 95% CI, 0.79–1.16;  $n = 6,087$ ; moderate-quality evidence), but was associated with increased risk of infection (RR, 1.12; 95% CI, 1.02–1.24; 3 trials;  $n = 6,054$ ; moderate-quality evidence) (**Supplemental Digital Content 14**, <http://links.lww.com/CCM/C335>). Length of ventilation outcomes were reported divergently in the two large trials, with one suggesting an increase (567) and the other a decrease (564) in ventilation time associated with early parenteral nutrition. One trial also reported less muscle wasting and fat loss in the early parenteral nutrition group according to a Subjective Global Assessment Score (564). In summary, due to the lack of mortality benefit, the increased risk of infection, and the extra cost for parenteral nutrition in the absence of clinical benefit (568), current evidence does not support the initiation of early parenteral nutrition over the first 7 days of care for patients with contraindications or intolerance to enteral nutrition. Specific patient groups may benefit more or incur more harm with early initiation of parenteral nutrition in this context. We encourage future research according to individual patient level meta-analyses to characterize these subgroups and plan for future randomized trials. It is important to note that patients who were malnourished were either excluded or rarely represented in the included trials from our systematic review. Since so few malnourished patients were enrolled, evidence to guide practice is lacking. Malnourished patients may represent a subgroup of critically ill patients for whom the clinician may consider initiating parenteral nutrition early when enteral feeding is not feasible.

3. **We suggest the early initiation of enteral feeding rather than a complete fast or only IV glucose in critically ill patients with sepsis or septic shock who can be fed enterally (weak recommendation, low quality of evidence).**
4. **We suggest either early trophic/hypocaloric or early full enteral feeding in critically ill patients with sepsis or septic shock; if trophic/hypocaloric feeding is the initial strategy, then feeds should be advanced according to patient tolerance (weak recommendation, moderate quality of evidence).**

**Rationale:** The early administration of enteral nutrition in patients with sepsis and septic shock has potential physiologic advantages related to the maintenance of gut integrity and prevention of intestinal permeability, dampening of the inflammatory response, and modulation of metabolic responses that may reduce insulin resistance (561, 562). To examine evidence for this nutrition strategy, we asked if early full feeding (started within the first 48 hours and feeding goals to be met within 72 hours of ICU admission or injury) as compared to a delayed strategy (feeds delayed for at least 48 hours) improved the outcome of our critically ill patients. In our systematic review, we identified a total of 11 trials in heterogeneous critically ill patient populations ( $n = 412$  patients) (569–579). Only one trial was specifically conducted in patients with sepsis ( $n = 43$  patients) (577). The risk of death was not significantly different between the groups (RR, 0.75; 95% CI, 0.43–1.31;  $n = 188$  patients), and infections were not significantly reduced (RR, 0.60; 95% CI, 0.34–12.07;  $n = 122$  patients). Other recent systematic reviews in the critically ill focused specifically on trauma (three trials, 126 patients) or more heterogeneous critically ill populations (6 trials,  $n = 234$  patients) and found that early enteral feeding reduced death and pneumonia (580, 581). However, in contrast to our systematic review, these latter reviews did not include studies in which enteral feeding in the intervention arm was both early and full and where the control arm feeding strategy was delayed for at least the first 48 hours. We also examined whether the provision of an early trophic/hypocaloric feeding strategy (defined by enteral feeding started within the first 48 hours and up to 70% of target caloric goals for at least 48 hours) was superior to a delayed enteral feeding strategy. In the two trials that fit these criteria, there were no statistical differences in death (RR, 0.67; 95% CI, 0.35–1.29;  $n = 229$ ; low-quality evidence) or infection (RR, 0.92; 95% CI, 0.61–1.37;  $n = 229$ ; very low-quality evidence) between the groups (582, 583). Since the present evidence does not suggest harm with early versus delayed institution of enteral feeding, and there is possible benefit from physiologic evidence suggesting reduced gut permeability, inflammation, and infection risk, the committee issued a weak recommendation to start feeding early in patients with sepsis and septic shock.

Some evidence suggests that intentional early underfeeding as compared to early full feeding of critically ill patients may lead to immune hyporesponsiveness and an increase in infectious complications (549). Further, because critical illness is associated with loss of skeletal mass, it is possible that not administering adequate protein may lead to challenges weaning from the ventilator and more general weakness. However, a biological rationale for a trophic/hypocaloric or hypocaloric feeding strategy exists, at least as the initial approach to feeding the critically ill as compared to a fully fed strategy. Limiting caloric intake stimulates autophagy, which is considered a defense mechanism against intracellular organisms and therefore raises the possibility that this approach could reduce infection risk (584, 585).

We defined feeds as trophic/hypocaloric if goal feeds were 70% or less of standard caloric targets for at least a 48-hour

period before they were titrated toward goal. Our systematic review identified seven randomized trials and 2,665 patients studied (584, 586–591). Patient populations included heterogeneous critically ill patients and those with acute lung injury and/or ARDS. Patients who were malnourished were excluded from four of the trials (588–591) and the average body mass index in the remaining three trials ranged from 28 to 30 (584, 586, 587). Targets for trophic/hypocaloric feeding groups ranged from 10 to 20 kcal/hr to up to 70% of target goal. Study intervention periods ranged from 6 to 14 days (or until ICU discharge). In three of the trials, protein (0.8–1.5 g/kg/d) was administered to the trophic/hypocaloric group to meet protein requirements (584, 586, 587). Overall, there were no differences in mortality (RR, 0.95; 95% CI, 0.82–1.10;  $n = 2,665$ ; high-quality evidence), infections (RR, 0.96; 95% CI, 0.83–1.12;  $n = 2,667$ ; moderate-quality evidence), or ICU LOS (MD,  $-0.27$  days; 95% CI,  $-1.40$  to  $0.86$ ,  $n = 2,567$ ; moderate-quality evidence between the study groups) (**Supplemental Digital Content 15**, <http://links.lww.com/CCM/C336>). One trial that instituted hypocaloric feeding (goal 40%–60% target feeds for up to 14 days) reported a subgroup of 292 patients with sepsis; there were also no detectable differences in death at 90 days between the study groups (RR, 0.95; 95% CI, 0.71–1.27;  $p = 0.82$  for interaction) (584). A recently published systematic review of normocaloric versus hypocaloric feeding also found no differences in hospital mortality, infections, ICU LOS, or ventilator-free days between the study groups (585). Some evidence also suggests a lack of adverse consequences even with longer-term outcomes. A trophic/hypocaloric feeding trial of 525 patients, which instituted the most significant restrictions in enteral feeding (20% of caloric goal) for up to 6 days, found no differences in muscle strength, muscle mass, and 6-minute walk test at 6 months or 1 year, although patients in the trophic/hypocaloric feeding group were more likely to be admitted to a rehabilitation facility during the first 12 months of follow-up (592). The current evidence base would suggest that a trophic/hypocaloric or early full enteral feeding strategy is appropriate. However, for patients with sepsis or septic shock who are not tolerating enteral feeds, trophic/hypocaloric feeding may be preferred, with feeds titrated over time according to patient tolerance. There is insufficient evidence to confirm that a trophic/hypocaloric feeding strategy is effective and safe in patients who are malnourished (body mass index  $< 18.5$ ) because these patients were either excluded or rarely represented in the clinical trials from our systematic review. Until further clinical evidence is generated for this subpopulation, the clinician may consider titrating enteral feeds more aggressively in accordance with patient tolerance while monitoring for re-feeding syndrome. Current evidence did not specifically address patients with high vasopressor requirements, and the decision about withholding the feeds should be individualized.

**5. We recommend against the use of omega-3 fatty acids as an immune supplement in critically ill patients with sepsis or septic shock (strong recommendation, low quality of evidence).**

**Rationale:** Use of omega-3 fatty acids in the context of clinical trials in the critically ill has been a subject of interest during the past several years because of the immunomodulatory potential (593). However, systematic reviews of parenteral or enteral omega-3 supplementation in critically ill and ARDS patients have not confirmed their therapeutic benefit (594, 595). Further, a recent randomized trial of 272 patients with acute lung injury found excess harm related to mortality as well as fewer ventilator- and ICU-free days in the omega-3 arm as compared to the control arm (596). A limitation of this trial as well as several other omega-3 trials is that the intervention arm also contained vitamins and trace mineral supplementation, making omega-3 fatty acids alone difficult to isolate as the cause for harm or benefit. For these reasons, we conducted a systematic review of clinical trials in the critically ill that administered omega-3 alone in the intervention arm. In a total of 16 trials ( $n = 1,216$  patients), there were no significant reductions in death (RR, 0.86; 95% CI, 0.71–1.03; low quality evidence); however, ICU LOS was significantly reduced in the omega-3 group (MD,  $-3.84$  days; 95% CI,  $-5.57$  to  $-2.12$ , very low-quality evidence). The overall quality of the evidence was graded as low. Due to the uncertainty of benefit, the potential for harm, and the excess cost and varied availability of omega-3 fatty acids, we make a strong recommendation against the use of omega-3 fatty acids for patients with sepsis and septic shock outside the conduct of RCTs.

**6. We suggest against routinely monitoring gastric residual volumes (GRVs) in critically ill patients with sepsis or septic shock (weak recommendation, low quality of evidence). However, we suggest measurement of gastric residuals in patients with feeding intolerance or who are considered to be at high risk of aspiration (weak recommendation, very low quality of evidence).**

**Remarks:** This recommendation refers to nonsurgical critically ill patients with sepsis or septic shock.

**Rationale.** Critically ill patients are at significant risk for GI dysmotility, which may then predispose them to regurgitation or vomiting, aspiration, and the development of aspiration pneumonia. The rationale for measurement of GRVs is to reduce the risk for aspiration pneumonia by either ceasing or modifying the enteral feeding strategy based on the detection of excess gastric residuals. The inherent controversy is that observational and interventional studies have not consistently confirmed a relationship between the measurement of GRVs (with thresholds ranging from 200 mL to no monitoring of GRVs) and outcomes of vomiting, aspiration, or pneumonia (597–603). In our systematic review, we identified one multicenter non-inferiority trial of 452 critically ill patients who were randomized to not monitoring GRVs versus monitoring GRVs at 6-hour intervals (602). Intolerance to feeds was defined as vomiting in the intervention group versus a GRV of  $> 250$  mL, vomiting, or both in the control group. Although vomiting was more frequent (39.6% versus 27%; median difference, 12.6; 95% CI, 5.4–19.9) in the group in which GRVs were not monitored, a strategy of not monitoring GRVs was

found to be non-inferior compared to monitoring at 6-hour intervals with regard to the primary outcome of VAP (16.7% versus 15.8% respectively; difference, 0.9%; 95% CI, -4.8% to 6.7%). No detectable differences in death were shown between the study groups at 28 and 90 days. Patients who had surgery up to one month prior to study eligibility were not included in this study, so these results should not be applied to surgical critically ill patients. However, the results of this trial question the need to measure GRVs as a method to reduce aspiration pneumonia in all critically ill patients. Due to the absence of harm and the potential reduction in nursing resources needed to monitor patients, we suggest against routine monitoring of GRVs in all patients with sepsis unless the patient has demonstrated feeding intolerance (e.g., vomiting, reflux of feeds into the oral cavity) or for patients who are considered to be at high risk for aspiration (e.g., surgery, hemodynamic instability). We recommend the generation of further evidence through the conduct of future randomized controlled trials targeted to higher-risk patient groups such as the surgical population or those in shock to determine the threshold and frequency with which GRVs should be monitored.

**7. We suggest the use of prokinetic agents in critically ill patients with sepsis or septic shock and feeding intolerance (weak recommendation, low quality of evidence).**

**Rationale:** Feeding intolerance is defined as vomiting, aspiration of gastric contents, or high GRVs. For multiple reasons, feeding intolerance commonly develops in critically ill patients. Patients with preexisting gastroparesis or diabetes or those who are receiving sedatives and vasopressors are at risk. Prokinetic agents, including metoclopramide, domperidone, and erythromycin, are frequently used in the ICU. Each of these agents has different pharmacodynamics and pharmacokinetic properties; however, these agents may be associated with prolongation of QT interval and ventricular arrhythmias. A large case-control study in non-ICU patients showed a threefold increase in risk of sudden cardiac death with domperidone use at doses > 30 mg/day (604). Another retrospective cohort study showed that outpatient use of erythromycin is associated with a twofold increase in the risk of sudden cardiac death, especially if concomitantly used with other CYP3A inhibitors (605). The impact on ventricular arrhythmias in ICU patients is less clear.

A recent systematic review and meta-analysis included 13 RCTs enrolling 1,341 critically ill patients showed that prokinetic agent use was associated with lower risk of feeding intolerance (RR, 0.73; 95% CI, 0.55–0.97; moderate-quality evidence). This was equivalent to an absolute risk reduction of 17%. The use of prokinetic agents did not significantly increase mortality (RR, 0.97; 95% CI, 0.81–1.1; low-quality evidence); however, the incidence of fatal or nonfatal cardiac arrhythmias was not consistently reported across studies. There was no significant effect on the risk of pneumonia or vomiting. The majority of trials examined the effect of metoclopramide or erythromycin; subgroup analysis by drug class was underpowered to detect important subgroup differences (606). We considered the desirable consequences (lower risk of feeding

intolerance) and the low quality of evidence showing no difference in mortality or pneumonia, and issued a weak recommendation for using prokinetic agents (metoclopramide or erythromycin) to treat feeding intolerance in patients with sepsis. Future large comparative trials are needed to determine the relative efficacy and safety of different agents.

Monitoring the QT interval with serial electrocardiograms is required when these agents are used in the ICU, especially if concomitantly used with other agents that could prolong the QT interval (607). The need for prokinetic agents should be assessed daily, and they should be stopped when clinically not indicated.

**8. We suggest placement of post-pyloric feeding tubes in critically ill patients with sepsis or septic shock with feeding intolerance or who are considered to be at high risk of aspiration (weak recommendation, low quality of evidence).**

**Rationale:** Feeding intolerance is defined as vomiting, abdominal distention, or high GRVs that result in interruption of enteral nutrition. Critically ill patients are at risk of gastroparesis and feeding intolerance; evidence of delayed gastric emptying can be found in approximately 50% of critically ill patients (608). The proportion of patients who will progress to develop clinical symptoms is less clear. Feeding intolerance can result in interruption of nutritional support, vomiting, aspiration of gastric contents, or pneumonia (609). The pathophysiology is not completely understood and is likely to be multifactorial. Gastroparesis can be caused by pharmacologic agents that are frequently used in the ICU (e.g., sedatives, opioids, or NMBA), gastric hypoperfusion in the context of shock, hyperglycemia, or vasopressor use (610–612).

Post-pyloric tubes have the theoretical advantage of improving feeding intolerance in patients with gastroparesis, consequently improving the delivery of nutrition into the gut. Post-pyloric feeding tubes, although safe, are not always available, and require technical skill for successful insertion. Gastric air insufflation and prokinetic agents are both effective strategies to facilitate the insertion of post-pyloric tubes in critically ill patients (613). Endoscopy and an external magnet device can also be used to guide post-pyloric tube insertion, but are not always available, are expensive, and require a higher level of expertise.

We conducted a systematic review and meta-analysis of randomized trials to examine the effect of post-pyloric (compared to gastric) feeding on patient-important outcomes. We identified 21 eligible RCTs enrolling 1,579 patients. Feeding via post-pyloric tube reduced the risk of pneumonia compared to gastric tube feeding (RR, 0.75; 95% CI, 0.59–0.94; low-quality evidence). This translates into a 2.5% (95% CI, 0.6%–4.1%) absolute reduction in pneumonia risk. However, there was no significant effect on the risk of death, aspiration, or vomiting (**Supplemental Digital Content 16**, <http://links.lww.com/CCM/C337>). This is consistent with the results of older meta-analyses (614, 615). Although the use of post-pyloric tubes reduced risk of pneumonia, the quality of evidence was low,

the magnitude of benefit was small, and there was uncertainty about the effect on other patient-important outcomes. Cost-effectiveness studies that describe the economic consequences of using post-pyloric feeding tubes are lacking. Therefore, we decided that the balance between desirable and undesirable consequences was unclear in low-risk patients; however, the use of post-pyloric feeding tubes may be justified in patients at high risk of aspiration (i.e., patients with history of recurrent aspiration, severe gastroparesis, feeding intolerance, or refractory medical treatment).

**9. We recommend against the use of IV selenium to treat sepsis and septic shock (strong recommendation, moderate quality of evidence).**

**Rationale:** Selenium was administered in the hope that it could correct the known reduction of selenium concentration in sepsis patients and provide a pharmacologic effect through an antioxidant defense. Although some RCTs are available, the evidence for the use of IV selenium is not convincing. Two recent meta-analyses suggest, with weak findings, a potential benefit of selenium supplementation in sepsis (616, 617). However, a recent large RCT also examined the effect on mortality rates (618). Overall pooled odds ratio (0.94; CI, 0.77–1.15) suggests no significant impact on mortality with sepsis. Also, no differences in secondary outcomes of development of nosocomial pneumonia or ICU LOS were found. When updating our meta-analysis to include the results of this recent study, there was no difference in mortality between both groups (**Supplemental Digital Content 17**, <http://links.lww.com/CCM/C338>).

**10. We suggest against the use of arginine to treat sepsis and septic shock (weak recommendation, low quality of evidence).**

**Rationale:** Arginine availability is reduced in sepsis, which can lead to reduced nitric oxide synthesis, loss of microcirculatory regulation, and enhanced production of superoxide and peroxynitrite. However, arginine supplementation could lead to unwanted vasodilation and hypotension (619, 620). Human trials of L-arginine supplementation have generally been small and reported variable effects on mortality (621–624). The only study in septic patients showed improved survival, but had limitations in study design (623). Other studies suggested no benefit or possible harm in the subgroup of septic patients (621, 624, 625). Some authors found improvement in secondary outcomes in septic patients, such as reduced infectious complications) and hospital LOS, but the relevance of these findings in the face of potential harm is unclear.

**11. We recommend against the use of glutamine to treat sepsis and septic shock (strong recommendation, moderate quality of evidence).**

**Rationale:** Glutamine levels are also reduced during critical illness. Exogenous supplementation can improve gut mucosal atrophy and permeability, possibly leading to reduced bacterial translocation. Other potential benefits are enhanced

immune cell function, decreased proinflammatory cytokine production, and higher levels of glutathione and antioxidative capacity (619, 620). However, the clinical significance of these findings is not clearly established.

Although a previous meta-analysis showed mortality reduction (626), several other meta-analyses did not (627–630). Four recent well-designed studies also failed to show a mortality benefit in the primary analyses, although none focused specifically on septic patients (631–634). Two small studies on septic patients showed no benefit in mortality rates (635, 636), but showed a significant reduction in infectious complications (636) and a faster recovery of organ dysfunction.

**12. We make no recommendation about the use of carnitine for sepsis and septic shock.**

**Rationale:** Massive disruption in energy metabolism contributes to sepsis severity and end organ failure. The magnitude of the energy shift, and, possibly more importantly, the host's metabolic adaptiveness to the shift in energy demand, likely influence patient survival. Carnitine, endogenously manufactured from lysine and methionine, is required for the transport of long-chain fatty acids into the mitochondria and the generation of energy. As such, carnitine utilization is essential for enabling the switch from glucose to long-chain fatty acid metabolism during the sepsis energy crisis. This is the basis for the rationale of employing L-carnitine as a therapeutic in sepsis. One small randomized trial in patients with sepsis reported a 28-day mortality decrease in septic shock patients treated with IV L-carnitine therapy within 24 hours of shock onset; however, the trial was underpowered to detect such a difference (637). Larger, ongoing trials should provide more evidence of the usefulness of carnitine supplementation.

## U. SETTING GOALS OF CARE

- 1. We recommend that goals of care and prognosis be discussed with patients and families (BPS).**
- 2. We recommend that goals of care be incorporated into treatment and end-of-life care planning, utilizing palliative care principles where appropriate (strong recommendation, moderate quality of evidence).**
- 3. We suggest that goals of care be addressed as early as feasible, but no later than within 72 hours of ICU admission (weak recommendation, low quality of evidence).**

**Rationale:** Patients with sepsis and multiple organ system failure have a high mortality rate; some will not survive or will have a poor quality of life. Although the outcome of intensive care treatment in critically ill patients may be difficult to prognosticate accurately, establishing realistic ICU treatment goals is paramount (638), especially because inaccurate expectations about prognosis are common among surrogates (639). Nonbeneficial ICU advanced life-prolonging treatment is not consistent with setting goals of care (640, 641). Models for structuring initiatives to enhance care in the ICU highlight the importance of incorporating goals of care, along with prognosis,

into treatment plans (642). The use of proactive family care conferences to identify advance directives and treatment goals within 72 hours of ICU admission has been demonstrated to promote communication and understanding between the patient's family and the treating team; improve family satisfaction; decrease stress, anxiety, and depression in surviving relatives; facilitate end-of-life decision-making; and shorten ICU LOS for patients who die in the ICU (643, 644). Promoting shared-decision-making with patients and families is beneficial in ensuring appropriate care in the ICU and that futile care is avoided (641, 645, 646).

Palliative care is increasingly accepted as an essential component of comprehensive care for critically ill patients regardless of diagnosis or prognosis (642, 647). Use of palliative care in the ICU enhances the ability to recognize pain and distress; establish the patient's wishes, beliefs, and values, and their impact on decision-making; develop flexible communication strategies; conduct family meetings and establish goals of care; provide family support during the dying process; help resolve team conflicts; and establish reasonable goals for life support and resuscitation (648).

A recent systematic review of the effect of palliative care interventions and advanced care planning on ICU utilization identified that, despite wide variation in study type and quality among nine randomized control trials and 13 nonrandomized controlled trials, patients who received advance care planning or palliative care interventions consistently showed a pattern toward decreased ICU admissions and reduced ICU LOS (649).

However, significant inter-hospital variation in ratings and delivery of palliative care is consistent with prior studies showing variation in intensity of care at the end of life (650). Despite differences in geographic location, legal system, religion, and culture, there is worldwide professional consensus for key end-of-life practices in the ICU (651).

Promoting patient- and family-centered care in the ICU has emerged as a priority and includes implementation of early and repeated care conferencing to reduce family stress and improve consistency in communication; open flexible visitation; family presence during clinical rounds, resuscitation, and invasive procedures; and attention to cultural and spiritual support (652–655).

## ACKNOWLEDGMENTS

We would like to acknowledge the members of the systematic review team: Drs. Emile Belley-Cote, Faye Alshamsi, Sunjay Sharma, Eric Duan, Kim Lewis, and Clara Lu for their invaluable help in the systematic review process. We also would like to acknowledge professors Gordon Guyatt and Roman Jaeschke for sharing their methodology expertise. Finally, we thank Deborah McBride for the incredible editorial support.

## REFERENCES

1. Singer M, Deutschman CS, Seymour CW, et al: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016; 315:801–810
2. Shankar-Hari M, Phillips GS, Levy ML, et al: Sepsis Definitions Task Force: Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016; 315:775–787
3. Seymour CW, Liu VX, Iwashyna TJ, et al: Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016; 315:762–774
4. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med* 2001; 29:1303–1310
5. Dellinger RP: Cardiovascular management of septic shock. *Crit Care Med* 2003; 31:946–955
6. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med* 2003; 348:1546–1554
7. Levy MM, Fink MP, Marshall JC, et al: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Crit Care Med*. 2003;31(4):1250–1256
8. Dellinger RP, Levy MM, Rhodes A, et al: Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. *Intensive Care Med* 2013; 39:165–228
9. Dellinger RP, Levy MM, Rhodes A, et al: Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. *Crit Care Med* 2013; 41:580–637
10. Dellinger RP, Carlet JM, Masur H, et al: Surviving Sepsis Campaign Management Guidelines Committee: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. *Crit Care Med* 2004; 32:858–873
11. Dellinger RP, Levy MM, Carlet JM, et al: International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. *Crit Care Med* 2008; 36:296–327
12. Dellinger RP, Levy MM, Carlet JM, et al: International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. *Crit Care Med* 2008; 36:296–327
13. Guyatt GH, Oxman AD, Kunz R, et al: GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol* 2011; 64:395–400
14. Guyatt GH, Oxman AD, Vist GE, et al: GRADE Working Group: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; 336:924–926
15. Guyatt GH, Schünemann HJ, Djulbegovic B, et al: Guideline panels should not GRADE good practice statements. *J Clin Epidemiol* 2015; 68:597–600
16. Rivers E, Nguyen B, Havstad S, et al: Early Goal-Directed Therapy Collaborative Group: Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med* 2001; 345:1368–1377

17. Peake SL, Delaney A, Bailey M, et al: Goal-directed resuscitation for patients with early septic shock. *N Engl J Med*. 2014;371(16): 1496–1506
18. Yealy DM, Kellum JA, Huang DT, et al: A randomized trial of protocol-based care for early septic shock. *N Engl J Med*. 2014;370(18): 1683–1693
19. Mouncey PR, Osborn TM, Power GS, et al; ProMISe Trial Investigators: Trial of early, goal-directed resuscitation for septic shock. *N Engl J Med* 2015; 372:1301–1311
20. Levy MM, Dellinger RP, Townsend SR, et al; Surviving Sepsis Campaign: The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. *Crit Care Med* 2010; 38:367–374
21. Levy MM, Rhodes A, Phillips GS, et al; Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study. *Crit Care Med* 2015; 43:3–12
22. Cecconi M, De Backer D, Antonelli M, et al; Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. *Intensive Care Med* 2014; 40:1795–1815
23. Eskesen TG, Wetterslev M, Perner A: Systematic review including re-analyses of 1148 individual data sets of central venous pressure as a predictor of fluid responsiveness. *Intensive Care Med* 2016; 42:324–332
24. Monnet X, Marik P, Teboul JL: Passive leg raising for predicting fluid responsiveness: a systematic review and meta-analysis. *Intensive Care Med* 2016; 42:1935–1947
25. Cecconi M, Hofer C, Teboul JL, et al; FENICE Investigators; ESICM Trial Group: Fluid challenges in intensive care: the FENICE study: A global inception cohort study. *Intensive Care Med* 2015; 41: 1529–1537
26. LeDoux D, Astiz ME, Carpati CM, et al: Effects of perfusion pressure on tissue perfusion in septic shock. *Crit Care Med* 2000; 28: 2729–2732
27. Bourgoin A, Leone M, Delmas A, et al: Increasing mean arterial pressure in patients with septic shock: effects on oxygen variables and renal function. *Crit Care Med* 2005; 33:780–786
28. Thooft A, Favory R, Salgado DR, et al: Effects of changes in arterial pressure on organ perfusion during septic shock. *Crit Care* 2011; 15:R222
29. Asfar P, Meziani F, Hamel JF, et al; SEPSISPAM Investigators: High versus low blood-pressure target in patients with septic shock. *N Engl J Med* 2014; 370:1583–1593
30. Lamontagne F, Meade MO, Hébert PC, et al; Canadian Critical Care Trials Group: Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial. *Intensive Care Med* 2016; 42:542–550
31. Levy B: Lactate and shock state: the metabolic view. *Curr Opin Crit Care* 2006; 12:315–321
32. Casserly B, Phillips GS, Schorr C, et al: Lactate measurements in sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis Campaign database. *Crit Care Med* 2015; 43:567–573
33. Jansen TC, van Bommel J, Schoonderbeek FJ, et al; LACTATE study group: Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial. *Am J Respir Crit Care Med* 2010; 182:752–761
34. Jones AE, Shapiro NI, Trzeciak S, et al; Emergency Medicine Shock Research Network (EMShockNet) Investigators: Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. *JAMA* 2010; 303:739–746
35. Lyu X, Xu Q, Cai G, et al: [Efficacies of fluid resuscitation as guided by lactate clearance rate and central venous oxygen saturation in patients with septic shock]. *Zhonghua Yi Xue Za Zhi* 2015; 95:496–500
36. Tian HH, Han SS, Lv CJ, et al: [The effect of early goal lactate clearance rate on the outcome of septic shock patients with severe pneumonia]. *Zhongguo Wei Zhong Bing Ji Jiu Yi Xue* 2012; 24:42–45
37. Yu B, Tian HY, Hu ZJ, et al: [Comparison of the effect of fluid resuscitation as guided either by lactate clearance rate or by central venous oxygen saturation in patients with sepsis]. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 2013; 25:578–583
38. Gu WJ, Zhang Z, Bakker J: Early lactate clearance-guided therapy in patients with sepsis: a meta-analysis with trial sequential analysis of randomized controlled trials. *Intensive Care Med* 2015; 41:1862–1863
39. Simpson SQ, Gaines M, Hussein Y, et al: Early goal-directed therapy for severe sepsis and septic shock: A living systematic review. *J Crit Care* 2016; 36:43–48
40. Dellinger RP: Foreword. The Future of Sepsis Performance Improvement. *Crit Care Med* 2015; 43:1787–1789
41. Murphy DJ, Ogbu OC, Coopersmith CM: ICU director data: using data to assess value, inform local change, and relate to the external world. *Chest* 2015; 147:1168–1178
42. Black MD, Schorr C, Levy MM: Knowledge translation and the multifaceted intervention in the intensive care unit. *Crit Care Med* 2012; 40:1324–1328
43. Gatewood MO, Wemple M, Greco S, et al: A quality improvement project to improve early sepsis care in the emergency department. *BMJ Qual Saf* 2015; 24:787–795
44. Hayden GE, Tuuri RE, Scott R, et al: Triage sepsis alert and sepsis protocol lower times to fluids and antibiotics in the ED. *Am J Emerg Med*. 2016;34(1):1–9
45. Jones SL, Ashton CM, Kiehne L, et al: Reductions in Sepsis Mortality and Costs After Design and Implementation of a Nurse-Based Early Recognition and Response Program. *Jt Comm J Qual Patient Saf* 2015; 41:483–491
46. Levy MM, Pronovost PJ, Dellinger RP, et al: Sepsis change bundles: converting guidelines into meaningful change in behavior and clinical outcome. *Crit Care Med* 2004; 32:S595–S597
47. Damiani E, Donati A, Serafini G, et al: Effect of performance improvement programs on compliance with sepsis bundles and mortality: a systematic review and meta-analysis of observational studies. *PLoS One* 2015; 10:e0125827
48. Rhodes A, Phillips G, Beale R, et al: The Surviving Sepsis Campaign bundles and outcome: results from the International Multicentre Prevalence Study on Sepsis (the IMPReSS study). *Intensive Care Med* 2015; 41:1620–1628
49. Zadroga R, Williams DN, Gottschall R, et al: Comparison of 2 blood culture media shows significant differences in bacterial recovery for patients on antimicrobial therapy. *Clin Infect Dis* 2013; 56:790–797
50. Kanegaye JT, Soliemanzadeh P, Bradley JS: Lumbar puncture in pediatric bacterial meningitis: defining the time interval for recovery of cerebrospinal fluid pathogens after parenteral antibiotic pretreatment. *Pediatrics* 2001; 108:1169–1174
51. Pollack LA, van Santen KL, Weiner LM, et al: Antibiotic Stewardship Programs in U.S. Acute Care Hospitals: Findings From the 2014 National Healthcare Safety Network Annual Hospital Survey. *Clin Infect Dis* 2016; 63:443–449
52. Cardoso T, Carneiro AH, Ribeiro O, et al: Reducing mortality in severe sepsis with the implementation of a core 6-hour bundle: results from the Portuguese community-acquired sepsis study (SACiUCI study). *Crit Care* 2010; 14:R83
53. De Sousa AG, Fernandes Junior CJ, Santos GPD, et al: The impact of each action in the Surviving Sepsis Campaign measures on hospital mortality of patients with severe sepsis/septic shock. *Einstein*. 2008;6(3):323–327
54. Garnacho-Montero J, Gutiérrez-Pizarra A, Escobresca-Ortega A, et al: De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. *Intensive Care Med*. 2013:1–9
55. Weiss CH, Persell SD, Wunderink RG, et al: Empiric antibiotic, mechanical ventilation, and central venous catheter duration as potential factors mediating the effect of a checklist prompting intervention on mortality: an exploratory analysis. *BMC Health Serv Res* 2012; 12:198
56. Ferrer R, Artigas A, Suarez D, et al; Edusepsis Study Group: Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. *Am J Respir Crit Care Med* 2009; 180: 861–866

57. Kumar A, Roberts D, Wood KE, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. *Crit Care Med* 2006; 34:1589–1596
58. Vaughn VM, Chopra V: Revisiting the panculture. *BMJ Qual Saf*. 2016 Feb 19. doi:10.1136/bmjqs-2015-004821 [Epub ahead of print]
59. Weinstein MP, Reller LB, Murphy JR, et al: The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. *Rev Infect Dis* 1983; 5:35–53
60. Li J, Plorde JJ, Carlson LG: Effects of volume and periodicity on blood cultures. *J Clin Microbiol* 1994; 32:2829–2831
61. Baron EJ, Miller JM, Weinstein MP, et al: A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)(a). *Clin Infect Dis* 2013; 57:e22–e121
62. O'Grady NP, Alexander M, Burns LA, et al; Healthcare Infection Control Practices Advisory Committee (HICPAC): Guidelines for the prevention of intravascular catheter-related infections. *Clin Infect Dis* 2011; 52:e162–e193
63. Blot F, Schmidt E, Nitenberg G, et al: Earlier positivity of central-venous- versus peripheral-blood cultures is highly predictive of catheter-related sepsis. *J Clin Microbiol* 1998; 36:105–109
64. Kaasch AJ, Rieg S, Hellmich M, et al: Differential time to positivity is not predictive for central line-related Staphylococcus aureus bloodstream infection in routine clinical care. *J Infect* 2014; 68:58–61
65. Malgrange VB, Escande MC, Theobald S: Validity of earlier positivity of central venous blood cultures in comparison with peripheral blood cultures for diagnosing catheter-related bacteremia in cancer patients. *J Clin Microbiol* 2001; 39:274–278
66. O'Grady NP, Barie PS, Bartlett JG, et al; American College of Critical Care Medicine; Infectious Diseases Society of America: Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. *Crit Care Med* 2008; 36:1330–1349
67. Mermel LA, Allon M, Bouza E, et al: Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2009; 49:1–45
68. Boyce JM, Nadeau J, Dumigan D, et al: Obtaining blood cultures by venipuncture versus from central lines: impact on blood culture contamination rates and potential effect on central line-associated bloodstream infection reporting. *Infect Control Hosp Epidemiol* 2013; 34:1042–1047
69. Beekmann SE, Diekema DJ, Huskins WC, et al; Infectious Diseases Society of America Emerging Infections Network: Diagnosing and reporting of central line-associated bloodstream infections. *Infect Control Hosp Epidemiol* 2012; 33:875–882
70. Garcia RA, Spitzer ED, Beaudry J, et al: Multidisciplinary team review of best practices for collection and handling of blood cultures to determine effective interventions for increasing the yield of true-positive bacteremias, reducing contamination, and eliminating false-positive central line-associated bloodstream infections. *Am J Infect Control*. 2015;43(11):1222–1237
71. Vincent JL, Brealey D, Libert N, et al; Rapid Diagnosis of Infections in the Critically Ill Team: Rapid Diagnosis of Infection in the Critically Ill, a Multicenter Study of Molecular Detection in Bloodstream Infections, Pneumonia, and Sterile Site Infections. *Crit Care Med* 2015; 43:2283–2291
72. Makristathis A, Riss S, Hirschl AM: A novel fluorescence in situ hybridization test for rapid pathogen identification in positive blood cultures. *Clin Microbiol Infect* 2014; 20:O760–O763
73. Tissari P, Zumla A, Tarkka E, et al: Accurate and rapid identification of bacterial species from positive blood cultures with a DNA-based microarray platform: an observational study. *Lancet* 2010; 375: 224–230
74. Ferrer R, Martin-Loeches I, Phillips G, et al: Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. *Crit Care Med* 2014; 42:1749–1755
75. Zhang D, Micek ST, Kollef MH: Time to Appropriate Antibiotic Therapy Is an Independent Determinant of Postinfection ICU and Hospital Lengths of Stay in Patients With Sepsis. *Crit Care Med* 2015; 43:2133–2140
76. Bagshaw SM, Lapinsky S, Dial S, et al; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group: Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. *Intensive Care Med* 2009; 35:871–881
77. Iscimen R, Cartin-Ceba R, Yilmaz M, et al: Risk factors for the development of acute lung injury in patients with septic shock: an observational cohort study. *Crit Care Med* 2008; 36:1518–1522
78. Garnacho-Montero J, Aldabo-Pallas T, Garnacho-Montero C, et al: Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis. *Crit Care* 2006; 10:R111
79. Barie PS, Hydo LJ, Shou J, et al: Influence of antibiotic therapy on mortality of critical surgical illness caused or complicated by infection. *Surg Infect (Larchmt)* 2005; 6:41–54
80. Barochia AV, Cui X, Vitberg D, et al: Bundled care for septic shock: an analysis of clinical trials. *Crit Care Med* 2010; 38:668–678
81. Gaieski DF, Mikkelsen ME, Band RA, et al: Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. *Crit Care Med* 2010; 38:1045–1053
82. Kumar A: Systematic Bias in Meta-Analyses of Time to Antimicrobial in Sepsis Studies. *Crit Care Med* 2016; 44:e234–e235
83. Shirakura Y, Kuriyama A: Timing of Antibiotic Administration in Sepsis and Septic Shock: The Impact That a Meta-Analysis Does Not Depict. *Crit Care Med* 2016; 44:e1004
84. Kaasch AJ, Rieg S, Kuetscher J, et al; preSABATO study group: Delay in the administration of appropriate antimicrobial therapy in Staphylococcus aureus bloodstream infection: a prospective multicenter hospital-based cohort study. *Infection* 2013; 41:979–985
85. Corona A, Bertolini G, Lipman J, et al: Antibiotic use and impact on outcome from bacteraemic critical illness: the BActeraemia Study in Intensive Care (BASIC). *J Antimicrob Chemother* 2010; 65:1276–1285
86. Giner AM, Kuster SP, Zbinden R, et al: Initial management of and outcome in patients with pneumococcal bacteremia: a retrospective study at a Swiss university hospital, 2003-2009. *Infection* 2011; 39:519–526
87. Lin MY, Weinstein RA, Hota B: Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. *Antimicrob Agents Chemother* 2008; 52:3188–3194
88. Amaral AC, Fowler RA, Pinto R, et al; Cooperative Antimicrobial Therapy of Septic Shock Database Research Group: Patient and Organizational Factors Associated With Delays in Antimicrobial Therapy for Septic Shock. *Crit Care Med* 2016; 44:2145–2153
89. Funk DJ, Kumar A: Antimicrobial therapy for life-threatening infections: speed is life. *Crit Care Clin* 2011; 27:53–76
90. Pettipas F, Guenezan J, Vendevre T, et al: Use of intra-osseous access in adults: a systematic review. *Crit Care* 2016; 20:102
91. Buck ML, Wiggins BS, Sesler JM: Intraosseous drug administration in children and adults during cardiopulmonary resuscitation. *Ann Pharmacother* 2007; 41:1679–1686
92. Romanelli G, Cravarezza P: Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian Intramuscular Meropenem Study Group. *J Antimicrob Chemother* 1995; 36 Suppl A:109–119
93. Cormio L, Berardi B, Callea A, et al: Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective study of ciprofloxacin vs piperacillin/tazobactam. *BJU Int* 2002; 90:700–702
94. Barbhaiya RH, Knupp CA, Tenney J, et al: Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects. *J Clin Pharmacol* 1990; 30:900–910
95. Kumar A, Ellis P, Arabi Y, et al; Cooperative Antimicrobial Therapy of Septic Shock Database Research Group: Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. *Chest* 2009; 136:1237–1248



96. Ibrahim EH, Sherman G, Ward S, et al: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. *Chest* 2000; 118:146–155
97. Paul M, Shani V, Muchtar E, et al: Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. *Antimicrob Agents Chemother* 2010; 54:4851–4863
98. Kreger BE, Craven DE, McCabe WR: Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. *Am J Med* 1980; 68:344–355
99. Mermel LA, Maki DG: Detection of bacteremia in adults: consequences of culturing an inadequate volume of blood. *Ann Intern Med* 1993; 119:270–272
100. Bow EJ, Evans G, Fuller J, et al: Canadian clinical practice guidelines for invasive candidiasis in adults. *Can J Infect Dis Med Microbiol* 2010; 21:e122–e150
101. Connolly S: *Clinical Practice Guidelines: Burn Patient Management*. ACI Statewide Burn Injury Service. Chatswood, NSW, Australia: NSW Agency for Clinical Innovation; 2011
102. Cornely OA, Bassetti M, Calandra T, et al; ESCMID Fungal Infection Study Group: ESCMID\* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. *Clin Microbiol Infect* 2012; 18 Suppl 7:19–37
103. Kalil AC, Metersky ML, Klompas M, et al: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis* 2016; 63:e61–e111
104. Liu C, Bayer A, Cosgrove SE, et al; Infectious Diseases Society of America: Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis* 2011; 52:e18–e55
105. Pappas PG, Kauffman CA, Andes DR, et al: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2016; 62:e1–50
106. Penack O, Becker C, Buchheidt D, et al: Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). *Ann Hematol* 2014; 93:1083–1095
107. Penack O, Buchheidt D, Christopheit M, et al; German Society of Hematology and Oncology: Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology. *Ann Oncol* 2011; 22:1019–1029
108. Solomkin JS, Mazuski JE, Bradley JS, et al: Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. *Surg Infect (Larchmt)* 2010; 11:79–109
109. Stevens DL, Bisno AL, Chambers HF, et al: Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. *Clin Infect Dis* 2014; 59:147–159
110. Micek ST, Welch EC, Khan J, et al: Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. *Antimicrob Agents Chemother* 2010; 54:1742–1748
111. Pittet D, Monod M, Suter PM, et al: Candida colonization and subsequent infections in critically ill surgical patients. *Ann Surg* 1994; 220:751–758
112. Blumberg HM, Jarvis WR, Soucie JM, et al; National Epidemiology of Mycoses Survey(NEMIS) Study Group: Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. *Clin Infect Dis* 2001; 33:177–186
113. Green DL: Selection of an empiric antibiotic regimen for hospital-acquired pneumonia using a unit and culture-type specific antibiogram. *J Intensive Care Med* 2005; 20:296–301
114. Kaufman D, Haas CE, Edinger R, et al: Antibiotic susceptibility in the surgical intensive care unit compared with the hospital-wide antibiogram. *Arch Surg* 1998; 133:1041–1045
115. Kerremans JJ, Verbrugh HA, Vos MC: Frequency of microbiologically correct antibiotic therapy increased by infectious disease consultations and microbiological results. *J Clin Microbiol* 2012; 50:2066–2068
116. Raineri E, Pan A, Mondello P, et al: Role of the infectious diseases specialist consultant on the appropriateness of antimicrobial therapy prescription in an intensive care unit. *Am J Infect Control* 2008; 36:283–290
117. Bai AD, Showler A, Burry L, et al: Impact of Infectious Disease Consultation on Quality of Care, Mortality, and Length of Stay in *Staphylococcus aureus* Bacteremia: Results From a Large Multicenter Cohort Study. *Clin Infect Dis* 2015; 60:1451–1461
118. Guo Y, Gao W, Yang H, et al: De-escalation of empiric antibiotics in patients with severe sepsis or septic shock: A meta-analysis. *Heart Lung* 2016; 45:454–459
119. Bernard GR, Vincent JL, Laterre PF, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med* 2001; 344:699–709
120. Klein Klouwenberg PM, Cremer OL, van Vught LA, et al: Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: a cohort study. *Crit Care* 2015; 19:319
121. Working Group IAP/APA Acute Pancreatitis Guidelines: IAP/APA evidence-based guidelines for the management of acute pancreatitis. *Pancreatology*. 2013;13(4):e1–e15
122. Wittau M, Mayer B, Scheele J, et al: Systematic review and meta-analysis of antibiotic prophylaxis in severe acute pancreatitis. *Scand J Gastroenterol* 2011; 46:261–270
123. Avni T, Levcovich A, Ad-El DD, et al: Prophylactic antibiotics for burns patients: systematic review and meta-analysis. *BMJ* 2010; 340:c241
124. Barajas-Nava LA, López-Alcalde J, Roqué i Figuls M, Solà I, Bonfill Cosp X: Antibiotic prophylaxis for preventing burn wound infection. *Cochrane Database Syst Rev*. 2013;(6):CD008738
125. Chelluri L, Jastremski MS: Inadequacy of standard aminoglycoside loading doses in acutely ill patients. *Crit Care Med* 1987; 15:1143–1145
126. Pletz MW, Bloos F, Burkhardt O, et al: Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock. *Intensive Care Med* 2010; 36:979–983
127. van Zanten AR, Polderman KH, van Geijlswijk IM, et al: Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. *J Crit Care* 2008; 23:422–430
128. Blot S, Koulenti D, Akova M, et al: Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. *Crit Care* 2014; 18:R99
129. Moore RD, Smith CR, Lietman PS: Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. *Am J Med* 1984; 77:657–662
130. Men P, Li HB, Zhai SD, et al: Association between the AUC<sub>0-24</sub>/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-Analysis. *PLoS One* 2016; 11:e0146224
131. Moise-Broder PA, Forrest A, Birmingham MC, et al: Pharmacodynamics of vancomycin and other antimicrobials in patients with *Staphylococcus aureus* lower respiratory tract infections. *Clin Pharmacokinet* 2004; 43:925–942
132. Zelenitsky S, Rubinstein E, Ariano R, et al; Cooperative Antimicrobial Therapy of Septic Shock-CATSS Database Research Group: Vancomycin pharmacodynamics and survival in patients with methicillin-resistant *Staphylococcus aureus*-associated septic shock. *Int J Antimicrob Agents* 2013; 41:255–260
133. Forrest A, Nix DE, Ballow CH, et al: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. *Antimicrob Agents Chemother* 1993; 37:1073–1081
134. Preston SL, Drusano GL, Berman AL, et al: Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. *JAMA* 1998; 279:125–129
135. Drusano GL, Preston SL, Fowler C, et al: Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting

- pathogen, in patients with nosocomial pneumonia. *J Infect Dis* 2004; 189:1590–1597
136. Kashuba AD, Nafziger AN, Drusano GL, et al: Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. *Antimicrob Agents Chemother* 1999; 43:623–629
  137. Schentag JJ, Smith IL, Swanson DJ, et al: Role for dual individualization with cefmenoxime. *Am J Med* 1984; 77:43–50
  138. Crandon JL, Bulik CC, Kuti JL, et al: Clinical pharmacodynamics of cefepime in patients infected with *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2010; 54:1111–1116
  139. McKinnon PS, Paladino JA, Schentag JJ: Evaluation of area under the inhibitory curve (AUC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. *Int J Antimicrob Agents* 2008; 31:345–351
  140. Roberts JA, Abdul-Aziz MH, Davis JS, et al: Continuous versus Intermittent  $\beta$ -Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials. *Am J Respir Crit Care Med* 2016; 194:681–691
  141. Barza M, Ioannidis JP, Cappelleri JC, et al: Single or multiple daily doses of aminoglycosides: a meta-analysis. *BMJ* 1996; 312:338–345
  142. Hatala R, Dinh T, Cook DJ: Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. *Ann Intern Med* 1996; 124:717–725
  143. Zelenitsky SA, Ariano RE: Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection. *J Antimicrob Chemother* 2010; 65:1725–1732
  144. Dunbar LM, Wunderink RG, Habib MP, et al: High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. *Clin Infect Dis* 2003; 37:752–760
  145. Rybak MJ, Lomaestro BM, Rotschafer JC, et al: Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. *Clin Infect Dis* 2009; 49:325–327
  146. Matsumoto K, Takesue Y, Ohmagari N, et al: Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. *J Infect Chemother* 2013; 19:365–380
  147. Steinmetz T, Eliakim-Raz N, Goldberg E, et al: Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis. *Clin Microbiol Infect* 2015; 21:665–673
  148. Mohamed AF, Karaiskos I, Plachouras D, et al: Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. *Antimicrob Agents Chemother* 2012; 56:4241–4249
  149. Pea F, Brollo L, Viale P, et al: Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. *J Antimicrob Chemother* 2003; 51:971–975
  150. Pea F, Viale P: Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock—does the dose matter? *Crit Care* 2009; 13:214
  151. Wang JT, Fang CT, Chen YC, et al: Necessity of a loading dose when using vancomycin in critically ill patients. *J Antimicrob Chemother* 2001; 47:246
  152. Kumar A: An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy. *Virulence* 2014; 5:80–97
  153. Rhodes NJ, MacVane SH, Kuti JL, et al: Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes. *Clin Infect Dis* 2014; 59:905–907
  154. Lodise TP Jr, Lomaestro B, Drusano GL: Piperacillin-tazobactam for *Pseudomonas aeruginosa* infection: clinical implications of an extended-infusion dosing strategy. *Clin Infect Dis* 2007; 44:357–363
  155. Yost RJ, Cappelletty DM; RECEIPT Study group: The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study. *Pharmacotherapy* 2011; 31:767–775
  156. Falagas ME, Tansarli GS, Ikawa K, et al: Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. *Clin Infect Dis* 2013; 56:272–282
  157. Yusuf E, Spapen H, Piérard D: Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review. *J Crit Care* 2014; 29:1089–1095
  158. Mah GT, Mabasa VH, Chow I, et al: Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review. *Ann Pharmacother* 2012; 46:265–275
  159. Roberts JA, Abdul-Aziz MH, Lipman J, et al; International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases: Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. *Lancet Infect Dis* 2014; 14:498–509
  160. Baptista JP, Sousa E, Martins PJ, et al: Augmented renal clearance in septic patients and implications for vancomycin optimisation. *Int J Antimicrob Agents* 2012; 39:420–423
  161. Hobbs AL, Shea KM, Roberts KM, et al: Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics. *Pharmacotherapy* 2015; 35:1063–1075
  162. Udy AA, Varghese JM, Altkroni M, et al: Subtherapeutic initial  $\beta$ -lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. *Chest* 2012; 142:30–39
  163. Blot S, Kourenti D, Akova M, et al: Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. *Crit Care* 2014; 18:R99
  164. Roberts JA, Paul SK, Akova M, et al; DALI Study: DALI: defining antibiotic levels in intensive care unit patients: are current  $\beta$ -lactam antibiotic doses sufficient for critically ill patients? *Clin Infect Dis* 2014; 58:1072–1083
  165. Taccone FS, Laterre PF, Spapen H, et al: Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. *Crit Care* 2010; 14:R53
  166. Rea RS, Capitano B, Bies R, et al: Suboptimal aminoglycoside dosing in critically ill patients. *Ther Drug Monit* 2008; 30:674–681
  167. Kumar A, Safdar N, Kethireddy S, et al: A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. *Crit Care Med* 2010; 38:1651–1664
  168. Kumar A, Zarychanski R, Light B, et al; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group: Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. *Crit Care Med* 2010; 38:1773–1785
  169. Al-Hasan MN, Wilson JW, Lahr BD, et al: Beta-lactam and fluoroquinolone combination antibiotic therapy for bacteremia caused by gram-negative bacilli. *Antimicrob Agents Chemother* 2009; 53:1386–1394
  170. Delannoy PY, Boussekey N, Devos P, et al: Impact of combination therapy with aminoglycosides on the outcome of ICU-acquired bacteraemias. *Eur J Clin Microbiol Infect Dis* 2012; 31:2293–2299
  171. Diaz-Martín A, Martínez-González ML, Ferrer R, et al; Edusepsis Study Group: Antibiotic prescription patterns in the empiric therapy of severe sepsis: combination of antimicrobials with different mechanisms of action reduces mortality. *Crit Care* 2012; 16:R223
  172. Martin-Loeches I, Lisboa T, Rodriguez A, et al: Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. *Intensive Care Med* 2010; 36:612–620
  173. Brunkhorst FM, Oppert M, Marx G, et al; German Study Group Competence Network Sepsis (SepNet): Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. *JAMA* 2012; 307:2390–2399

174. Safdar N, Handelsman J, Maki DG: Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. *Lancet Infect Dis* 2004; 4:519–527
175. Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L: Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. *Cochrane Database Syst Rev*. 2006;(1):CD003344
176. Rodríguez A, Mendia A, Sirvent JM, et al; CAPUCI Study Group: Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. *Crit Care Med* 2007; 35:1493–1498
177. Baddour LM, Yu VL, Klugman KP, et al; International Pneumococcal Study Group: Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. *Am J Respir Crit Care Med* 2004; 170:440–444
178. Hilf M, Yu VL, Sharp J, et al: Antibiotic therapy for *Pseudomonas aeruginosa* bacteremia: outcome correlations in a prospective study of 200 patients. *Am J Med* 1989; 87:540–546
179. Tumbarello M, Viale P, Viscoli C, et al: Predictors of mortality in bloodstream infections caused by *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*: importance of combination therapy. *Clin Infect Dis* 2012; 55:943–950
180. Bass SN, Bauer SR, Neuner EA, et al: Impact of combination antimicrobial therapy on mortality risk for critically ill patients with carbapenem-resistant bacteremia. *Antimicrob Agents Chemother* 2015; 59:3748–3753
181. Poulidakos P, Tansarli GS, Falagas ME: Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant *Acinetobacter* infections: a systematic review. *Eur J Clin Microbiol Infect Dis* 2014; 33:1675–1685
182. Falagas ME, Lourida P, Poulidakos P, et al: Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. *Antimicrob Agents Chemother* 2014; 58:654–663
183. Hu Y, Li L, Li W, et al: Combination antibiotic therapy versus monotherapy for *Pseudomonas aeruginosa* bacteraemia: a meta-analysis of retrospective and prospective studies. *Int J Antimicrob Agents* 2013; 42:492–496
184. Vardakas KZ, Tansarli GS, Bliziotis IA, et al:  $\beta$ -Lactam plus aminoglycoside or fluoroquinolone combination versus  $\beta$ -lactam monotherapy for *Pseudomonas aeruginosa* infections: a meta-analysis. *Int J Antimicrob Agents* 2013; 41:301–310
185. Stevens DL, Tanner MH, Winship J, et al: Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. *N Engl J Med* 1989; 321:1–7
186. Zimbelman J, Palmer A, Todd J: Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive *Streptococcus pyogenes* infection. *Pediatr Infect Dis J* 1999; 18:1096–1100
187. Paul M, Soares-Weiser K, Leibovici L: Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. *BMJ* 2003; 326:1111
188. Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. *Clin Infect Dis* 2011; 52:e56–e93
189. Gomes Silva BN, Andriolo RB, Atallah AN, Salomão R: De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. *Cochrane Database Syst Rev*. 2010;(12):CD007934
190. Morel J, Casotto J, Jospé R, et al: De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit. *Crit Care* 2010; 14:R225
191. Joung MK, Lee JA, Moon SY, et al: Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia. *Crit Care* 2011; 15:R79
192. Leone M, Bechis C, Baumstarck K, et al; AZUREA Network Investigators: De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. *Intensive Care Med* 2014; 40:1399–1408
193. Riccio LM, Popovsky KA, Hranjec T, et al: Association of excessive duration of antibiotic therapy for intra-abdominal infection with subsequent extra-abdominal infection and death: a study of 2,552 consecutive infections. *Surg Infect (Larchmt)* 2014; 15:417–424
194. Aarts MA, Brun-Buisson C, Cook DJ, et al: Antibiotic management of suspected nosocomial ICU-acquired infection: does prolonged empiric therapy improve outcome? *Intensive Care Med* 2007; 33:1369–1378
195. Stevens V, Dumyati G, Fine LS, et al: Cumulative antibiotic exposures over time and the risk of *Clostridium difficile* infection. *Clin Infect Dis* 2011; 53:42–48
196. Goossens H: Antibiotic consumption and link to resistance. *Clin Microbiol Infect* 2009; 15 Suppl 3:12–15
197. Chastre J, Wolff M, Fagon JY, et al; PneumA Trial Group: Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. *JAMA* 2003; 290:2588–2598
198. Choudhury G, Mandal P, Singanayagam A, et al: Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia—a propensity-adjusted analysis. *Clin Microbiol Infect* 2011; 17:1852–1858
199. Pugh R, Grant C, Cooke RP, Dempsey G: Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. *Cochrane Database Syst Rev*. 2015;(8):CD007577
200. Sawyer RG, Claridge JA, Nathens AB, et al: Trial of short-course antimicrobial therapy for intraabdominal infection. *N Engl J Med* 2015; 372:1996–2005
201. Eliakim-Raz N, Yahav D, Paul M, et al: Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection—7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. *J Antimicrob Chemother* 2013; 68:2183–2191
202. Rattan R, Allen CJ, Sawyer RG, et al: Patients with Complicated Intra-Abdominal Infection Presenting with Sepsis Do Not Require Longer Duration of Antimicrobial Therapy. *J Am Coll Surg* 2016; 222:440–446
203. Hepburn MJ, Dooley DP, Skidmore PJ, et al: Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. *Arch Intern Med* 2004; 164:1669–1674
204. Chaudhry ZI, Nisar S, Ahmed U, Ali M: Short course of antibiotic treatment in spontaneous bacterial peritonitis: a randomized controlled study. *J Coll Physicians Surg Pak*. 2000;10(8):284–288
205. Jack L, Bal AM, Harte S, et al: International guidelines: the need to standardize the management of candidaemia. *Infect Dis (Lond)* 2016; 48:779–781
206. Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council: Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. *Circulation* 2015; 132:1435–1486
207. Habib G, Lancellotti P, Antunes MJ, et al; Document Reviewers: 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). *Eur Heart J* 2015; 36:3075–3128
208. Weiss CH, Moazed F, McEvoy CA, et al: Prompting physicians to address a daily checklist and process of care and clinical outcomes: a single-site study. *Am J Respir Crit Care Med* 2011; 184:680–686
209. Aguado JM, Vázquez L, Fernández-Ruiz M, et al; PCRAGA Study Group; Spanish Stem Cell Transplantation Group; Study Group of Medical Mycology of the Spanish Society of Clinical Microbiology and Infectious Diseases; Spanish Network for Research in Infectious

- Diseases: Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based *Aspergillus* DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial. *Clin Infect Dis* 2015; 60:405–414
210. Hou TY, Wang SH, Liang SX, et al: The Screening Performance of Serum 1,3-Beta-D-Glucan in Patients with Invasive Fungal Diseases: A Meta-Analysis of Prospective Cohort Studies. *PLoS One* 2015; 10:e0131602
  211. Schuetz P, Briel M, Christ-Crain M, et al: Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. *Clin Infect Dis* 2012; 55:651–662
  212. Matthaiou DK, Ntani G, Kontogiorgi M, et al: An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. *Intensive Care Med* 2012; 38:940–949
  213. Prkno A, Wacker C, Brunkhorst FM, et al: Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock—a systematic review and meta-analysis. *Crit Care* 2013; 17:R291
  214. Westwood M, Ramaekers B, Whiting P, et al: Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. *Health Technol Assess*. 2015;19(96):v–xxv, 1–236
  215. Wacker C, Prkno A, Brunkhorst FM, et al: Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. *Lancet Infect Dis* 2013; 13:426–435
  216. Soni NJ, Samson DJ, Galaydick JL, et al: Procalcitonin-guided antibiotic therapy: a systematic review and meta-analysis. *J Hosp Med* 2013; 8:530–540
  217. de Jong E, van Oers JA, Beishuizen A, et al: Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. *Lancet Infect Dis* 2016; 16:819–827
  218. Lesprit P, Landelle C, Girou E, et al: Reassessment of intravenous antibiotic therapy using a reminder or direct counselling. *J Antimicrob Chemother* 2010; 65:789–795
  219. Paul M, Dickstein Y, Raz-Pasteur A: Antibiotic de-escalation for bloodstream infections and pneumonia: systematic review and meta-analysis. *Clin Microbiol Infect* 2016; 22:960–967
  220. Schuetz P, Kutz A, Grolimund E, et al; ProHOSP Study Group: Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. *Int J Cardiol* 2014; 175:464–472
  221. Hoeboer SH, van der Geest PJ, Nieboer D, et al: The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis. *Clin Microbiol Infect* 2015; 21:474–481
  222. Jimenez MF, Marshall JC; International Sepsis Forum: Source control in the management of sepsis. *Intensive Care Med* 2001; 27 Suppl 1:S49–S62
  223. Azuhata T, Kinoshita K, Kawano D, et al: Time from admission to initiation of surgery for source control is a critical determinant of survival in patients with gastrointestinal perforation with associated septic shock. *Crit Care* 2014; 18:R87
  224. Bloos F, Thomas-Rüddel D, Rüddel H, et al; MEDUSA Study Group: Impact of compliance with infection management guidelines on outcome in patients with severe sepsis: a prospective observational multi-center study. *Crit Care* 2014; 18:R42
  225. Moss RL, Musemeche CA, Kosloske AM: Necrotizing fasciitis in children: prompt recognition and aggressive therapy improve survival. *J Pediatr Surg* 1996; 31:1142–1146
  226. Wong CH, Chang HC, Pasupathy S, et al: Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. *J Bone Joint Surg Am* 2003; 85-A:1454–1460
  227. Chao WN, Tsai CF, Chang HR, et al: Impact of timing of surgery on outcome of *Vibrio vulnificus*-related necrotizing fasciitis. *Am J Surg* 2013; 206:32–39
  228. Buck DL, Vester-Andersen M, Møller MH; Danish Clinical Register of Emergency Surgery: Surgical delay is a critical determinant of survival in perforated peptic ulcer. *Br J Surg* 2013; 100:1045–1049
  229. Karvellas CJ, Abalde JG, Zepeda-Gomez S, et al; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group: The impact of delayed biliary decompression and antimicrobial therapy in 260 patients with cholangitis-associated septic shock. *Aliment Pharmacol Ther* 2016; 44:755–766
  230. Maitland K, Kiguli S, Opoka RO, et al; FEAST Trial Group: Mortality after fluid bolus in African children with severe infection. *N Engl J Med* 2011; 364:2483–2495
  231. Acheampong A, Vincent JL: A positive fluid balance is an independent prognostic factor in patients with sepsis. *Crit Care* 2015; 19:251
  232. Brotfain E, Koyfman L, Toledano R, et al: Positive fluid balance as a major predictor of clinical outcome of patients with sepsis/septic shock after ICU discharge. *Am J Emerg Med* 2016; 34:2122–2126
  233. Mitchell KH, Carlborn D, Caldwell E, et al: Volume Overload: Prevalence, Risk Factors, and Functional Outcome in Survivors of Septic Shock. *Ann Am Thorac Soc* 2015; 12:1837–1844
  234. de Oliveira FS, Freitas FG, Ferreira EM, et al: Positive fluid balance as a prognostic factor for mortality and acute kidney injury in severe sepsis and septic shock. *J Crit Care* 2015; 30:97–101
  235. Malbrain ML, Marik PE, Witters I, et al: Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice. *Anaesthesiol Intensive Ther* 2014; 46:361–380
  236. Yunos NM, Bellomo R, Hegarty C, et al: Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. *JAMA* 2012; 308:1566–1572
  237. Rochwerg B, Alhazzani W, Sindi A, et al; Fluids in Sepsis and Septic Shock Group: Fluid resuscitation in sepsis: a systematic review and network meta-analysis. *Ann Intern Med* 2014; 161:347–355
  238. Young P, Bailey M, Beasley R, et al; SPLIT Investigators; ANZICS CTG: Effect of a Buffered Crystalloid Solution vs Saline on Acute Kidney Injury Among Patients in the Intensive Care Unit: The SPLIT Randomized Clinical Trial. *JAMA* 2015; 314:1701–1710
  239. Finfer S, Norton R, Bellomo R, et al: The SAFE study: saline vs. albumin for fluid resuscitation in the critically ill. *Vox Sang* 2004; 87 Suppl 2:123–131
  240. Delaney AP, Dan A, McCaffrey J, et al: The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. *Crit Care Med* 2011; 39:386–391
  241. Rochwerg B, Alhazzani W, Gibson A, et al; FISSH Group (Fluids in Sepsis and Septic Shock): Fluid type and the use of renal replacement therapy in sepsis: a systematic review and network meta-analysis. *Intensive Care Med* 2015; 41:1561–1571
  242. Xu JY, Chen QH, Xie JF, et al: Comparison of the effects of albumin and crystalloid on mortality in adult patients with severe sepsis and septic shock: a meta-analysis of randomized clinical trials. *Crit Care* 2014; 18:702
  243. Uhlig C, Silva PL, Deckert S, et al: Albumin versus crystalloid solutions in patients with the acute respiratory distress syndrome: a systematic review and meta-analysis. *Crit Care* 2014; 18:R10
  244. Patel A, Laffan MA, Waheed U, et al: Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality. *BMJ* 2014; 349:g4561
  245. Jiang L, Jiang S, Zhang M, et al: Albumin versus other fluids for fluid resuscitation in patients with sepsis: a meta-analysis. *PLoS One* 2014; 9:e114666
  246. Boldt J, Heesen M, Müller M, et al: The effects of albumin versus hydroxyethyl starch solution on cardiorespiratory and circulatory variables in critically ill patients. *Anesth Analg* 1996; 83:254–261
  247. Boldt J, Heesen M, Welters I, et al: Does the type of volume therapy influence endothelial-related coagulation in the critically ill? *Br J Anaesth* 1995; 75:740–746
  248. Boldt J, Müller M, Heesen M, et al: Influence of different volume therapies on platelet function in the critically ill. *Intensive Care Med* 1996; 22:1075–1081

249. Caironi P, Tognoni G, Masson S, et al; ALBIOS Study Investigators: Albumin replacement in patients with severe sepsis or septic shock. *N Engl J Med* 2014; 370:1412–1421
250. Haase N, Perner A, Hennings LI, et al: Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. *BMJ* 2013; 346:f839
251. Moeller C, Fleischmann C, Thomas-Rueddel D, et al: How safe is gelatin? A systematic review and meta-analysis of gelatin-containing plasma expanders vs crystalloids and albumin. *J Crit Care* 2016; 35:75–83
252. Day NP, Phu NH, Bethell DP, et al: The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection. *Lancet* 1996; 348:219–223
253. De Backer D, Creteur J, Silva E, et al: Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? *Crit Care Med* 2003; 31:1659–1667
254. Martin C, Papazian L, Perrin G, et al: Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? *Chest* 1993; 103:1826–1831
255. Martin C, Viviani X, Leone M, et al: Effect of norepinephrine on the outcome of septic shock. *Crit Care Med* 2000; 28:2758–2765
256. Bollaert PE, Bauer P, Audibert G, et al: Effects of epinephrine on hemodynamics and oxygen metabolism in dopamine-resistant septic shock. *Chest* 1990; 98:949–953
257. Levy B, Bollaert PE, Charpentier C, et al: Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. *Intensive Care Med* 1997; 23:282–287
258. Zhou SX, Qiu HB, Huang YZ, et al: Effects of norepinephrine, epinephrine, and norepinephrine-dobutamine on systemic and gastric mucosal oxygenation in septic shock. *Acta Pharmacol Sin* 2002; 23:654–658
259. Mackenzie SJ, Kapadia F, Nimmo GR, et al: Adrenaline in treatment of septic shock: effects on haemodynamics and oxygen transport. *Intensive Care Med* 1991; 17:36–39
260. Moran JL, O’Fathartaigh MS, Peisach AR, et al: Epinephrine as an inotropic agent in septic shock: a dose-profile analysis. *Crit Care Med* 1993; 21:70–77
261. Yamazaki T, Shimada Y, Taenaka N, et al: Circulatory responses to afterloading with phenylephrine in hyperdynamic sepsis. *Crit Care Med* 1982; 10:432–435
262. Regnier B, Rapin M, Gory G, et al: Haemodynamic effects of dopamine in septic shock. *Intensive Care Med* 1977; 3:47–53
263. Beck GCh, Brinkkoetter P, Hanusch C, et al: Clinical review: immunomodulatory effects of dopamine in general inflammation. *Crit Care*. 2004;8(6):485–491
264. Avni T, Lador A, Lev S, et al: Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis. *PLoS One* 2015; 10:e0129305
265. Myburgh JA, Higgins A, Jovanovska A, et al; CAT Study investigators: A comparison of epinephrine and norepinephrine in critically ill patients. *Intensive Care Med* 2008; 34:2226–2234
266. Landry DW, Levin HR, Gallant EM, et al: Vasopressin deficiency contributes to the vasodilation of septic shock. *Circulation* 1997; 95:1122–1125
267. Patel BM, Chittock DR, Russell JA, et al: Beneficial effects of short-term vasopressin infusion during severe septic shock. *Anesthesiology* 2002; 96:576–582
268. Dünser MW, Mayr AJ, Ulmer H, et al: Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. *Circulation* 2003; 107:2313–2319
269. Lauzier F, Lévy B, Lamarre P, et al: Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. *Intensive Care Med* 2006; 32:1782–1789
270. Holmes CL, Walley KR, Chittock DR, et al: The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. *Intensive Care Med* 2001; 27:1416–1421
271. Malay MB, Ashton RC Jr, Landry DW, et al: Low-dose vasopressin in the treatment of vasodilatory septic shock. *J Trauma* 1999; 47:699–703; discussion 703
272. O’Brien A, Clapp L, Singer M: Terlipressin for norepinephrine-resistant septic shock. *Lancet* 2002; 359:1209–1210
273. Sharshar T, Blanchard A, Paillard M, et al: Circulating vasopressin levels in septic shock. *Crit Care Med* 2003; 31:1752–1758
274. Russell JA, Walley KR, Singer J, et al; VASST Investigators: Vasopressin versus norepinephrine infusion in patients with septic shock. *N Engl J Med* 2008; 358:877–887
275. Dünser MW, Mayr AJ, Tür A, et al: Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. *Crit Care Med* 2003; 31:1394–1398
276. Gordon AC, Mason AJ, Thirunavukkarasu N, et al; VANISH Investigators: Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. *JAMA* 2016; 316:509–518
277. Albanèse J, Leone M, Delmas A, et al: Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. *Crit Care Med* 2005; 33:1897–1902
278. Morelli A, Ertmer C, Lange M, et al: Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. *Br J Anaesth* 2008; 100:494–503
279. Morelli A, Ertmer C, Rehberg S, et al: Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. *Crit Care* 2009; 13:R130
280. Zhou F, Mao Z, Zeng X, et al: Vasopressors in septic shock: a systematic review and network meta-analysis. *Ther Clin Risk Manag* 2015; 11:1047–1059
281. De Backer D, Aldecoa C, Njimi H, et al: Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis\*. *Crit Care Med* 2012; 40:725–730
282. De Backer D, Biston P, Devriendt J, et al; SOAP II Investigators: Comparison of dopamine and norepinephrine in the treatment of shock. *N Engl J Med* 2010; 362:779–789
283. Parker MM, Shelhamer JH, Bacharach SL, et al: Profound but reversible myocardial depression in patients with septic shock. *Ann Intern Med* 1984; 100:483–490
284. Gattinoni L, Brazzi L, Pelosi P, et al: A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO<sub>2</sub> Collaborative Group. *N Engl J Med* 1995; 333:1025–1032
285. Hayes MA, Timmins AC, Yau EH, et al: Elevation of systemic oxygen delivery in the treatment of critically ill patients. *N Engl J Med* 1994; 330:1717–1722
286. Hollenberg SM, Ahrens TS, Annane D, et al: Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. *Crit Care Med* 2004; 32:1928–1948
287. Annane D, Vignon P, Renault A, et al; CATS Study Group: Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. *Lancet* 2007; 370:676–684
288. ProCESS Investigators, Yealy DM, Kellum JA, et al: A randomized trial of protocol-based care for early septic shock. *N Engl J Med*. 2014;370(18):1683–1693
289. ARISE Investigators, Anzics Clinical Trials Group, Peake SL, et al: Goal-directed resuscitation for patients with early septic shock. *N Engl J Med*. 2014;371(16):1496–1506
290. Barton P, Garcia J, Kouatli A, et al: Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock. A prospective, double-blinded, randomized, placebo-controlled, interventional study. *Chest* 1996; 109:1302–1312
291. Morelli A, Teboul JL, Maggiore SM, et al: Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. *Crit Care Med* 2006; 34:2287–2293
292. Morelli A, De Castro S, Teboul JL, et al: Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. *Intensive Care Med* 2005; 31:638–644
293. Gordon AC, Perkins GD, Singer M, et al: Levosimendan for the prevention of acute organ dysfunction in sepsis. *N Engl J Med*. [Epub ahead of print]
294. Cohn JN: Blood pressure measurement in shock. Mechanism of inaccuracy in auscultatory and palpatory methods. *JAMA* 1967; 199:118–122

295. Hollenberg SM, Parrillo JE. Shock. In: Braunwald E, Isselbacher KJ, Wilson JD, et al. *Harrison's Principles of Internal Medicine*. 14th ed. New York: McGraw-Hill; 1997:214–222
296. Scheer B, Perel A, Pfeiffer UJ: Clinical review: complications and risk factors of peripheral arterial catheters used for haemodynamic monitoring in anaesthesia and intensive care medicine. *Crit Care* 2002; 6:199–204
297. Gu WJ, Wu XD, Wang F, et al: Ultrasound Guidance Facilitates Radial Artery Catheterization: A Meta-analysis With Trial Sequential Analysis of Randomized Controlled Trials. *Chest* 2016; 149:166–179
298. O'Horo JC, Maki DG, Krupp AE, et al: Arterial catheters as a source of bloodstream infection: a systematic review and meta-analysis. *Crit Care Med* 2014; 42:1334–1339
299. Annane D, Bellissant E, Bollaert PE, et al: Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. *JAMA* 2009; 301:2362–2375
300. Bollaert PE, Charpentier C, Levy B, et al: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. *Crit Care Med* 1998; 26:645–650
301. Briegel J, Forst H, Haller M, et al: Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. *Crit Care Med* 1999; 27:723–732
302. Sprung CL, Annane D, Keh D, et al; CORTICUS Study Group: Hydrocortisone therapy for patients with septic shock. *N Engl J Med* 2008; 358:111–124
303. Sligl WI, Milner DA Jr, Sundar S, et al: Safety and efficacy of corticosteroids for the treatment of septic shock: A systematic review and meta-analysis. *Clin Infect Dis* 2009; 49:93–101
304. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y: Corticosteroids for treating sepsis. *Cochrane Database Syst Rev*. 2015(12):CD002243
305. Volbeda M, Wetterslev J, Gluud C, et al: Glucocorticosteroids for sepsis: a systematic review with meta-analysis and trial sequential analysis. *Intensive Care Med* 2015; 41:1220–1234
306. Annane D, Sébille V, Charpentier C, et al: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. *JAMA* 2002; 288:862–871
307. Briegel J, Sprung CL, Annane D, et al; CORTICUS Study Group: Multicenter comparison of cortisol as measured by different methods in samples of patients with septic shock. *Intensive Care Med* 2009; 35:2151–2156
308. Allolio B, Dörr H, Stuttmann R, et al: Effect of a single bolus of etomidate upon eight major corticosteroid hormones and plasma ACTH. *Clin Endocrinol (Oxf)* 1985; 22:281–286
309. Jabre P, Combes X, Lapostolle F, et al; KETASED Collaborative Study Group: Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. *Lancet* 2009; 374:293–300
310. Oppert M, Schindler R, Husung C, et al: Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. *Crit Care Med* 2005; 33:2457–2464
311. Yildiz O, Doganay M, Aygen B, et al: Physiological-dose steroid therapy in sepsis [ISRCTN36253388]. *Crit Care* 2002; 6:251–259
312. Keh D, Boehnke T, Weber-Cartens S, et al: Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. *Am J Respir Crit Care Med* 2003; 167:512–520
313. Huh JW, Choi HS, Lim CM, et al: Low-dose hydrocortisone treatment for patients with septic shock: a pilot study comparing 3 days with 7 days. *Respirology* 2011; 16:1088–1095
314. Keh D, Trips E, Marx G, et al; SepNet–Critical Care Trials Group: Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis: The HYPRESS Randomized Clinical Trial. *JAMA* 2016; 316:1775–1785
315. Weber-Carstens S, Deja M, Bercker S, et al: Impact of bolus application of low-dose hydrocortisone on glycemic control in septic shock patients. *Intensive Care Med* 2007; 33:730–733
316. Holst LB, Haase N, Wetterslev J, et al; TRISS Trial Group; Scandinavian Critical Care Trials Group: Lower versus higher hemoglobin threshold for transfusion in septic shock. *N Engl J Med* 2014; 371:1381–1391
317. Corwin HL, Gettinger A, Pearl RG, et al; EPO Critical Care Trials Group: Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. *JAMA* 2002; 288:2827–2835
318. Corwin HL, Gettinger A, Rodriguez RM, et al: Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. *Crit Care Med* 1999; 27:2346–2350
319. Liembruno G, Bennardello F, Lattanzio A, et al; Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Work Group: Recommendations for the transfusion of plasma and platelets. *Blood Transfus* 2009; 7:132–150
320. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. *Br J Haematol*. 2003;122(1):10–23
321. Diedrich B, Remberger M, Shanwell A, et al: A prospective randomized trial of a prophylactic platelet transfusion trigger of  $10 \times 10^9$  per L versus  $30 \times 10^9$  per L in allogeneic hematopoietic progenitor cell transplant recipients. *Transfusion* 2005; 45:1064–1072
322. Kaufman RM, Djulbegovic B, Gernsheimer T, et al; AABB: Platelet transfusion: a clinical practice guideline from the AABB. *Ann Intern Med* 2015; 162:205–213
323. Schiffer CA, Anderson KC, Bennett CL, et al; American Society of Clinical Oncology: Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. *J Clin Oncol* 2001; 19:1519–1538
324. Stanworth SJ, Estcourt LJ, Llewelyn CA, et al; TOPPS Study Investigators: Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. *Transfusion* 2014; 54:2385–2393
325. Stanworth SJ, Estcourt LJ, Powter G, et al; TOPPS Investigators: A no-prophylaxis platelet-transfusion strategy for hematologic cancers. *N Engl J Med* 2013; 368:1771–1780
326. Wandt H, Schaefer-Eckart K, Wendelin K, et al; Study Alliance Leukemia: Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. *Lancet* 2012; 380:1309–1316
327. Zumberg MS, del Rosario ML, Nejame CF, et al: A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger. *Biol Blood Marrow Transplant* 2002; 8:569–576
328. Werdan K, Pilz G, Bujdoso O, et al; Score-Based Immunoglobulin Therapy of Sepsis (SBITS) Study Group: Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. *Crit Care Med* 2007; 35:2693–2701
329. Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd: Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. *Cochrane Database Syst Rev*. 2013(9):CD001090
330. Soares MO, Welton NJ, Harrison DA, et al: An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. *Health Technol Assess* 2012; 16:1–186
331. Laupland KB, Kirkpatrick AW, Delaney A: Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. *Crit Care Med* 2007; 35:2686–2692
332. Pidal J, Göttsche PC: Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. *Clin Infect Dis* 2004; 39:38–46
333. Kreymann KG, de Heer G, Nierhaus A, et al: Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. *Crit Care Med* 2007; 35:2677–2685
334. Shankar-Hari M, Culshaw N, Post B, et al: Endogenous IgG hypogammaglobulinaemia in critically ill adults with sepsis: systematic review and meta-analysis. *Intensive Care Med* 2015; 41:1393–1401

335. Turgeon AF, Hutton B, Fergusson DA, et al: Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. *Ann Intern Med* 2007; 146:193–203
336. Zhou F, Peng Z, Murugan R, et al: Blood purification and mortality in sepsis: a meta-analysis of randomized trials. *Crit Care Med* 2013; 41:2209–2220
337. Payen DM, Guilhot J, Launey Y, et al; ABDOMIX Group: Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. *Intensive Care Med* 2015; 41:975–984
338. Klein DJ, Foster D, Schorr CA, et al: The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial. *Trials* 2014; 15:218
339. Livigni S, Bertolini G, Rossi C, et al; GiViTI: Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva (Italian Group for the Evaluation of Interventions in Intensive Care Medicine) is an independent collaboration network of Italian Intensive Care units: Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. *BMJ Open* 2014; 4:e003536
340. Allingstrup M, Wetterslev J, Ravn FB, et al: Antithrombin III for critically ill patients. *Cochrane Database Syst Rev* 2016; 2:CD005370
341. Warren BL, Eid A, Singer P, et al; KyberSept Trial Study Group: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. *JAMA* 2001; 286:1869–1878
342. Vincent JL, Ramesh MK, Ernest D, et al: A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. *Crit Care Med* 2013; 41:2069–2079
343. Yamakawa K, Ogura H, Fujimi S, et al: Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. *Intensive Care Med* 2013; 39:644–652
344. Zarychanski R, Abou-Setta AM, Kanji S, et al; Canadian Critical Care Trials Group: The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis. *Crit Care Med* 2015; 43:511–518
345. Ranieri VM, Thompson BT, Barie PS, et al; PROWESS-SHOCK Study Group: Drotrecogin alfa (activated) in adults with septic shock. *N Engl J Med* 2012; 366:2055–2064
346. Bernard GR, Artigas A, Brigham KL, et al: The American-European consensus conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical-trial coordination. *Am J Respir Crit Care Med*. 1994;149(3):818–824
347. Ranieri VM, Rubenfeld GD, Thompson BT, et al; ARDS Definition Task Force: Acute respiratory distress syndrome: the Berlin Definition. *JAMA* 2012; 307:2526–2533
348. Amato MB, Barbas CS, Medeiros DM, et al: Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. *N Engl J Med* 1998; 338:347–354
349. Brochard L, Roudot-Thoraval F, Roupie E, et al: Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome. The Multicenter Trial Group on Tidal Volume reduction in ARDS. *Am J Respir Crit Care Med* 1998; 158:1831–1838
350. Brower RG, Matthay MA, Morris A, et al: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med*. 2000;342(18):1301–1308
351. Brower RG, Shanholtz CB, Fessler HE, et al: Prospective, randomized, controlled clinical trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients. *Crit Care Med* 1999; 27:1492–1498
352. Eichacker PQ, Gerstenberger EP, Banks SM, et al: Meta-analysis of acute lung injury and acute respiratory distress syndrome trials testing low tidal volumes. *Am J Respir Crit Care Med* 2002; 166:1510–1514
353. Burns KE, Adhikari NK, Slutsky AS, et al: Pressure and volume limited ventilation for the ventilatory management of patients with acute lung injury: a systematic review and meta-analysis. *PLoS One* 2011; 6:e14623
354. Putensen C, Theuerkauf N, Zinserling J, et al: Meta-analysis: ventilation strategies and outcomes of the acute respiratory distress syndrome and acute lung injury. *Ann Intern Med* 2009; 151:566–576
355. Marini JJ, Gattinoni L: Ventilatory management of acute respiratory distress syndrome: a consensus of two. *Crit Care Med* 2004; 32:250–255
356. Tobin MJ: Culmination of an era in research on the acute respiratory distress syndrome. *N Engl J Med* 2000; 342:1360–1361
357. Hager DN, Krishnan JA, Hayden DL, et al; ARDS Clinical Trials Network: Tidal volume reduction in patients with acute lung injury when plateau pressures are not high. *Am J Respir Crit Care Med* 2005; 172:1241–1245
358. Checkley W, Brower R, Korpak A, et al; Acute Respiratory Distress Syndrome Network Investigators: Effects of a clinical trial on mechanical ventilation practices in patients with acute lung injury. *Am J Respir Crit Care Med* 2008; 177:1215–1222
359. Amato MB, Meade MO, Slutsky AS, et al: Driving pressure and survival in the acute respiratory distress syndrome. *N Engl J Med* 2015; 372:747–755
360. Gattinoni L, Marcolin R, Caspani ML, et al: Constant mean airway pressure with different patterns of positive pressure breathing during the adult respiratory distress syndrome. *Bull Eur Physiopathol Respir* 1985; 21:275–279
361. Marini JJ, Ravenscraft SA: Mean airway pressure: physiologic determinants and clinical importance—Part 1: Physiologic determinants and measurements. *Crit Care Med* 1992; 20:1461–1472
362. Pesenti A, Marcolin R, Prato P, et al: Mean airway pressure vs. positive end-expiratory pressure during mechanical ventilation. *Crit Care Med* 1985; 13:34–37
363. Brower RG, Lanken PN, MacIntyre N, et al; National Heart, Lung, and Blood Institute ARDS Clinical Trials Network: Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. *N Engl J Med* 2004; 351:327–336
364. Meade MO, Cook DJ, Guyatt GH, et al; Lung Open Ventilation Study Investigators: Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 2008; 299:637–645
365. Mercat A, Richard JC, Vielle B, et al; Expiratory Pressure (Express) Study Group: Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 2008; 299:646–655
366. Villar J, Kacmarek RM, Pérez-Méndez L, et al: A high positive end-expiratory pressure, low tidal volume ventilatory strategy improves outcome in persistent acute respiratory distress syndrome: a randomized, controlled trial. *Crit Care Med* 2006; 34:1311–1318
367. Briel M, Meade M, Mercat A, et al: Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. *JAMA* 2010; 303:865–873
368. Goligher EC, Kavanagh BP, Rubenfeld GD, et al: Oxygenation response to positive end-expiratory pressure predicts mortality in acute respiratory distress syndrome. A secondary analysis of the LOVS and ExPress trials. *Am J Respir Crit Care Med* 2014; 190:70–76
369. Talmor D, Sarge T, Malhotra A, et al: Mechanical ventilation guided by esophageal pressure in acute lung injury. *N Engl J Med* 2008; 359:2095–2104
370. Amato MB, Barbas CS, Medeiros DM, et al: Beneficial effects of the “open lung approach” with low distending pressures in acute respiratory distress syndrome. A prospective randomized study on mechanical ventilation. *Am J Respir Crit Care Med* 1995; 152:1835–1846
371. Gattinoni L, Caironi P, Cressoni M, et al: Lung recruitment in patients with the acute respiratory distress syndrome. *N Engl J Med* 2006; 354:1775–1786
372. Pieling MR, Fan E: Therapies for refractory hypoxemia in acute respiratory distress syndrome. *JAMA* 2010; 304:2521–2527
373. Fan E, Wilcox ME, Brower RG, et al: Recruitment maneuvers for acute lung injury: a systematic review. *Am J Respir Crit Care Med* 2008; 178:1156–1163

374. Guérin C, Reignier J, Richard JC, et al; PROSEVA Study Group: Prone positioning in severe acute respiratory distress syndrome. *N Engl J Med* 2013; 368:2159–2168
375. Beitler JR, Shaefi S, Montesi SB, et al: Prone positioning reduces mortality from acute respiratory distress syndrome in the low tidal volume era: a meta-analysis. *Intensive Care Med* 2014; 40:332–341
376. Joliet P, Bulpa P, Chevrolet JC: Effects of the prone position on gas exchange and hemodynamics in severe acute respiratory distress syndrome. *Crit Care Med* 1998; 26:1977–1985
377. Lamm WJ, Graham MM, Albert RK: Mechanism by which the prone position improves oxygenation in acute lung injury. *Am J Respir Crit Care Med* 1994; 150:184–193
378. Stocker R, Neff T, Stein S, et al: Prone positioning and low-volume pressure-limited ventilation improve survival in patients with severe ARDS. *Chest* 1997; 111:1008–1017
379. Guerin C, Gaillard S, Lemasson S, et al: Effects of systematic prone positioning in hypoxemic acute respiratory failure: a randomized controlled trial. *JAMA* 2004; 292:2379–2387
380. Peek GJ, Mugford M, Tiruvoipati R, et al; CESAR trial collaboration: Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. *Lancet* 2009; 374:1351–1363
381. Sud S, Sud M, Friedrich JO, et al: High frequency oscillation in patients with acute lung injury and acute respiratory distress syndrome (ARDS): systematic review and meta-analysis. *BMJ* 2010; 340:c2327
382. Noah MA, Peek GJ, Finney SJ, et al: Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). *JAMA* 2011; 306:1659–1668
383. Checkley W: Extracorporeal membrane oxygenation as a first-line treatment strategy for ARDS: is the evidence sufficiently strong? *JAMA* 2011; 306:1703–1704
384. Ferguson ND, Cook DJ, Guyatt GH, et al; OSCILLATE Trial Investigators; Canadian Critical Care Trials Group: High-frequency oscillation in early acute respiratory distress syndrome. *N Engl J Med* 2013; 368:795–805
385. Young D, Lamb SE, Shah S, et al; OSCAR Study Group: High-frequency oscillation for acute respiratory distress syndrome. *N Engl J Med* 2013; 368:806–813
386. Meade MO, Cook DJ, Guyatt GH, et al; Lung Open Ventilation Study Investigators: Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 2008; 299:637–645
387. Antonelli M, Conti G, Rocco M, et al: A comparison of noninvasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure. *N Engl J Med* 1998; 339:429–435
388. Ferrer M, Esquinas A, Leon M, et al: Noninvasive ventilation in severe hypoxemic respiratory failure: a randomized clinical trial. *Am J Respir Crit Care Med* 2003; 168:1438–1444
389. Frat JP, Thille AW, Mercat A, et al; FLORALI Study Group; REVA Network: High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. *N Engl J Med* 2015; 372:2185–2196
390. Klessig HT, Geiger HJ, Murray MJ, et al: A national survey on the practice patterns of anesthesiologist intensivists in the use of muscle relaxants. *Crit Care Med* 1992; 20:1341–1345
391. Murray MJ, Cowen J, DeBlock H, et al; Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians: Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. *Crit Care Med* 2002; 30:142–156
392. Hansen-Flaschen JH, Brazinsky S, Basile C, et al: Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure. A national survey. *JAMA* 1991; 266:2870–2875
393. Freebairn RC, Derrick J, Gomersall CD, et al: Oxygen delivery, oxygen consumption, and gastric intramucosal pH are not improved by a computer-controlled, closed-loop, vecuronium infusion in severe sepsis and septic shock. *Crit Care Med* 1997; 25:72–77
394. Papazian L, Forel JM, Gacouin A, et al; ACURASYS Study Investigators: Neuromuscular blockers in early acute respiratory distress syndrome. *N Engl J Med* 2010; 363:1107–1116
395. Alhazzani W, Alshahrani M, Jaeschke R, et al: Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. *Crit Care* 2013; 17:R43
396. Forel JM, Roch A, Marin V, et al: Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. *Crit Care Med* 2006; 34:2749–2757
397. Shapiro BA, Warren J, Egol AB, et al: Practice parameters for sustained neuromuscular blockade in the adult critically ill patient: an executive summary. Society of Critical Care Medicine. *Crit Care Med* 1995; 23:1601–1605
398. Meyer KC, Prielipp RC, Grossman JE, et al: Prolonged weakness after infusion of atracurium in two intensive care unit patients. *Anesth Analg* 1994; 78:772–774
399. Lacomis D, Petrella JT, Giuliani MJ: Causes of neuromuscular weakness in the intensive care unit: a study of ninety-two patients. *Muscle Nerve* 1998; 21:610–617
400. Johnson KL, Cheung RB, Johnson SB, et al: Therapeutic paralysis of critically ill trauma patients: perceptions of patients and their family members. *Am J Crit Care* 1999; 8:490–498
401. Ballard N, Robley L, Barrett D, et al: Patients' recollections of therapeutic paralysis in the intensive care unit. *Am J Crit Care* 2006; 15:86–94; quiz 95
402. Murray MJ, DeBlock H, Erstad B, et al: Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. *Crit Care Med* 2016; 44:2079–2103
403. Sibbald WJ, Short AK, Warshawski FJ, et al: Thermal dye measurements of extravascular lung water in critically ill patients. Intravascular Starling forces and extravascular lung water in the adult respiratory distress syndrome. *Chest* 1985; 87:585–592
404. Martin GS, Mangialardi RJ, Wheeler AP, et al: Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. *Crit Care Med* 2002; 30:2175–2182
405. Mitchell JP, Schuller D, Calandrino FS, et al: Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization. *Am Rev Respir Dis* 1992; 145:990–998
406. Schuller D, Mitchell JP, Calandrino FS, et al: Fluid balance during pulmonary edema. Is fluid gain a marker or a cause of poor outcome? *Chest* 1991; 100:1068–1075
407. Wiedemann HP, Wheeler AP, Bernard GR, et al: Comparison of two fluid-management strategies in acute lung injury. *N Engl J Med* 2006; 354(24):2564–2575
408. Perkins GD, McAuley DF, Thickett DR, et al: The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. *Am J Respir Crit Care Med* 2006; 173:281–287
409. Gao Smith F, Perkins GD, Gates S, et al; BALTI-2 study investigators: Effect of intravenous  $\beta$ -2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. *Lancet* 2012; 379:229–235
410. Matthay MA, Brower RG, Carson S, et al: Randomized, placebo-controlled clinical trial of an aerosolized beta(2)-agonist for treatment of acute lung injury. *Am J Respir Crit Care Med* 2011; 184(5):561–568
411. Matthay MA, Brower RG, Carson S, et al: Randomized, placebo-controlled clinical trial of an aerosolized beta(2)-agonist for treatment of acute lung injury. *Am J Respir Crit Care Med* 2011; 184(5):561–568
412. Singh B, Tiwari AK, Singh K, et al:  $\beta$ 2 agonist for the treatment of acute lung injury: a systematic review and meta-analysis. *Respir Care* 2014; 59:288–296
413. Connors AF Jr, Speroff T, Dawson NV, et al: The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. *JAMA* 1996; 276:889–897
414. Iberti TJ, Fischer EP, Leibowitz AB, et al: A multicenter study of physicians' knowledge of the pulmonary artery catheter. Pulmonary Artery Catheter Study Group. *JAMA* 1990; 264:2928–2932



415. Osman D, Ridel C, Ray P, et al: Cardiac filling pressures are not appropriate to predict hemodynamic response to volume challenge. *Crit Care Med* 2007; 35:64–68
416. Richard C, Warszawski J, Anguel N, et al; French Pulmonary Artery Catheter Study Group: Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 2003; 290:2713–2720
417. Wheeler AP, Bernard GR, Thompson BT, et al: Pulmonary artery versus central venous catheter to guide treatment of acute lung injury. *N Engl J Med*. 2006;354(21):2213–2224
418. Harvey S, Harrison DA, Singer M, et al; PAC-Man study collaboration: Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. *Lancet* 2005; 366:472–477
419. Rhodes A, Cusack RJ, Newman PJ, Grounds RM, Bennett ED: A randomised, controlled trial of the pulmonary artery catheter in critically ill patients. *Intensive Care Med*. 2002;28(3):256–264
420. Sandham JD, Hull RD, Brant RF, et al; Canadian Critical Care Clinical Trials Group: A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. *N Engl J Med* 2003; 348:5–14
421. Shah MR, Hasselblad V, Stevenson LW, et al: Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. *JAMA* 2005; 294:1664–1670
422. Petrucci N, De Feo C: Lung protective ventilation strategy for the acute respiratory distress syndrome. *Cochrane Database Syst Rev*. 2013(2):CD003844
423. Futier E, Constantin JM, Paugam-Burtz C, et al; IMPROVE Study Group: A trial of intraoperative low-tidal-volume ventilation in abdominal surgery. *N Engl J Med* 2013; 369:428–437
424. Pinheiro de Oliveira R, Hetzel MP, dos Anjos Silva M, Dallegrave D, Friedman G: Mechanical ventilation with high tidal volume induces inflammation in patients without lung disease. *Crit Care*. 2010;14(2):R39
425. Drakulovic MB, Torres A, Bauer TT, et al: Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. *Lancet* 1999; 354:1851–1858
426. van Nieuwenhoven CA, Vandenbroucke-Grauls C, van Tiel FH, et al: Feasibility and effects of the semirecumbent position to prevent ventilator-associated pneumonia: a randomized study. *Crit Care Med* 2006; 34:396–402
427. Ouellette DR, Patel S, Girard TD, et al: Liberation from mechanical ventilation: an official American College of Chest Physicians/ American Thoracic Society clinical practice guideline: inspiratory pressure augmentation during spontaneous breathing trials, protocols minimizing sedation, and non-invasive ventilation immediately after extubation. *Chest*. 2016 [Epub ahead of print]
428. Blackwood B, Burns KE, Cardwell CR, O'Halloran P: Protocolized versus non-protocolized weaning for reducing the duration of mechanical ventilation in critically ill adult patients. *Cochrane Database Syst Rev*. 2014(11):CD006904
429. Ely EW, Baker AM, Dunagan DP, et al: Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. *N Engl J Med* 1996; 335:1864–1869
430. Kress JP, Pohlman AS, O'Connor MF, et al: Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. *N Engl J Med* 2000; 342:1471–1477
431. Girard TD, Kress JP, Fuchs BD, et al: Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. *Lancet* 2008; 371:126–134
432. Sevransky JE, Checkley W, Herrera P, et al; United States Critical Illness and Injury Trials Group-Critical Illness Outcomes Study Investigators: Protocols and Hospital Mortality in Critically Ill Patients: The United States Critical Illness and Injury Trials Group Critical Illness Outcomes Study. *Crit Care Med* 2015; 43:2076–2084
433. Schweickert WD, Pohlman MC, Pohlman AS, et al: Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. *Lancet* 2009; 373:1874–1882
434. Shehabi Y, Bellomo R, Reade MC, et al; Sedation Practice in Intensive Care Evaluation (SPICE) Study Investigators; ANZICS Clinical Trials Group: Early intensive care sedation predicts long-term mortality in ventilated critically ill patients. *Am J Respir Crit Care Med* 2012; 186:724–731
435. Brook AD, Ahrens TS, Schaiff R, et al: Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. *Crit Care Med* 1999; 27:2609–2615
436. Bucknall TK, Manias E, Presneill JJ: A randomized trial of protocol-directed sedation management for mechanical ventilation in an Australian intensive care unit. *Crit Care Med* 2008; 36:1444–1450
437. Kollef MH, Levy NT, Ahrens TS, et al: The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation. *Chest* 1998; 114:541–548
438. Carson SS, Kress JP, Rodgers JE, et al: A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. *Crit Care Med* 2006; 34:1326–1332
439. Mehta S, Burry L, Cook D, et al; SLEAP Investigators; Canadian Critical Care Trials Group: Daily sedation interruption in mechanically ventilated critically ill patients cared for with a sedation protocol: a randomized controlled trial. *JAMA* 2012; 308:1985–1992
440. Jansen JP, Naci H: Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. *BMC Med* 2013; 11:159
441. Strøm T, Martinussen T, Toft P: A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomised trial. *Lancet* 2010; 375:475–480
442. Lonardo NW, Mone MC, Nirula R, et al: Propofol is associated with favorable outcomes compared with benzodiazepines in ventilated intensive care unit patients. *Am J Respir Crit Care Med* 2014; 189:1383–1394
443. Fraser GL, Devlin JW, Worby CP, et al: Benzodiazepine versus non-benzodiazepine-based sedation for mechanically ventilated, critically ill adults: a systematic review and meta-analysis of randomized trials. *Crit Care Med* 2013; 41:S30–S38
444. Reade MC, Eastwood GM, Bellomo R, et al; DahLIA Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group: Effect of Dexmedetomidine Added to Standard Care on Ventilator-Free Time in Patients With Agitated Delirium: A Randomized Clinical Trial. *JAMA* 2016; 315:1460–1468
445. Barr J, Fraser GL, Puntillo K, et al; American College of Critical Care Medicine: Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. *Crit Care Med* 2013; 41:263–306
446. van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in critically ill patients. *N Engl J Med* 2001; 345:1359–1367
447. Van den Berghe G, Wilmer A, Hermans G, et al: Intensive insulin therapy in the medical ICU. *N Engl J Med* 2006; 354:449–461
448. Arabi YM, Dabbagh OC, Tamim HM, et al: Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients. *Crit Care Med* 2008; 36:3190–3197
449. Brunkhorst FM, Engel C, Bloos F, et al; German Competence Network Sepsis (SepNet): Intensive insulin therapy and pentastarch resuscitation in severe sepsis. *N Engl J Med* 2008; 358:125–139
450. De La Rosa Gdel C, Donado JH, Restrepo AH, et al: Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trial. *Crit Care*. 2008;12(5):R120
451. Finfer S, Blair D, Bellomo R, et al: Intensive versus conventional glucose control in critically ill patients. *N Engl J Med*. 2009;360(13):1283–1297
452. Annane D, Cariou A, Maxime V, et al: Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. *JAMA*. 2010;303(4):341–348
453. Kalfon P, Giraudeau B, Ichai C, et al; CGAO-REA Study Group: Tight computerized versus conventional glucose control in the ICU: a randomized controlled trial. *Intensive Care Med* 2014; 40:171–181
454. Preiser JC, Devos P, Ruiz-Santana S, et al: A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. *Intensive Care Med* 2009; 35:1738–1748

455. Zhang RH, W; Li, T et al: Evaluation of optimal goal of glucose control in critically ill patients. *Chinese J Clin Nutr*. 2008;16:204–208
456. Friedrich JO, Chant C, Adhikari NK: Does intensive insulin therapy really reduce mortality in critically ill surgical patients? A reanalysis of meta-analytic data. *Crit Care* 2010; 14:324
457. Griesdale DE, de Souza RJ, van Dam RM, et al: Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. *CMAJ* 2009; 180:821–827
458. Kansagara D, Fu R, Freeman M, et al: Intensive insulin therapy in hospitalized patients: a systematic review. *Ann Intern Med* 2011; 154:268–282
459. Marik PE, Preiser JC: Toward understanding tight glycemic control in the ICU: a systematic review and metaanalysis. *Chest* 2010; 137:544–551
460. Wiener RS, Wiener DC, Larson RJ: Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. *JAMA* 2008; 300:933–944
461. Ling Y, Li X, Gao X: Intensive versus conventional glucose control in critically ill patients: a meta-analysis of randomized controlled trials. *Eur J Intern Med* 2012; 23:564–574
462. Song F, Zhong LJ, Han L, et al: Intensive insulin therapy for septic patients: a meta-analysis of randomized controlled trials. *Biomed Res Int* 2014; 2014:698265
463. American Diabetes Association: Standards of medical care in diabetes—2014. *Diabetes Care*. 2014;37 Suppl 1:S14–S80
464. Marvin MR, Inzucchi SE, Besterman BJ: Computerization of the Yale insulin infusion protocol and potential insights into causes of hypoglycemia with intravenous insulin. *Diabetes Technol Ther* 2013; 15:246–252
465. Qaseem A, Chou R, Humphrey LL, et al; Clinical Guidelines Committee of the American College of Physicians: Inpatient glycemic control: best practice advice from the Clinical Guidelines Committee of the American College of Physicians. *Am J Med Qual* 2014; 29:95–98
466. Siegelar SE, Hermanides J, Oudemans-van Straaten HM, et al: Mean glucose during ICU admission is related to mortality by a U-shaped curve in surgical and medical patients: a retrospective cohort study. *Crit Care* 2010; 14:R224
467. Badawi O, Waite MD, Fuhrman SA, et al: Association between intensive care unit-acquired dysglycemia and in-hospital mortality. *Crit Care Med* 2012; 40:3180–3188
468. Finfer S, Liu B, Chittock DR, et al: Hypoglycemia and risk of death in critically ill patients. *N Engl J Med*. 2012;367(12):1108–1118
469. Kalfon P, Le Manach Y, Ichaï C, et al; CGAO-REA Study Group: Severe and multiple hypoglycemic episodes are associated with increased risk of death in ICU patients. *Crit Care* 2015; 19:153
470. Krinsley JS: Glycemic variability: a strong independent predictor of mortality in critically ill patients. *Crit Care Med* 2008; 36:3008–3013
471. Todi S, Bhattacharya M: Glycemic variability and outcome in critically ill. *Indian J Crit Care Med* 2014; 18:285–290
472. Kauffmann RM, Hayes RM, Jenkins JM, et al: Provision of balanced nutrition protects against hypoglycemia in the critically ill surgical patient. *JPEN J Parenter Enteral Nutr* 2011; 35:686–694
473. Egi M, Bellomo R, Stachowski E, et al: Blood glucose concentration and outcome of critical illness: the impact of diabetes. *Crit Care Med* 2008; 36:2249–2255
474. Krinsley JS: Glycemic variability and mortality in critically ill patients: the impact of diabetes. *J Diabetes Sci Technol* 2009; 3:1292–1301
475. Krinsley JS, Preiser JC: Time in blood glucose range 70 to 140 mg/dl >80% is strongly associated with increased survival in non-diabetic critically ill adults. *Crit Care* 2015; 19:179
476. Egi M, Bellomo R, Stachowski E, et al: The interaction of chronic and acute glycemia with mortality in critically ill patients with diabetes. *Crit Care Med* 2011; 39:105–111
477. Sandler V, Misiash MR, Jones J, et al: Reducing the risk of hypoglycemia associated with intravenous insulin: experience with a computerized insulin infusion program in 4 adult intensive care units. *J Diabetes Sci Technol* 2014; 8:923–929
478. Pereira AJ, Corrêa TD, de Almeida FP, et al: Inaccuracy of Venous Point-of-Care Glucose Measurements in Critically Ill Patients: A Cross-Sectional Study. *PLoS One* 2015; 10:e0129568
479. Hoedemaekers CW, Klein Gunnewiek JM, Prinsen MA, et al: Accuracy of bedside glucose measurement from three glucometers in critically ill patients. *Crit Care Med* 2008; 36:3062–3066
480. Inoue S, Egi M, Kotani J, et al: Accuracy of blood-glucose measurements using glucose meters and arterial blood gas analyzers in critically ill adult patients: systematic review. *Crit Care* 2013; 17:R48
481. Kanji S, Buffie J, Hutton B, et al: Reliability of point-of-care testing for glucose measurement in critically ill adults. *Crit Care Med* 2005; 33:2778–2785
482. Khan AI, Vasquez Y, Gray J, et al: The variability of results between point-of-care testing glucose meters and the central laboratory analyzer. *Arch Pathol Lab Med* 2006; 130:1527–1532
483. Rice MJ, Coursin DB: Glucose Meters: Here Today, Gone Tomorrow? *Crit Care Med* 2016; 44:e97–100
484. Klonoff DC, Draznin B, Drincic A, et al: PRIDE Statement on the Need for a Moratorium on the CMS Plan to Cite Hospitals for Performing Point-of-Care Capillary Blood Glucose Monitoring on Critically Ill Patients. *J Clin Endocrinol Metab* 2015; 100:3607–3612
485. Wilson M, Weinreb J, Hoo GW: Intensive insulin therapy in critical care: a review of 12 protocols. *Diabetes Care* 2007; 30:1005–1011
486. Dortch MJ, Mowery NT, Ozdas A, et al: A computerized insulin infusion titration protocol improves glucose control with less hypoglycemia compared to a manual titration protocol in a trauma intensive care unit. *JPEN J Parenter Enteral Nutr* 2008; 32:18–27
487. Newton CA, Smiley D, Bode BW, et al: A comparison study of continuous insulin infusion protocols in the medical intensive care unit: computer-guided vs. standard column-based algorithms. *J Hosp Med* 2010; 5:432–437
488. Bartlett RH, Mault JR, Dechert RE, et al: Continuous arteriovenous hemofiltration: improved survival in surgical acute renal failure? *Surgery* 1986; 100:400–408
489. Bellomo R, Farmer M, Parkin G, et al: Severe acute renal failure: a comparison of acute continuous hemodiafiltration and conventional dialytic therapy. *Nephron* 1995; 71:59–64
490. Bellomo R, Mansfield D, Rumble S, et al: Acute renal failure in critical illness. Conventional dialysis versus acute continuous hemodiafiltration. *ASAIO J* 1992; 38:M654–M657
491. Kierdorf H. Continuous versus intermittent treatment: clinical results in acute renal failure. In: Sieberth HG, Mann H, Stummvoll HK, eds. *Continuous Hemofiltration*. Basel: Karger; 1991:1–12
492. Mauritz W, Sporn P, Schindler I, et al: [Acute renal failure in abdominal infection. Comparison of hemodialysis and continuous arteriovenous hemofiltration]. *Anasth Intensivther Notfallmed* 1986; 21:212–217
493. Guérin C, Girard R, Selli JM, et al: Intermittent versus continuous renal replacement therapy for acute renal failure in intensive care units: results from a multicenter prospective epidemiological survey. *Intensive Care Med* 2002; 28:1411–1418
494. van Bommel E, Bouvy ND, So KL, et al: Acute dialytic support for the critically ill: intermittent hemodialysis versus continuous arteriovenous hemodiafiltration. *Am J Nephrol* 1995; 15:192–200
495. Kellum JA, Angus DC, Johnson JP, et al: Continuous versus intermittent renal replacement therapy: a meta-analysis. *Intensive Care Med* 2002; 28:29–37
496. Tonelli M, Manns B, Feller-Kopman D: Acute renal failure in the intensive care unit: a systematic review of the impact of dialytic modality on mortality and renal recovery. *Am J Kidney Dis* 2002; 40:875–885
497. Augustine JJ, Sandy D, Seifert TH, et al: A randomized controlled trial comparing intermittent with continuous dialysis in patients with ARF. *Am J Kidney Dis* 2004; 44:1000–1007
498. Gasparović V, Filipović-Grcić I, Merkle M, et al: Continuous renal replacement therapy (CRRT) or intermittent hemodialysis (IHD)—what is the procedure of choice in critically ill patients? *Ren Fail* 2003; 25:855–862
499. Mehta RL, McDonald B, Gabbai FB, et al; Collaborative Group for Treatment of ARF in the ICU: A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. *Kidney Int* 2001; 60:1154–1163

500. Uehlinger DE, Jakob SM, Ferrari P, et al: Comparison of continuous and intermittent renal replacement therapy for acute renal failure. *Nephrol Dial Transplant* 2005; 20:1630–1637
501. Vinsonneau C, Camus C, Combes A, et al; Hemodiafe Study Group: Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial. *Lancet* 2006; 368:379–385
502. John S, Griesbach D, Baumgärtel M, et al: Effects of continuous haemofiltration vs intermittent haemodialysis on systemic haemodynamics and splanchnic regional perfusion in septic shock patients: a prospective, randomized clinical trial. *Nephrol Dial Transplant* 2001; 16:320–327
503. Misset B, Timsit JF, Chevret S, et al: A randomized cross-over comparison of the hemodynamic response to intermittent hemodialysis and continuous hemofiltration in ICU patients with acute renal failure. *Intensive Care Med* 1996; 22:742–746
504. Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, et al: Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. *Crit Care Med* 2002; 30:2205–2211
505. Ronco C, Bellomo R, Homel P, et al: Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. *Lancet* 2000; 356:26–30
506. Bellomo R, Cass A, Cole L, et al: Intensity of continuous renal-replacement therapy in critically ill patients. *N Engl J Med*. 2009;361(17):1627–1638
507. Palevsky PM, Zhang JH, O'Connor TZ, et al: Intensity of renal support in critically ill patients with acute kidney injury. *N Engl J Med*. 2008;359(1):7–20
508. Gaudry S, Hajage D, Schortgen F, et al; AKIKI Study Group: Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. *N Engl J Med* 2016; 375:122–133
509. Zarbock A, Kellum JA, Schmidt C, et al: Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. *JAMA* 2016; 315:2190–2199
510. Cooper DJ, Walley KR, Wiggs BR, et al: Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study. *Ann Intern Med* 1990; 112:492–498
511. Mathieu D, Neviere R, Billard V, et al: Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: a prospective, controlled clinical study. *Crit Care Med* 1991; 19:1352–1356
512. Cook D, Crowther M, Meade M, et al: Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. *Crit Care Med* 2005; 33:1565–1571
513. Kahn SR, Lim W, Dunn AS, et al: Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2012;141(2 Suppl):e195S–e226S
514. Alhazzani W, Lim W, Jaeschke RZ, et al: Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. *Crit Care Med* 2013; 41:2088–2098
515. Levi M, Levy M, Williams MD, et al; Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group: Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). *Am J Respir Crit Care Med* 2007; 176:483–490
516. Beitland S, Sandven I, Kjærvik LK, et al: Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis. *Intensive Care Med* 2015; 41:1209–1219
517. Phung OJ, Kahn SR, Cook DJ, et al: Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis. *Chest* 2011; 140:374–381
518. Mahan CE, Pini M, Spyropoulos AC: Venous thromboembolism prophylaxis with unfractionated heparin in the hospitalized medical patient: the case for thrice daily over twice daily dosing. *Intern Emerg Med* 2010; 5:299–306
519. Junqueira DR, Perini E, Penholati RR, Carvalho MG: Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. *Cochrane Database Syst Rev*. 2012(9):CD007557
520. Cook D, Meade M, Guyatt G, et al: Dalteparin versus unfractionated heparin in critically ill patients. *N Engl J Med*. 2011;364(14):1305–1314
521. Fowler RA, Mittmann N, Geerts W, et al; Canadian Critical Care Trials Group; Australia and New Zealand Intensive Care Society Clinical Trials Group: Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. *JAMA* 2014; 312:2135–2145
522. Douketis J, Cook D, Meade M, et al; Canadian Critical Care Trials Group: Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. *Arch Intern Med* 2008; 168:1805–1812
523. Arabi YM, Alsalamy S, Al-Dawood A, et al: Thromboprophylaxis using combined intermittent pneumatic compression and pharmacologic prophylaxis versus pharmacologic prophylaxis alone in critically ill patients: study protocol for a randomized controlled trial. *Trials* 2016; 17:390
524. Kakkos SK, Caprini JA, Geroulakos G, Nicolaidis AN, Stansby GP, Reddy DJ: Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. *Cochrane Database Syst Rev*. 2008;(4):CD005258
525. Falck-Ytter Y, Francis CW, Johanson NA, et al: Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2012;141(2 Suppl):e278S–e325S
526. Gould MK, Garcia DA, Wren SM, et al: Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl):e227S–e277S
527. Pavn JM, Adam SS, Razouki ZA, et al: Effectiveness of Intermittent Pneumatic Compression Devices for Venous Thromboembolism Prophylaxis in High-Risk Surgical Patients: A Systematic Review. *J Arthroplasty* 2016; 31:524–532
528. Sachdeva A, Dalton M, Amaragiri SV, Lees T: Graduated compression stockings for prevention of deep vein thrombosis. *Cochrane Database Syst Rev*. 2014(12):CD001484
529. Arabi YM, Khedr M, Dara SI, et al: Use of intermittent pneumatic compression and not graduated compression stockings is associated with lower incident VTE in critically ill patients: a multiple propensity scores adjusted analysis. *Chest* 2013; 144:152–159
530. Cook DJ, Griffith LE, Walter SD, et al; Canadian Critical Care Trials Group: The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. *Crit Care* 2001; 5:368–375
531. Bardou M, Quenot JP, Barkun A: Stress-related mucosal disease in the critically ill patient. *Nat Rev Gastroenterol Hepatol* 2015; 12:98–107
532. Cook DJ, Fuller HD, Guyatt GH, et al: Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. *N Engl J Med* 1994; 330:377–381
533. Krag M, Perner A, Wetterslev J, et al; SUP-ICU co-authors: Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients. *Intensive Care Med* 2015; 41:833–845
534. Andersson B, Nilsson J, Brandt J, et al: Gastrointestinal complications after cardiac surgery. *Br J Surg* 2005; 92:326–333
535. Bruno JJ, Canada TW, Wakefield CD, et al: Stress-related mucosal bleeding in critically ill oncology patients. *J Oncol Pharm Pract* 2009; 15:9–16
536. D'Ancona G, Baillet R, Poirier B, et al: Determinants of gastrointestinal complications in cardiac surgery. *Tex Heart Inst J* 2003; 30:280–285

537. Faisy C, Guerot E, Diehl JL, et al: Clinically significant gastrointestinal bleeding in critically ill patients with and without stress-ulcer prophylaxis. *Intensive Care Med* 2003; 29:1306–1313
538. Krag M, Perner A, Wetterslev J, et al: Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients. A systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. *Intensive Care Med* 2014; 40:11–22
539. Sasabuchi Y, Matsui H, Lefor AK, et al: Risks and Benefits of Stress Ulcer Prophylaxis for Patients With Severe Sepsis. *Crit Care Med* 2016; 44:e464–e469
540. Eastwood GM, Litton E, Bellomo R, et al: Opinions and practice of stress ulcer prophylaxis in Australian and New Zealand intensive care units. *Crit Care Resusc* 2014; 16:170–174
541. Krag M, Perner A, Wetterslev J, et al; SUP-ICU Collaborators: Stress ulcer prophylaxis in the intensive care unit: an international survey of 97 units in 11 countries. *Acta Anaesthesiol Scand* 2015; 59:576–585
542. Preslaski CR, Mueller SW, Kiser TH, et al: A survey of prescriber perceptions about the prevention of stress-related mucosal bleeding in the intensive care unit. *J Clin Pharm Ther* 2014; 39:658–662
543. Shears M, Alhazzani W, Marshall JC, et al: Stress ulcer prophylaxis in critical illness: a Canadian survey. *Can J Anaesth* 2016; 63:718–724
544. Alshamsi F, Belley-Cote E, Cook D, et al: Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. *Crit Care* 2016; 20:120
545. Alhazzani W, Alenezi F, Jaeschke RZ, et al: Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. *Crit Care Med* 2013; 41:693–705
546. Barkun AN, Bardou M, Pham CQ, Martel M: Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis. *Am J Gastroenterol*. 2012;107(4):507–520; quiz 21
547. Barkun AN, Adam V, Martel M, et al: Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists. *Value Health* 2013; 16:14–22
548. MacLaren R, Campbell J: Cost-effectiveness of histamine receptor-2 antagonist versus proton pump inhibitor for stress ulcer prophylaxis in critically ill patients\*. *Crit Care Med* 2014; 42:809–815
549. Villet S, Chiolerio RL, Bollmann MD, et al: Negative impact of hypocaloric feeding and energy balance on clinical outcome in ICU patients. *Clin Nutr* 2005; 24:502–509
550. Adams S, Dellinger EP, Wertz MJ, et al: Enteral versus parenteral nutritional support following laparotomy for trauma: a randomized prospective trial. *J Trauma* 1986; 26:882–891
551. Borzotta AP, Pennings J, Papisadero B, et al: Enteral versus parenteral nutrition after severe closed head injury. *J Trauma* 1994; 37:459–468
552. Dunham CM, Frankenfield D, Belzberg H, et al: Gut failure—predictor of or contributor to mortality in mechanically ventilated blunt trauma patients? *J Trauma* 1994; 37:30–34
553. Harvey SE, Parrott F, Harrison DA, et al; CALORIES Trial Investigators: Trial of the route of early nutritional support in critically ill adults. *N Engl J Med* 2014; 371:1673–1684
554. Justo Meirelles CM, de Aguiar-Nascimento JE: Enteral or parenteral nutrition in traumatic brain injury: a prospective randomised trial. *Nutr Hosp* 2011; 26:1120–1124
555. Kalfarentzos F, Kehagias J, Mead N, et al: Enteral nutrition is superior to parenteral nutrition in severe acute pancreatitis: results of a randomized prospective trial. *Br J Surg* 1997; 84:1665–1669
556. Moore FA, Moore EE, Jones TN, McCroskey BL, Peterson VM: TEN versus TPN following major abdominal trauma—reduced septic morbidity. *J Trauma*. 1989;29(7):916–922; discussion 22–23
557. Peterson VM, Moore EE, Jones TN, et al: Total enteral nutrition versus total parenteral nutrition after major torso injury: attenuation of hepatic protein reprioritization. *Surgery* 1988; 104:199–207
558. Sun JK, Mu XW, Li WQ, et al: Effects of early enteral nutrition on immune function of severe acute pancreatitis patients. *World J Gastroenterol* 2013; 19:917–922
559. Wang G, Wen J, Xu L, et al: Effect of enteral nutrition and ecoinutrition on bacterial translocation and cytokine production in patients with severe acute pancreatitis. *J Surg Res* 2013; 183:592–597
560. Harvey SE, Parrott F, Harrison DA, et al: A multicentre, randomised controlled trial comparing the clinical effectiveness and cost-effectiveness of early nutritional support via the parenteral versus the enteral route in critically ill patients (CALORIES). *Health Technol Assess* 2016; 20:1–144
561. Kudsk KA: Current aspects of mucosal immunology and its influence by nutrition. *Am J Surg* 2002; 183:390–398
562. McClave SA, Heyland DK: The physiologic response and associated clinical benefits from provision of early enteral nutrition. *Nutr Clin Pract* 2009; 24:305–315
563. Casaer MP, Mesotten D, Hermans G, et al: Early versus late parenteral nutrition in critically ill adults. *N Engl J Med* 2011; 365:506–517
564. Doig GS, Simpson F, Sweetman EA, et al; Early PN Investigators of the ANZICS Clinical Trials Group: Early parenteral nutrition in critically ill patients with short-term relative contraindications to early enteral nutrition: a randomized controlled trial. *JAMA* 2013; 309:2130–2138
565. Rapp RP, Donaldson ES, Bivins BA: Parenteral nutrition in a patient with familial Type IV hypertriglyceridemia: a dilemma. *Drug Intell Clin Pharm* 1983; 17:458–460
566. Young B, Ott L, Haack D, et al: Effect of total parenteral nutrition upon intracranial pressure in severe head injury. *J Neurosurg* 1987; 67:76–80
567. Sadique Z, Grieve R, Harrison D, et al: Cost-Effectiveness Of Early Parenteral Versus Enteral Nutrition In Critically Ill Patients. *Value Health* 2015; 18:A532
568. Chiarelli A, Enzi G, Casadei A, et al: Very early nutrition supplementation in burned patients. *Am J Clin Nutr* 1990; 51:1035–1039
569. Dvorak MF, Noonan VK, Bélanger L, et al: Early versus late enteral feeding in patients with acute cervical spinal cord injury: a pilot study. *Spine (Phila Pa 1976)* 2004; 29:E175–E180
570. Eyer SD, Micon LT, Konstantinides FN, et al: Early enteral feeding does not attenuate metabolic response after blunt trauma. *J Trauma* 1993; 34:639–43; discussion 643
571. Grahm TW, Zadrozny DB, Harrington T: The benefits of early jejunal hyperalimentation in the head-injured patient. *Neurosurgery* 1989; 25:729–735
572. Hasse JM, Blue LS, Liepa GU, et al: Early enteral nutrition support in patients undergoing liver transplantation. *JPEN J Parenter Enteral Nutr* 1995; 19:437–443
573. Minard G, Kudsk KA, Melton S, et al: Early versus delayed feeding with an immune-enhancing diet in patients with severe head injuries. *JPEN J Parenter Enteral Nutr* 2000; 24:145–149
574. Moore EE, Jones TN: Benefits of immediate jejunostomy feeding after major abdominal trauma—a prospective, randomized study. *J Trauma* 1986; 26:874–881
575. Nguyen NQ, Fraser RJ, Bryant LK, et al: The impact of delaying enteral feeding on gastric emptying, plasma cholecystokinin, and peptide YY concentrations in critically ill patients. *Crit Care Med* 2008; 36:1469–1474
576. Peng YZ, Yuan ZQ, Xiao GX: Effects of early enteral feeding on the prevention of enterogenic infection in severely burned patients. *Burns* 2001; 27:145–149
577. Singh G, Ram RP, Khanna SK: Early postoperative enteral feeding in patients with nontraumatic intestinal perforation and peritonitis. *J Am Coll Surg* 1998; 187:142–146
578. Chuntarakul C, Chinswangwatanakul V, Chockvivanavanit S, Siltharm S, Pongprasobchai T, Bunnak A: Early nutritional support in severe traumatic patients. *J Med Assoc Thai*. 1996;79(1):21–26
579. Chourdakis M, Kraus MM, Tzellos T, et al: Effect of early compared with delayed enteral nutrition on endocrine function in patients with traumatic brain injury: an open-labeled randomized trial. *JPEN J Parenter Enteral Nutr* 2012; 36:108–116
580. Doig GS, Heighes PT, Simpson F, et al: Early enteral nutrition reduces mortality in trauma patients requiring intensive care: a meta-analysis of randomised controlled trials. *Injury* 2011; 42:50–56

581. Doig GS, Heighes PT, Simpson F, et al: Early enteral nutrition, provided within 24 h of injury or intensive care unit admission, significantly reduces mortality in critically ill patients: a meta-analysis of randomised controlled trials. *Intensive Care Med* 2009; 35:2018–2027
582. Malhotra A, Mathur AK, Gupta S: Early enteral nutrition after surgical treatment of gut perforations: a prospective randomised study. *J Postgrad Med* 2004; 50:102–106
583. Pupelis G, Austrums E, Jansone A, et al: Randomised trial of safety and efficacy of postoperative enteral feeding in patients with severe pancreatitis: preliminary report. *Eur J Surg* 2000; 166:383–387
584. Arabi YM, Aldawood AS, Haddad SH, et al; PermiT Trial Group: Permissive Underfeeding or Standard Enteral Feeding in Critically Ill Adults. *N Engl J Med* 2015; 372:2398–2408
585. Marik PE, Hooper MH: Normocaloric versus hypocaloric feeding on the outcomes of ICU patients: a systematic review and meta-analysis. *Intensive Care Med* 2016; 42:316–323
586. Arabi YM, Tamim HM, Dhar GS, et al: Permissive underfeeding and intensive insulin therapy in critically ill patients: a randomized controlled trial. *Am J Clin Nutr* 2011; 93:569–577
587. Charles EJ, Petroze RT, Metzger R, et al: Hypocaloric compared with eucaloric nutritional support and its effect on infection rates in a surgical intensive care unit: a randomized controlled trial. *Am J Clin Nutr* 2014; 100:1337–1343
588. Ibrahim EH, Mehringer L, Prentice D, et al: Early versus late enteral feeding of mechanically ventilated patients: results of a clinical trial. *JPEN J Parenter Enteral Nutr* 2002; 26:174–181
589. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Rice TW, Wheeler AP, et al: Initial trophic vs full enteral feeding in patients with acute lung injury: the EDEN randomized trial. *JAMA* 2012;307(8):795–803
590. Petros S, Horbach M, Seidel F, et al: Hypocaloric vs Normocaloric Nutrition in Critically Ill Patients: A Prospective Randomized Pilot Trial. *JPEN J Parenter Enteral Nutr* 2016; 40:242–249
591. Rice TW, Mogan S, Hays MA, et al: Randomized trial of initial trophic versus full-energy enteral nutrition in mechanically ventilated patients with acute respiratory failure. *Crit Care Med* 2011; 39:967–974
592. Needham DM, Dinglas VD, Bienvenu OJ, et al; NIH NHLBI ARDS Network: One year outcomes in patients with acute lung injury randomised to initial trophic or full enteral feeding: prospective follow-up of EDEN randomised trial. *BMJ* 2013; 346:f1532
593. Garcia de Acilu M, Leal S, Caralt B, Roca O, Sabater J, Masclans JR: The role of omega-3 polyunsaturated fatty acids in the treatment of patients with acute respiratory distress syndrome: a clinical review. *Biomed Res Int*. 2015;2015:653750
594. Manzanares W, Dhaliwal R, Jurewitsch B, et al: Parenteral fish oil lipid emulsions in the critically ill: a systematic review and meta-analysis. *JPEN J Parenter Enteral Nutr* 2014; 38:20–28
595. Zhu D, Zhang Y, Li S, et al: Enteral omega-3 fatty acid supplementation in adult patients with acute respiratory distress syndrome: a systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. *Intensive Care Med* 2014; 40:504–512
596. Rice TW, Wheeler AP, Thompson BT, et al; NIH NHLBI Acute Respiratory Distress Syndrome Network of Investigators; NHLBI ARDS Clinical Trials Network: Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. *JAMA* 2011; 306:1574–1581
597. McClave SA, DeMeo MT, DeLegge MH, et al: North American Summit on Aspiration in the Critically Ill Patient: consensus statement. *JPEN J Parenter Enteral Nutr* 2002; 26:S80–S85
598. McClave SA, Lukan JK, Stefater JA, et al: Poor validity of residual volumes as a marker for risk of aspiration in critically ill patients. *Crit Care Med* 2005; 33:324–330
599. Metheny NA, Schallom L, Oliver DA, Clouse RE: Gastric residual volume and aspiration in critically ill patients receiving gastric feedings. *Am J Crit Care*. 2008;17(6):512–519; quiz 20
600. Montejo JC, Miñambres E, Bordejé L, et al: Gastric residual volume during enteral nutrition in ICU patients: the REGANE study. *Intensive Care Med* 2010; 36:1386–1393
601. Poulard F, Dimet J, Martin-Lefevre L, et al: Impact of not measuring residual gastric volume in mechanically ventilated patients receiving early enteral feeding: a prospective before-after study. *JPEN J Parenter Enteral Nutr* 2010; 34:125–130
602. Reignier J, Mercier E, Le Gouge A, et al; Clinical Research in Intensive Care and Sepsis (CRICS) Group: Effect of not monitoring residual gastric volume on risk of ventilator-associated pneumonia in adults receiving mechanical ventilation and early enteral feeding: a randomized controlled trial. *JAMA* 2013; 309:249–256
603. Elke G, Felbinger TW, Heyland DK: Gastric residual volume in critically ill patients: a dead marker or still alive? *Nutr Clin Pract* 2015; 30:59–71
604. van Noord C, Dieleman JP, van Herpen G, et al: Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. *Drug Saf* 2010; 33:1003–1014
605. Ray WA, Murray KT, Meredith S, et al: Oral erythromycin and the risk of sudden death from cardiac causes. *N Engl J Med* 2004; 351:1089–1096
606. Lewis K, Alqahtani Z, McIntyre L, et al: The efficacy and safety of prokinetic agents in critically ill patients receiving enteral nutrition: a systematic review and meta-analysis of randomized trials. *Crit Care* 2016; 20:259
607. Freeman BD, Dixon DJ, Coopersmith CM, et al: Pharmacoeconomics of QT-interval prolonging drug administration in critically ill patients. *Pharmacoeconom Drug Saf* 2008; 17:971–981
608. Fruhwald S, Kainz J: Effect of ICU interventions on gastrointestinal motility. *Curr Opin Crit Care* 2010; 16:159–164
609. Mentec H, Dupont H, Bocchetti M, et al: Upper digestive intolerance during enteral nutrition in critically ill patients: frequency, risk factors, and complications. *Crit Care Med* 2001; 29:1955–1961
610. Dive A, Foret F, Jamart J, et al: Effect of dopamine on gastrointestinal motility during critical illness. *Intensive Care Med* 2000; 26:901–907
611. Dive A, Miesse C, Jamart J, et al: Duodenal motor response to continuous enteral feeding is impaired in mechanically ventilated critically ill patients. *Clin Nutr* 1994; 13:302–306
612. Zaloga GP, Marik P: Promotility agents in the intensive care unit. *Crit Care Med* 2000; 28:2657–2659
613. Tiancha H, Jiyong J, Min Y: How to Promote Bedside Placement of the Postpyloric Feeding Tube: A Network Meta-Analysis of Randomized Controlled Trials. *JPEN J Parenter Enteral Nutr* 2015; 39:521–530
614. Alhazzani W, Almasoud A, Jaeschke R, et al: Small bowel feeding and risk of pneumonia in adult critically ill patients: a systematic review and meta-analysis of randomized trials. *Crit Care* 2013; 17:R127
615. Deane AM, Dhaliwal R, Day AG, Ridley EJ, Davies AR, Heyland DK: Comparisons between intragastric and small intestinal delivery of enteral nutrition in the critically ill: a systematic review and meta-analysis. *Crit Care*. 2013;17(3):R125
616. Alhazzani W, Jacobi J, Sindi A, et al: The effect of selenium therapy on mortality in patients with sepsis syndrome: a systematic review and meta-analysis of randomized controlled trials. *Crit Care Med* 2013; 41:1555–1564
617. Valenta J, Brodska H, Drabek T, et al: High-dose selenium substitution in sepsis: a prospective randomized clinical trial. *Intensive Care Med* 2011; 37:808–815
618. Bloos F, Trips E, Nierhaus A, et al; for SepNet Critical Care Trials Group: Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients With Severe Sepsis or Septic Shock: A Randomized Clinical Trial. *JAMA Intern Med* 2016; 176:1266–1276
619. Bertolini G, Iapichino G, Radrizzani D, et al: Early enteral immunonutrition in patients with severe sepsis: results of an interim analysis of a randomized multicentre clinical trial. *Intensive Care Med* 2003; 29:834–840
620. Suchner U, Kuhn KS, Fürst P: The scientific basis of immunonutrition. *Proc Nutr Soc* 2000; 59:553–563
621. Bower RH, Cerra FB, Bershadsky B, et al: Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial. *Crit Care Med* 1995; 23:436–449

622. Caparrós T, Lopez J, Grau T: Early enteral nutrition in critically ill patients with a high-protein diet enriched with arginine, fiber, and antioxidants compared with a standard high-protein diet. The effect on nosocomial infections and outcome. *JPEN J Parenter Enteral Nutr* 2001; 25:299–308; discussion 308
623. Galbán C, Montejo JC, Mesejo A, et al: An immune-enhancing enteral diet reduces mortality rate and episodes of bacteremia in septic intensive care unit patients. *Crit Care Med* 2000; 28:643–648
624. Santora R, Kozar RA: Molecular mechanisms of pharmacconutrients. *J Surg Res* 2010; 161:288–294
625. Kieft H, Roos AN, van Drunen JD, et al: Clinical outcome of immunonutrition in a heterogeneous intensive care population. *Intensive Care Med* 2005; 31:524–532
626. Marik PE, Zaloga GP: Early enteral nutrition in acutely ill patients: a systematic review. *Crit Care Med* 2001; 29:2264–2270
627. Avenell A: Glutamine in critical care: current evidence from systematic reviews. *Proc Nutr Soc* 2006; 65:236–241
628. Avenell A: Hot topics in parenteral nutrition. Current evidence and ongoing trials on the use of glutamine in critically-ill patients and patients undergoing surgery. *Proc Nutr Soc* 2009; 68:261–268
629. Jiang H, Chen W, Hu W, et al: [The impact of glutamine-enhanced enteral nutrition on clinical outcome of patients with critical illness: a systematic review of randomized controlled trials]. *Zhonghua Shao Shang Za Zhi* 2009; 25:325–330
630. Novak F, Heyland DK, Avenell A, et al: Glutamine supplementation in serious illness: a systematic review of the evidence. *Crit Care Med* 2002; 30:2022–2029
631. Grau T, Bonet A, Miñambres E, et al; Metabolism, Nutrition Working Group, SEMICYUC, Spain: The effect of L-alanyl-L-glutamine dipeptide supplemented total parenteral nutrition on infectious morbidity and insulin sensitivity in critically ill patients. *Crit Care Med* 2011; 39:1263–1268
632. Wang Z, Forceville X, Van Antwerpen P, et al: A large-bolus injection, but not continuous infusion of sodium selenite improves outcome in peritonitis. *Shock* 2009; 32:140–146
633. Wernerman J, Kirketeig T, Andersson B, et al; Scandinavian Critical Care Trials Group: Scandinavian glutamine trial: a pragmatic multi-centre randomised clinical trial of intensive care unit patients. *Acta Anaesthesiol Scand* 2011; 55:812–818
634. Heyland D, Muscedere J, Wischmeyer PE, et al; Canadian Critical Care Trials Group: A randomized trial of glutamine and antioxidants in critically ill patients. *N Engl J Med* 2013; 368:1489–1497
635. Beale RJ, Sherry T, Lei K, et al: Early enteral supplementation with key pharmacconutrients improves Sequential Organ Failure Assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double-blind trial. *Crit Care Med* 2008; 36:131–144
636. Fuentes-Orozco C, Anaya-Prado R, González-Ojeda A, et al: L-alanyl-L-glutamine-supplemented parenteral nutrition improves infectious morbidity in secondary peritonitis. *Clin Nutr* 2004; 23:13–21
637. Puskarich MA, Kline JA, Krabill V, et al: Preliminary safety and efficacy of L-carnitine infusion for the treatment of vasopressor-dependent septic shock: a randomized control trial. *JPEN J Parenter Enteral Nutr* 2014; 38:736–743
638. White DB, Engelberg RA, Wenrich MD, et al: The language of prognostication in intensive care units. *Med Decis Making* 2010; 30:76–83
639. Chiarichiaro J, Buddadhumaruk P, Arnold RM, et al: Quality of communication in the ICU and surrogate's understanding of prognosis. *Crit Care Med* 2015; 43:542–548
640. Downar J, You JJ, Bagshaw SM, et al; Canadian Critical Care Trials Group: Nonbeneficial treatment Canada: definitions, causes, and potential solutions from the perspective of healthcare practitioners\*. *Crit Care Med* 2015; 43:270–281
641. Kon AA, Shepard EK, Sederstrom NO, et al: Defining Futile and Potentially Inappropriate Interventions: A Policy Statement From the Society of Critical Care Medicine Ethics Committee. *Crit Care Med* 2016; 44:1769–1774
642. Nelson JE, Curtis JR, Mulkerin C, et al; Improving Palliative Care in the ICU (IPAL-ICU) Project Advisory Board: Choosing and using screening criteria for palliative care consultation in the ICU: a report from the Improving Palliative Care in the ICU (IPAL-ICU) Advisory Board. *Crit Care Med* 2013; 41:2318–2327
643. Detering KM, Hancock AD, Reade MC, et al: The impact of advance care planning on end of life care in elderly patients: randomised controlled trial. *BMJ* 2010; 340:c1345
644. Scheunemann LP, McDevitt M, Carson SS, et al: Randomized, controlled trials of interventions to improve communication in intensive care: a systematic review. *Chest* 2011; 139:543–554
645. Bosslet GT, Pope TM, Rubinfeld GD, et al; American Thoracic Society ad hoc Committee on Futile and Potentially Inappropriate Treatment; American Thoracic Society; American Association for Critical Care Nurses; American College of Chest Physicians; European Society for Intensive Care Medicine; Society of Critical Care: An Official ATS/AACN/ACCP/ESICM/SCCM Policy Statement: Responding to Requests for Potentially Inappropriate Treatments in Intensive Care Units. *Am J Respir Crit Care Med* 2015; 191:1318–1330
646. Kon AA, Davidson JE, Morrison W, et al; American College of Critical Care Medicine; American Thoracic Society: Shared Decision Making in ICUs: An American College of Critical Care Medicine and American Thoracic Society Policy Statement. *Crit Care Med* 2016; 44:188–201
647. Aslakson R, Cheng J, Vollenweider D, et al: Evidence-based palliative care in the intensive care unit: a systematic review of interventions. *J Palliat Med* 2014; 17:219–235
648. Schulz V, Novick RJ: The distinct role of palliative care in the surgical intensive care unit. *Semin Cardiothorac Vasc Anesth* 2013; 17:240–248
649. Khandelwal N, Kross EK, Engelberg RA, et al: Estimating the effect of palliative care interventions and advance care planning on ICU utilization: a systematic review. *Crit Care Med* 2015; 43:1102–1111
650. DeCato TW, Engelberg RA, Downey L, et al: Hospital variation and temporal trends in palliative and end-of-life care in the ICU. *Crit Care Med* 2013; 41:1405–1411
651. Sprung CL, Truog RD, Curtis JR, et al: Seeking worldwide professional consensus on the principles of end-of-life care for the critically ill. The Consensus for Worldwide End-of-Life Practice for Patients in Intensive Care Units (WELPICUS) study. *Am J Respir Crit Care Med* 2014; 190:855–866
652. Davidson JE: Family presence on rounds in neonatal, pediatric, and adult intensive care units. *Ann Am Thorac Soc* 2013; 10:152–156
653. Flanders SA, Strasen JH: Review of evidence about family presence during resuscitation. *Crit Care Nurs Clin North Am* 2014; 26:533–550
654. Oczkowski SJ, Mazzetti I, Cupido C, et al: The offering of family presence during resuscitation: a systematic review and meta-analysis. *J Intensive Care* 2015; 3:41
655. Oczkowski SJ, Mazzetti I, Cupido C, et al; Canadian Critical Care Society: Family presence during resuscitation: A Canadian Critical Care Society position paper. *Can Respir J* 2015; 22:201–205v

## APPENDIX 1. Recommendations and Best Practice Statements

### A. INITIAL RESUSCITATION

1. Sepsis and septic shock are medical emergencies, and we recommend that treatment and resuscitation begin immediately (BPS).
2. We recommend that, in the resuscitation from sepsis-induced hypoperfusion, at least 30 mL/kg of IV crystalloid fluid be given within the first 3 hours (strong recommendation, low quality of evidence).
3. We recommend that, following initial fluid resuscitation, additional fluids be guided by frequent reassessment of hemodynamic status (BPS).

Remarks: Reassessment should include a thorough clinical examination and evaluation of available physiologic variables (heart rate, blood pressure, arterial oxygen saturation, respiratory rate, temperature, urine output, and others, as available) as well as other noninvasive or invasive monitoring, as available.

4. We recommend further hemodynamic assessment (such as assessing cardiac function) to determine the type of shock if the clinical examination does not lead to a clear diagnosis (BPS).
5. We suggest that dynamic over static variables be used to predict fluid responsiveness, where available (weak recommendation, low quality of evidence).
6. We recommend an initial target mean arterial pressure of 65 mm Hg in patients with septic shock requiring vasopressors (strong recommendation, moderate quality of evidence).
7. We suggest guiding resuscitation to normalize lactate in patients with elevated lactate levels as a marker of tissue hypoperfusion (weak recommendation, low quality of evidence).

### B. SCREENING FOR SEPSIS AND PERFORMANCE IMPROVEMENT

1. We recommend that hospitals and hospital systems have a performance improvement program for sepsis, including sepsis screening for acutely ill, high risk patients (BPS).

### C. DIAGNOSIS

1. We recommend that appropriate routine microbiologic cultures (including blood) be obtained before starting antimicrobial therapy in patients with suspected sepsis or septic shock if doing so results in no substantial delay in the start of antimicrobials (BPS).

**Remarks: Appropriate routine microbiologic cultures always include at least two sets of blood cultures (aerobic and anaerobic).**

### D. ANTIMICROBIAL THERAPY

1. We recommend that administration of IV antimicrobials should be initiated as soon as possible after recognition and within one hour for both sepsis and septic shock (strong recommendation, moderate quality of evidence).
2. We recommend empiric broad-spectrum therapy with one or more antimicrobials for patients presenting with sepsis or septic shock to cover all likely pathogens (including bacterial and potentially fungal or viral coverage) (strong recommendation, moderate quality of evidence).
3. We recommend that empiric antimicrobial therapy be narrowed once pathogen identification and sensitivities are established and/or adequate clinical improvement is noted (BPS).
4. We recommend against sustained systemic antimicrobial prophylaxis in patients with severe inflammatory states of noninfectious origin (e.g., severe pancreatitis, burn injury) (BPS).
5. We recommend that dosing strategies of antimicrobials be optimized based on accepted pharmacokinetic/pharmacodynamic principles and specific drug properties in patients with sepsis or septic shock (BPS).
6. We suggest empiric combination therapy (using at least two antibiotics of different antimicrobial classes) aimed at the most likely bacterial pathogen(s) for the initial management of septic shock (weak recommendation, low quality of evidence).

Remarks: Readers should review Table 6 for definitions of empiric, targeted/definitive, broad-spectrum, combination, and multidrug therapy before reading this section.

7. We suggest that combination therapy not be routinely used for ongoing treatment of most other serious infections, including bacteremia and sepsis without shock (weak recommendation, low quality of evidence).

Remarks: This does not preclude the use of multidrug therapy to broaden antimicrobial activity.

8. We recommend against combination therapy for the routine treatment of neutropenic sepsis/bacteremia (strong recommendation, moderate quality of evidence).

**Remarks: This does not preclude the use of multidrug therapy to broaden antimicrobial activity.**

(Continued)

## APPENDIX 1. (Continued). Recommendations and Best Practice Statements

9. If combination therapy is used for septic shock, we recommend de-escalation with discontinuation of combination therapy within the first few days in response to clinical improvement and/or evidence of infection resolution. This applies to both targeted (for culture-positive infections) and empiric (for culture-negative infections) combination therapy (BPS).
10. We suggest that an antimicrobial treatment duration of 7 to 10 days is adequate for most serious infections associated with sepsis and septic shock (weak recommendation, low quality of evidence).
11. We suggest that longer courses are appropriate in patients who have a slow clinical response, undrainable foci of infection, bacteremia with *Staphylococcus aureus*, some fungal and viral infections, or immunologic deficiencies, including neutropenia (weak recommendation, low quality of evidence).
12. We suggest that shorter courses are appropriate in some patients, particularly those with rapid clinical resolution following effective source control of intra-abdominal or urinary sepsis and those with anatomically uncomplicated pyelonephritis (weak recommendation, low quality of evidence).
13. We recommend daily assessment for de-escalation of antimicrobial therapy in patients with sepsis and septic shock (BPS).
14. We suggest that measurement of procalcitonin levels can be used to support shortening the duration of antimicrobial therapy in sepsis patients (weak recommendation, low quality of evidence).
15. We suggest that procalcitonin levels can be used to support the discontinuation of empiric antibiotics in patients who initially appeared to have sepsis, but subsequently have limited clinical evidence of infection (weak recommendation, low quality of evidence).

### E. SOURCE CONTROL

1. We recommend that a specific anatomic diagnosis of infection requiring emergent source control should be identified or excluded as rapidly as possible in patients with sepsis or septic shock, and that any required source control intervention should be implemented as soon as medically and logistically practical after the diagnosis is made (BPS).
2. We recommend prompt removal of intravascular access devices that are a possible source of sepsis or septic shock after other vascular access has been established (BPS).

### F. FLUID THERAPY

1. We recommend that a fluid challenge technique be applied where fluid administration is continued as long as hemodynamic factors continue to improve (BPS).
2. We recommend crystalloids as the fluid of choice for initial resuscitation and subsequent intravascular volume replacement in patients with sepsis and septic shock (strong recommendation, moderate quality of evidence).
3. We suggest using either balanced crystalloids or saline for fluid resuscitation of patients with sepsis or septic shock (weak recommendation, low quality of evidence).
4. We suggest using albumin in addition to crystalloids for initial resuscitation and subsequent intravascular volume replacement in patients with sepsis and septic shock, when patients require substantial amounts of crystalloids (weak recommendation, low quality of evidence).
5. We recommend against using hydroxyethyl starches for intravascular volume replacement in patients with sepsis or septic shock (strong recommendation, high quality of evidence).
6. We suggest using crystalloids over gelatins when resuscitating patients with sepsis or septic shock (weak recommendation, low quality of evidence).

### G. VASOACTIVE MEDICATIONS

1. We recommend norepinephrine as the first-choice vasopressor (strong recommendation, moderate quality of evidence).
2. We suggest adding either vasopressin (up to 0.03 U/min) (weak recommendation, moderate quality of evidence) or epinephrine (weak recommendation, low quality of evidence) to norepinephrine with the intent of raising mean arterial pressure to target, or adding vasopressin (up to 0.03 U/min) (weak recommendation, moderate quality of evidence) to decrease norepinephrine dosage.
3. We suggest using dopamine as an alternative vasopressor agent to norepinephrine only in highly selected patients (e.g., patients with low risk of tachyarrhythmias and absolute or relative bradycardia) (weak recommendation, low quality of evidence).
4. We recommend against using low-dose dopamine for renal protection (strong recommendation, high quality of evidence).
5. We suggest using dobutamine in patients who show evidence of persistent hypoperfusion despite adequate fluid loading and the use of vasopressor agents (weak recommendation, low quality of evidence).

(Continued)



## APPENDIX 1. (Continued). Recommendations and Best Practice Statements

**Remarks: If initiated, dosing should be titrated to an end point reflecting perfusion, and the agent reduced or discontinued in the face of worsening hypotension or arrhythmias.**

- We suggest that all patients requiring vasopressors have an arterial catheter placed as soon as practical if resources are available (weak recommendation, very low quality of evidence).

### H. CORTICOSTEROIDS

- We suggest against using IV hydrocortisone to treat septic shock patients if adequate fluid resuscitation and vasopressor therapy are able to restore hemodynamic stability. If this is not achievable, we suggest IV hydrocortisone at a dose of 200 mg per day (weak recommendation, low quality of evidence).

### I. BLOOD PRODUCTS

- We recommend that RBC transfusion occur only when hemoglobin concentration decreases to  $< 7.0$  g/dL in adults in the absence of extenuating circumstances, such as myocardial ischemia, severe hypoxemia, or acute hemorrhage (strong recommendation, high quality of evidence).
- We recommend against the use of erythropoietin for treatment of anemia associated with sepsis (strong recommendation, moderate quality of evidence).
- We suggest against the use of fresh frozen plasma to correct clotting abnormalities in the absence of bleeding or planned invasive procedures (weak recommendation, very low quality of evidence).
- We suggest prophylactic platelet transfusion when counts are  $< 10,000/\text{mm}^3$  ( $10 \times 10^9/\text{L}$ ) in the absence of apparent bleeding and when counts are  $< 20,000/\text{mm}^3$  ( $20 \times 10^9/\text{L}$ ) if the patient has a significant risk of bleeding. Higher platelet counts ( $\geq 50,000/\text{mm}^3$  [ $50 \times 10^9/\text{L}$ ]) are advised for active bleeding, surgery, or invasive procedures (weak recommendation, very low quality of evidence).

### J. IMMUNOGLOBULINS

- We suggest against the use of IV immunoglobulins in patients with sepsis or septic shock (weak recommendation, low quality of evidence).

### K. BLOOD PURIFICATION

- We make no recommendation regarding the use of blood purification techniques.

### L. ANTICOAGULANTS

- We recommend against the use of antithrombin for the treatment of sepsis and septic shock (strong recommendation, moderate quality of evidence).
- We make no recommendation regarding the use of thrombomodulin or heparin for the treatment of sepsis or septic shock.

### M. MECHANICAL VENTILATION

- We recommend using a target tidal volume of 6 mL/kg predicted body weight compared with 12 mL/kg in adult patients with sepsis-induced acute respiratory distress syndrome (ARDS) (strong recommendation, high quality of evidence).
- We recommend using an upper limit goal for plateau pressures of 30 cm H<sub>2</sub>O over higher plateau pressures in adult patients with sepsis-induced severe ARDS (strong recommendation, moderate quality of evidence).
- We suggest using higher positive end-expiratory pressure (PEEP) over lower PEEP in adult patients with sepsis-induced moderate to severe ARDS (weak recommendation, moderate quality of evidence).
- We suggest using recruitment maneuvers in adult patients with sepsis-induced, severe ARDS (weak recommendation, moderate quality of evidence).
- We recommend using prone over supine position in adult patients with sepsis-induced ARDS and a Pao<sub>2</sub>/Fio<sub>2</sub> ratio  $< 150$  (strong recommendation, moderate quality of evidence).
- We recommend against using high-frequency oscillatory ventilation in adult patients with sepsis-induced ARDS (strong recommendation, moderate quality of evidence).
- We make no recommendation regarding the use of noninvasive ventilation for patients with sepsis-induced ARDS.
- We suggest using neuromuscular blocking agents for  $\leq 48$  hours in adult patients with sepsis-induced ARDS and a Pao<sub>2</sub>/Fio<sub>2</sub> ratio  $< 150$  mm Hg (weak recommendation, moderate quality of evidence).
- We recommend a conservative fluid strategy for patients with established sepsis-induced ARDS who do not have evidence of tissue hypoperfusion (strong recommendation, moderate quality of evidence).

(Continued)

**APPENDIX 1. (Continued). Recommendations and Best Practice Statements**

10. We recommend against the use of  $\beta$ -2 agonists for the treatment of patients with sepsis-induced ARDS without bronchospasm (strong recommendation, moderate quality of evidence).
11. We recommend against the routine use of the pulmonary artery catheter for patients with sepsis-induced ARDS (strong recommendation, high quality of evidence).
12. We suggest using lower tidal volumes over higher tidal volumes in adult patients with sepsis-induced respiratory failure without ARDS (weak recommendation, low quality of evidence).
13. We recommend that mechanically ventilated sepsis patients be maintained with the head of the bed elevated between 30 and 45 degrees to limit aspiration risk and to prevent the development of ventilator-associated pneumonia (strong recommendation, low quality of evidence).
14. We recommend using spontaneous breathing trials in mechanically ventilated patients with sepsis who are ready for weaning (strong recommendation, high quality of evidence).
15. We recommend using a weaning protocol in mechanically ventilated patients with sepsis-induced respiratory failure who can tolerate weaning (strong recommendation, moderate quality of evidence).

**N. SEDATION AND ANALGESIA**

1. We recommend that continuous or intermittent sedation be minimized in mechanically ventilated sepsis patients, targeting specific titration end points (BPS).

**O. GLUCOSE CONTROL**

1. We recommend a protocolized approach to blood glucose management in ICU patients with sepsis, commencing insulin dosing when two consecutive blood glucose levels are  $> 180$  mg/dL. This approach should target an upper blood glucose level  $\leq 180$  mg/dL rather than an upper target blood glucose level  $\leq 110$  mg/dL (strong recommendation, high quality of evidence).
2. We recommend that blood glucose values be monitored every 1 to 2 hours until glucose values and insulin infusion rates are stable, then every 4 hours thereafter in patients receiving insulin infusions (BPS).
3. We recommend that glucose levels obtained with point-of-care testing of capillary blood be interpreted with caution because such measurements may not accurately estimate arterial blood or plasma glucose values (BPS).
4. We suggest the use of arterial blood rather than capillary blood for point-of-care testing using glucose meters if patients have arterial catheters (weak recommendation, low quality of evidence).

**P. RENAL REPLACEMENT THERAPY**

1. We suggest that either continuous or intermittent renal replacement therapy (RRT) be used in patients with sepsis and acute kidney injury (weak recommendation, moderate quality of evidence).
2. We suggest using continuous therapies to facilitate management of fluid balance in hemodynamically unstable septic patients (weak recommendation, very low quality of evidence).
3. We suggest against the use of RRT in patients with sepsis and acute kidney injury for increase in creatinine or oliguria without other definitive indications for dialysis (weak recommendation, low quality of evidence).

**Q. BICARBONATE THERAPY**

1. We suggest against the use of sodium bicarbonate therapy to improve hemodynamics or to reduce vasopressor requirements in patients with hypoperfusion-induced lactic acidemia with  $\text{pH} \geq 7.15$  (weak recommendation, moderate quality of evidence).

**R. VENOUS THROMBOEMBOLISM PROPHYLAXIS**

1. We recommend pharmacologic prophylaxis (unfractionated heparin [UFH] or low-molecular-weight heparin [LMWH]) against venous thromboembolism (VTE) in the absence of contraindications to the use of these agents (strong recommendation, moderate quality of evidence).
2. We recommend LMWH rather than UFH for VTE prophylaxis in the absence of contraindications to the use of LMWH (strong recommendation, moderate quality of evidence).
3. We suggest combination pharmacologic VTE prophylaxis and mechanical prophylaxis, whenever possible (weak recommendation, low quality of evidence).
4. We suggest mechanical VTE prophylaxis when pharmacologic VTE is contraindicated (weak recommendation, low quality of evidence).

*(Continued)*

## APPENDIX 1. (Continued). Recommendations and Best Practice Statements

### S. STRESS ULCER PROPHYLAXIS

1. We recommend that stress ulcer prophylaxis be given to patients with sepsis or septic shock who have risk factors for gastrointestinal (GI) bleeding (strong recommendation, low quality of evidence).
2. We suggest using either proton pump inhibitors or histamine-2 receptor antagonists when stress ulcer prophylaxis is indicated (weak recommendation, low quality of evidence).
3. We recommend against stress ulcer prophylaxis in patients without risk factors for GI bleeding (BPS).

### T. NUTRITION

1. We recommend against the administration of early parenteral nutrition alone or parenteral nutrition in combination with enteral feedings (but rather initiate early enteral nutrition) in critically ill patients with sepsis or septic shock who can be fed enterally (strong recommendation, moderate quality of evidence).
2. We recommend against the administration of parenteral nutrition alone or in combination with enteral feeds (but rather to initiate IV glucose and advance enteral feeds as tolerated) over the first 7 days in critically ill patients with sepsis or septic shock for whom early enteral feeding is not feasible (strong recommendation, moderate quality of evidence).
3. We suggest the early initiation of enteral feeding rather than a complete fast or only IV glucose in critically ill patients with sepsis or septic shock who can be fed enterally (weak recommendation, low quality of evidence).
4. We suggest either early trophic/hypocaloric or early full enteral feeding in critically ill patients with sepsis or septic shock; if trophic/hypocaloric feeding is the initial strategy, then feeds should be advanced according to patient tolerance (weak recommendation, moderate quality of evidence).
5. We recommend against the use of omega-3 fatty acids as an immune supplement in critically ill patients with sepsis or septic shock (strong recommendation, low quality of evidence).

6. We suggest against routinely monitoring gastric residual volumes in critically ill patients with sepsis or septic shock (weak recommendation, low quality of evidence). However, we suggest measurement of gastric residuals in patients with feeding intolerance or who are considered to be at high risk of aspiration (weak recommendation, very low quality of evidence).

Remarks: This recommendation refers to nonsurgical critically ill patients with sepsis or septic shock.

7. We suggest the use of prokinetic agents in critically ill patients with sepsis or septic shock and feeding intolerance (weak recommendation, low quality of evidence).
8. We suggest placement of post-pyloric feeding tubes in critically ill patients with sepsis or septic shock with feeding intolerance or who are considered to be at high risk of aspiration (weak recommendation, low quality of evidence).
9. We recommend against the use of IV selenium to treat sepsis and septic shock (strong recommendation, moderate quality of evidence).
10. We suggest against the use of arginine to treat sepsis and septic shock (weak recommendation, low quality of evidence).
11. We recommend against the use of glutamine to treat sepsis and septic shock (strong recommendation, moderate quality of evidence).
12. We make no recommendation about the use of carnitine for sepsis and septic shock.

### U. SETTING GOALS OF CARE

1. We recommend that goals of care and prognosis be discussed with patients and families (BPS).
2. We recommend that goals of care be incorporated into treatment and end-of-life care planning, utilizing palliative care principles where appropriate (strong recommendation, moderate quality of evidence).
3. We suggest that goals of care be addressed as early as feasible, but no later than within 72 hours of ICU admission (weak recommendation, low quality of evidence).

## APPENDIX 2. Comparison of Recommendations From 2012 to 2016

2012 RECOMMENDATIONS	2016 RECOMMENDATIONS
<p><b>A. INITIAL RESUSCITATION</b></p> <ol style="list-style-type: none"> <li>1. Protocolized, quantitative resuscitation of patients with sepsis-induced tissue hypoperfusion (defined in this document as hypotension persisting after initial fluid challenge or blood lactate concentration <math>\geq 4</math> mmol/L). Goals during the first 6 hours of resuscitation:               <ol style="list-style-type: none"> <li>a. Central venous pressure 8–12 mm Hg</li> <li>b. Mean arterial pressure <math>\geq 65</math> mm Hg</li> <li>c. Urine output <math>\geq 0.5</math> mL/kg/hr</li> <li>d. Central venous (superior vena cava) or mixed venous oxygen saturation 70% or 65%, respectively (grade 1C).</li> </ol> </li> <li>2. In patients with elevated lactate levels, targeting resuscitation to normalize lactate (grade 2C).</li> </ol>	<p><b>A. INITIAL RESUSCITATION</b></p> <ol style="list-style-type: none"> <li>1. Sepsis and septic shock are medical emergencies, and we recommend that treatment and resuscitation begin immediately (BPS).</li> <li>2. We recommend that, in the resuscitation from sepsis-induced hypoperfusion, at least 30 mL/kg of IV crystalloid fluid be given within the first 3 hours (strong recommendation, low quality of evidence).</li> <li>3. We recommend that, following initial fluid resuscitation, additional fluids be guided by frequent reassessment of hemodynamic status (BPS).</li> </ol> <p><b>Remarks: Reassessment should include a thorough clinical examination and evaluation of available physiologic variables (heart rate, blood pressure, arterial oxygen saturation, respiratory rate, temperature, urine output, and others, as available) as well as other noninvasive or invasive monitoring, as available.</b></p> <ol style="list-style-type: none"> <li>4. We recommend further hemodynamic assessment (such as assessing cardiac function) to determine the type of shock if the clinical examination does not lead to a clear diagnosis (BPS).</li> <li>5. We suggest that dynamic over static variables be used to predict fluid responsiveness, where available (weak recommendation, low quality of evidence).</li> <li>6. We recommend an initial target mean arterial pressure of 65 mm Hg in patients with septic shock requiring vasopressors (strong recommendation, moderate quality of evidence).</li> <li>7. We suggest guiding resuscitation to normalize lactate in patients with elevated lactate levels as a marker of tissue hypoperfusion (weak recommendation, low quality of evidence).</li> </ol>
<p><b>B. SCREENING FOR SEPSIS AND PERFORMANCE IMPROVEMENT</b></p> <ol style="list-style-type: none"> <li>1. Routine screening of potentially infected seriously ill patients for severe sepsis to allow earlier implementation of therapy (grade 1C).</li> <li>2. Hospital-based performance improvement efforts in severe sepsis (UG).</li> </ol>	<p><b>B. SCREENING FOR SEPSIS AND PERFORMANCE IMPROVEMENT</b></p> <ol style="list-style-type: none"> <li>1. We recommend that hospitals and hospital systems have a performance improvement program for sepsis, including sepsis screening for acutely ill, high-risk patients (BPS).</li> </ol>
<p><b>C. DIAGNOSIS</b></p> <ol style="list-style-type: none"> <li>1. Cultures as clinically appropriate before antimicrobial therapy if no significant delay (<math>&gt; 45</math> min) in the start of antimicrobials (grade 1C). At least 2 sets of blood cultures (both aerobic and anaerobic bottles) be obtained before antimicrobial therapy with at least 1 drawn percutaneously and 1 drawn through each vascular access device, unless the device was recently (<math>&lt; 48</math> hrs) inserted (grade 1C).</li> <li>2. Use of the 1,3-B-D-glucan assay (grade 2B), mannan and anti-mannan antibody assays (2C), if available, and invasive candidiasis in differential diagnosis of cause of infection.</li> <li>3. Imaging studies performed promptly to confirm a potential source of infection (UG).</li> </ol>	<p><b>C. DIAGNOSIS</b></p> <ol style="list-style-type: none"> <li>1. We recommend that appropriate routine microbiologic cultures (including blood) be obtained before starting antimicrobial therapy in patients with suspected sepsis or septic shock if doing so results in no substantial delay in the start of antimicrobials (BPS).</li> </ol> <p>Remarks: Appropriate routine microbiologic cultures always include at least two sets of blood cultures (aerobic and anaerobic).</p>
<p><b>D. ANTIMICROBIAL THERAPY</b></p> <ol style="list-style-type: none"> <li>1. Administration of effective IV antimicrobials within the first hour of recognition of septic shock (grade 1B) and severe sepsis without septic shock (grade 1C) as the goal of therapy.</li> </ol>	<p><b>D. ANTIMICROBIAL THERAPY</b></p> <ol style="list-style-type: none"> <li>1. We recommend that administration of IV antimicrobials be initiated as soon as possible after recognition and within one hour for both sepsis and septic shock (strong recommendation, moderate quality of evidence).</li> </ol>

(Continued)

## APPENDIX 2. (Continued). Comparison of Recommendations From 2012 to 2016

2012 RECOMMENDATIONS	2016 RECOMMENDATIONS
<ol style="list-style-type: none"> <li>2. Initial empiric antiinfective therapy of one or more drugs that have activity against all likely pathogens (bacterial and/or fungal or viral) and that penetrate in adequate concentrations into tissues presumed to be the source of sepsis (grade 1B).</li> <li>3. Antimicrobial regimen should be reassessed daily for potential de-escalation (grade 1B).</li> <li>4. Use of low procalcitonin levels or similar biomarkers to assist the clinician in the discontinuation of empiric antibiotics in patients who initially appeared septic, but have no subsequent evidence of infection (grade 2C).</li> <li>5. Combination empirical therapy for neutropenic patients with severe sepsis (grade 2B) and for patients with difficult-to-treat, multidrug-resistant bacterial pathogens such as <i>Acinetobacter</i> and <i>Pseudomonas</i> species (grade 2B). For patients with severe infections associated with respiratory failure and septic shock, combination therapy with an extended-spectrum <math>\beta</math>-lactam and either an aminoglycoside or a fluoroquinolone for <i>Pseudomonas aeruginosa</i> bacteremia (grade 2B). A combination of <math>\beta</math>-lactam and macrolide for patients with septic shock from bacteremic <i>Streptococcus pneumoniae</i> infections (grade 2B).</li> <li>6. Empiric combination therapy should not be administered for more than 3 to 5 days. De-escalation to the most appropriate single therapy should be performed as soon as the susceptibility profile is known (grade 2B).</li> <li>7. Duration of therapy typically 7 to 10 days; longer courses may be appropriate in patients who have a slow clinical response, undrainable foci of infection, bacteremia with <i>Staphylococcus aureus</i>, some fungal and viral infections, or immunologic deficiencies, including neutropenia (grade 2C).</li> <li>8. Antiviral therapy initiated as early as possible in patients with severe sepsis or septic shock of viral origin (grade 2C).</li> <li>9. Antimicrobial agents should not be used in patients with severe inflammatory states determined to be of noninfectious cause (UG).</li> </ol>	<ol style="list-style-type: none"> <li>2. We recommend empiric broad-spectrum therapy with one or more antimicrobials for patients presenting with sepsis or septic shock to cover all likely pathogens (including bacterial and potentially fungal or viral coverage) (strong recommendation, moderate quality of evidence).</li> <li>3. We recommend that antimicrobial therapy is narrowed once pathogen identification and sensitivities are established and/or adequate clinical improvement is noted (BPS).</li> <li>4. We recommend against sustained systemic antimicrobial prophylaxis in patients with severe inflammatory states of noninfectious origin (e.g., severe pancreatitis, burn injury) (BPS).</li> <li>5. We recommend that dosing strategies of antimicrobials be optimized based on accepted pharmacokinetic/ pharmacodynamic principles and specific drug properties in patients with sepsis or septic shock (BPS).</li> <li>6. We suggest empiric combination therapy (using at least two antibiotics of different antimicrobial classes) aimed at the most likely bacterial pathogen(s) for the initial management of septic shock (weak recommendation, low quality of evidence). Remarks: Readers should review Table 6 for definitions of empiric, targeted/ definitive, broad-spectrum, combination, and multidrug therapy before reading this section.</li> <li>7. We suggest that combination therapy not be routinely used for ongoing treatment of most other serious infections, including bacteremia and sepsis without shock (weak recommendation, low quality of evidence). Remarks: This does not preclude the use of multidrug therapy to broaden antimicrobial activity.</li> <li>8. We recommend against combination therapy for the routine treatment of neutropenic sepsis/bacteremia (strong recommendation, moderate quality of evidence). Remarks: This does not preclude the use of multidrug therapy to broaden antimicrobial activity.</li> <li>9. If combination therapy is used for septic shock, we recommend de-escalation with discontinuation of combination therapy within the first few days in response to clinical improvement and/or evidence of infection resolution. This applies to both targeted (for culture-positive infections) and empiric (for culture-negative infections) combination therapy (BPS).</li> <li>10. We suggest that an antimicrobial treatment duration of 7 to 10 days is adequate for most serious infections associated with sepsis and septic shock (weak recommendation, low quality of evidence).</li> <li>11. We suggest that longer courses are appropriate in patients who have a slow clinical response, undrainable foci of infection, bacteremia with <i>Staphylococcus aureus</i>, some fungal and viral infections, or immunologic deficiencies, including neutropenia (Weak recommendation, low quality of evidence).</li> <li>12. We suggest that shorter courses are appropriate in some patients, particularly those with rapid clinical resolution following effective source control of intra-abdominal or urinary sepsis and those with anatomically uncomplicated pyelonephritis (weak recommendation, low quality of evidence).</li> <li>13. We recommend daily assessment for de-escalation of antimicrobial therapy in patients with sepsis and septic shock (BPS).</li> <li>14. We suggest that measurement of procalcitonin levels can be used to support shortening the duration of antimicrobial therapy in sepsis patients (weak recommendation, low quality of evidence).</li> <li>15. We suggest that procalcitonin levels can be used to support the discontinuation of empiric antibiotics in patients who initially appeared to have sepsis, but subsequently have limited clinical evidence of infection (weak recommendation, low quality of evidence).</li> </ol>

(Continued)

**APPENDIX 2. (Continued). Comparison of Recommendations From 2012 to 2016**

2012 RECOMMENDATIONS	2016 RECOMMENDATIONS
<p><b>E. SOURCE CONTROL</b></p> <ol style="list-style-type: none"> <li>1. A specific anatomic diagnosis of infection requiring consideration for emergent source control be sought and diagnosed or excluded as rapidly as possible, and intervention be undertaken for source control within the first 12 hours after the diagnosis is made, if feasible (grade 1C).</li> <li>2. When infected peripancreatic necrosis is identified as a potential source of infection, definitive intervention is best delayed until adequate demarcation of viable and nonviable tissues has occurred (grade 2B).</li> <li>3. When source control in a severely septic patient is required, the effective intervention associated with the least physiologic insult should be used (e.g., percutaneous rather than surgical drainage of an abscess) (UG).</li> <li>4. If intravascular access devices are a possible source of severe sepsis or septic shock, they should be removed promptly after other vascular access has been established (UG).</li> </ol>	<p><b>E. SOURCE CONTROL</b></p> <ol style="list-style-type: none"> <li>1. We recommend that a specific anatomic diagnosis of infection requiring emergent source control should be identified or excluded as rapidly as possible in patients with sepsis or septic shock, and that any required source control intervention should be implemented as soon as medically and logistically practical after the diagnosis is made (BPS).</li> <li>2. We recommend prompt removal of intravascular access devices that are a possible source of sepsis or septic shock after other vascular access has been established (BPS).</li> </ol>
<p><b>F. FLUID THERAPY</b></p> <ol style="list-style-type: none"> <li>1. Crystalloids as the initial fluid of choice in the resuscitation of severe sepsis and septic shock (grade 1B).</li> <li>2. Against the use of hydroxyethyl starches for fluid resuscitation of severe sepsis and septic shock (grade 1B).</li> <li>3. Albumin in the fluid resuscitation of severe sepsis and septic shock when patients require substantial amounts of crystalloids (grade 2C).</li> <li>4. Initial fluid challenge in patients with sepsis-induced tissue hypoperfusion with suspicion of hypovolemia to achieve a minimum of 30 mL/kg of crystalloids (a portion of this may be albumin equivalent). More rapid administration and greater amounts of fluid may be needed in some patients (grade 1C).</li> <li>5. Fluid challenge technique be applied wherein fluid administration is continued as long as there is hemodynamic improvement either based on dynamic (e.g., change in pulse pressure, stroke volume variation) or static (e.g., arterial pressure, heart rate) variables (UG).</li> </ol>	<p><b>F. FLUID THERAPY</b></p> <ol style="list-style-type: none"> <li>1. We recommend that a fluid challenge technique be applied where fluid administration is continued as long as hemodynamic factors continue to improve (BPS).</li> <li>2. We recommend crystalloids as the fluid of choice for initial resuscitation and subsequent intravascular volume replacement in patients with sepsis and septic shock (strong recommendation, moderate quality of evidence).</li> <li>3. We suggest using either balanced crystalloids or saline for fluid resuscitation of patients with sepsis or septic shock (weak recommendation, low quality of evidence).</li> <li>4. We suggest using albumin in addition to crystalloids for initial resuscitation and subsequent intravascular volume replacement in patients with sepsis and septic shock, when patients require substantial amounts of crystalloids (weak recommendation, low quality of evidence).</li> <li>5. We recommend against using hydroxyethyl starches for intravascular volume replacement in patients with sepsis or septic shock (strong recommendation, high quality of evidence).</li> <li>6. We suggest using crystalloids over gelatins when resuscitating patients with sepsis or septic shock (weak recommendation, low quality of evidence).</li> </ol>
<p><b>G. VASOACTIVE MEDICATIONS</b></p> <ol style="list-style-type: none"> <li>1. Vasopressor therapy initially to target a mean arterial pressure (MAP) of 65 mm Hg (grade 1C).</li> <li>2. Norepinephrine as the first-choice vasopressor (grade 1B).</li> <li>3. Epinephrine (added to and potentially substituted for norepinephrine) when an additional agent is needed to maintain adequate blood pressure (grade 2B).</li> <li>4. Vasopressin, 0.03 units/minute, can be added to norepinephrine with intent of either raising MAP or decreasing norepinephrine dosage (UG).</li> <li>5. Low-dose vasopressin is not recommended as the single initial vasopressor for treatment of sepsis-induced hypotension, and vasopressin doses higher than 0.03–0.04 units/minute should be reserved for salvage therapy (failure to achieve adequate MAP with other vasopressor agents) (UG).</li> </ol>	<p><b>G. VASOACTIVE MEDICATIONS</b></p> <ol style="list-style-type: none"> <li>1. We recommend norepinephrine as the first-choice vasopressor (strong recommendation, moderate quality of evidence).</li> <li>2. We suggest adding either vasopressin (up to 0.03 U/min) (weak recommendation, moderate quality of evidence) or epinephrine (weak recommendation, low quality of evidence) to norepinephrine with the intent of raising mean arterial pressure to target, or adding vasopressin (up to 0.03 U/min) (weak recommendation, moderate quality of evidence) to decrease norepinephrine dosage.</li> <li>3. We suggest using dopamine as an alternative vasopressor agent to norepinephrine only in highly selected patients (e.g., patients with low risk of tachyarrhythmias and absolute or relative bradycardia) (weak recommendation, low quality of evidence).</li> </ol>

(Continued)

**APPENDIX 2. (Continued). Comparison of Recommendations From 2012 to 2016**

2012 RECOMMENDATIONS	2016 RECOMMENDATIONS
<ol style="list-style-type: none"> <li>6. Dopamine as an alternative vasopressor agent to norepinephrine only in highly selected patients (e.g., patients with low risk of tachyarrhythmias and absolute or relative bradycardia) (grade 2C).</li> <li>7. Phenylephrine is not recommended in the treatment of septic shock except in circumstances where (a) norepinephrine is associated with serious arrhythmias, (b) cardiac output is known to be high and blood pressure persistently low, or (c) as salvage therapy when combined inotrope/vasopressor drugs and low-dose vasopressin have failed to achieve MAP target (grade 1C).</li> <li>8. Low-dose dopamine should not be used for renal protection (grade 1A).</li> <li>9. All patients requiring vasopressors have an arterial catheter placed as soon as practical if resources are available (UG).</li> <li>10. A trial of dobutamine infusion up to 20 µg/kg/min be administered or added to vasopressor (if in use) in the presence of (a) myocardial dysfunction as suggested by elevated cardiac filling pressures and low cardiac output or (b) ongoing signs of hypoperfusion, despite achieving adequate intravascular volume and adequate MAP (grade 1C).</li> <li>11. Not using a strategy to increase cardiac index to predetermined supranormal levels (grade 1B).</li> </ol>	<ol style="list-style-type: none"> <li>4. We recommend against using low-dose dopamine for renal protection (strong recommendation, high quality of evidence).</li> <li>5. We suggest using dobutamine in patients who show evidence of persistent hypoperfusion despite adequate fluid loading and the use of vasopressor agents (weak recommendation, low quality of evidence).</li> </ol> <p>Remarks: If initiated, dosing should be titrated to an end point reflecting perfusion, and the agent reduced or discontinued in the face of worsening hypotension or arrhythmias.</p> <ol style="list-style-type: none"> <li>6. We suggest that all patients requiring vasopressors have an arterial catheter placed as soon as practical if resources are available (weak recommendation, very low quality of evidence).</li> </ol>

**H. CORTICOSTEROIDS**

1. Not using IV hydrocortisone to treat adult septic shock patients if adequate fluid resuscitation and vasopressor therapy are able to restore hemodynamic stability (see goals for Initial Resuscitation). In case this is not achievable, we suggest IV hydrocortisone alone at a dose of 200 mg/day (grade 2C).
2. Not using the adrenocorticotropic hormone stimulation test to identify adults with septic shock who should receive hydrocortisone (grade 2B).
3. In treated patients, hydrocortisone tapered when vasopressors are no longer required (grade 2D).
4. Corticosteroids not be administered for the treatment of sepsis in the absence of shock (grade 1D).
5. When hydrocortisone is given, use continuous flow (grade 2D).

**H. CORTICOSTEROIDS**

1. We suggest against using IV hydrocortisone to treat septic shock patients if adequate fluid resuscitation and vasopressor therapy are able to restore hemodynamic stability. If this is not achievable, we suggest IV hydrocortisone at a dose of 200 mg per day (weak recommendation, low quality of evidence).

**I. BLOOD PRODUCTS**

1. Once tissue hypoperfusion has resolved and in the absence of extenuating circumstances, such as myocardial ischemia, severe hypoxemia, acute hemorrhage, or ischemic heart disease, we recommend that RBC transfusion occur only when hemoglobin concentration decreases to < 7.0 g/dL to target a hemoglobin concentration of 7.0–9.0 g/dL in adults (grade 1B).
2. Not using erythropoietin as a specific treatment of anemia associated with severe sepsis (grade 1B).
3. Fresh frozen plasma not be used to correct laboratory clotting abnormalities in the absence of bleeding or planned invasive procedures (grade 2D).
4. Not using antithrombin for the treatment of severe sepsis and septic shock (grade 1B).
5. In patients with severe sepsis, administer platelets prophylactically when counts are < 10,000/mm<sup>3</sup> (10 × 10<sup>9</sup>/L) in the absence of apparent bleeding. We suggest prophylactic platelet transfusion when counts are < 20,000/mm<sup>3</sup> (20 × 10<sup>9</sup>/L) if the patient has a significant risk of bleeding. Higher platelet counts (≥ 50,000/mm<sup>3</sup> [50 × 10<sup>9</sup>/L]) are advised for active bleeding, surgery, or invasive procedures (grade 2D).

**I. BLOOD PRODUCTS**

1. We recommend that RBC transfusion occur only when hemoglobin concentration decreases to < 7.0 g/dL in adults in the absence of extenuating circumstances, such as myocardial ischemia, severe hypoxemia, or acute hemorrhage (strong recommendation, high quality of evidence).
2. We recommend against the use of erythropoietin for treatment of anemia associated with sepsis (strong recommendation, moderate quality of evidence).
3. We suggest against the use of fresh frozen plasma to correct clotting abnormalities in the absence of bleeding or planned invasive procedures (weak recommendation, very low quality of evidence).
4. We suggest prophylactic platelet transfusion when counts are < 10,000/mm<sup>3</sup> (10 × 10<sup>9</sup>/L) in the absence of apparent bleeding and when counts are < 20,000/mm<sup>3</sup> (20 × 10<sup>9</sup>/L) if the patient has a significant risk of bleeding. Higher platelet counts (≥ 50,000/mm<sup>3</sup> [50 × 10<sup>9</sup>/L]) are advised for active bleeding, surgery, or invasive procedures (weak recommendation, very low quality of evidence).

(Continued)

**APPENDIX 2. (Continued). Comparison of Recommendations From 2012 to 2016**

2012 RECOMMENDATIONS	2016 RECOMMENDATIONS
<p><b>J. IMMUNOGLOBULINS</b></p> <p>1. Not using IV immunoglobulins in adult patients with severe sepsis or septic shock (grade 2B).</p>	<p><b>J. IMMUNOGLOBULINS</b></p> <p>1. We suggest against the use of IV immunoglobulins in patients with sepsis or septic shock (weak recommendation, low quality of evidence).</p>
<p><b>K. BLOOD PURIFICATION</b></p> <p>Not applicable.</p>	<p><b>K. BLOOD PURIFICATION</b></p> <p>1. We make no recommendation regarding the use of blood purification techniques.</p>
<p><b>L. ANTICOAGULANTS</b></p> <p>Not applicable.</p>	<p><b>L. ANTICOAGULANTS</b></p> <p>1. We recommend against the use of antithrombin for the treatment of sepsis and septic shock (strong recommendation, moderate quality of evidence).</p> <p>2. We make no recommendation regarding the use of thrombomodulin or heparin for the treatment of sepsis or septic shock.</p>
<p><b>M. MECHANICAL VENTILATION</b></p> <p>1. Target a tidal volume of 6 mL/kg predicted body weight in patients with sepsis-induced acute respiratory distress syndrome (ARDS) (grade 1A vs. 12 mL/kg).</p> <p>2. Plateau pressures be measured in patients with ARDS and initial upper-limit goal for plateau pressures in a passively inflated lung be <math>\leq 30</math> cm H<sub>2</sub>O (grade 1B).</p> <p>3. Positive end-expiratory pressure (PEEP) be applied to avoid alveolar collapse at end-expiration (atelectotrauma) (grade 1B).</p> <p>4. Strategies based on higher rather than lower levels of PEEP be used for patients with sepsis-induced moderate or severe ARDS (grade 2C).</p> <p>5. Recruitment maneuvers be used in sepsis patients with severe refractory hypoxemia (grade 2C).</p> <p>6. Prone positioning be used in sepsis-induced ARDS patients with a Pao<sub>2</sub>/Fio<sub>2</sub> ratio <math>\leq 100</math> mm Hg in facilities that have experience with such practices (grade 2B).</p> <p>7. Mechanically ventilated sepsis patients be maintained with the head of the bed elevated to 30–45 degrees to limit aspiration risk and to prevent the development of ventilator-associated pneumonia (grade 1B).</p> <p>8. Noninvasive mask ventilation (NIV) be used in that minority of sepsis-induced ARDS patients in whom the benefits of NIV have been carefully considered and are thought to outweigh the risks (grade 2B).</p> <p>9. A weaning protocol be in place, and that mechanically ventilated patients with severe sepsis undergo spontaneous breathing trials regularly to evaluate their ability to discontinue mechanical ventilation when they satisfy the following criteria: a) arousable, b) hemodynamically stable (without vasopressor agents), c) no new potentially serious conditions, d) low ventilatory and end-expiratory pressure requirements, and e) low Fio<sub>2</sub> requirements that can be met safely delivered with a face mask or nasal cannula. If the spontaneous breathing trial is successful, consideration should be given for extubation (grade 1A).</p> <p>10. Against the routine use of the pulmonary artery catheter for patients with sepsis-induced ARDS (grade 1A).</p> <p>11. A conservative rather than liberal fluid strategy for patients with established sepsis-induced ARDS who do not have evidence of tissue hypoperfusion (grade 1C).</p> <p>12. In the absence of specific indications such as bronchospasm, not using <math>\beta</math>-2 agonists for treatment of sepsis-induced ARDS (grade 1B).</p>	<p><b>M. MECHANICAL VENTILATION</b></p> <p>1. We recommend using a target tidal volume of 6 mL/kg predicted body weight compared with 12 mL/kg in adult patients with sepsis-induced acute respiratory distress syndrome (ARDS) (strong recommendation, high quality of evidence).</p> <p>2. We recommend using an upper limit goal for plateau pressures of 30 cm H<sub>2</sub>O over higher plateau pressures in adult patients with sepsis-induced severe ARDS (strong recommendation, moderate quality of evidence).</p> <p>3. We suggest using higher positive end-expiratory pressure (PEEP) over lower PEEP in adult patients with sepsis-induced moderate to severe ARDS (weak recommendation, moderate quality of evidence).</p> <p>4. We suggest using recruitment maneuvers in adult patients with sepsis-induced severe ARDS (weak recommendation, moderate quality of evidence).</p> <p>5. We recommend using prone over supine position in adult patients with sepsis-induced ARDS and a Pao<sub>2</sub>/Fio<sub>2</sub> ratio <math>&lt; 150</math> (strong recommendation, moderate quality of evidence).</p> <p>6. We recommend against using high-frequency oscillatory ventilation in adult patients with sepsis-induced ARDS (strong recommendation, moderate quality of evidence).</p> <p>7. We make no recommendation regarding the use of noninvasive ventilation for patients with sepsis-induced ARDS.</p> <p>8. We suggest using neuromuscular blocking agents for <math>\leq 48</math> hours in adult patients with sepsis-induced ARDS and a Pao<sub>2</sub>/Fio<sub>2</sub> ratio <math>&lt; 150</math> mm Hg (weak recommendation, moderate quality of evidence).</p> <p>9. We recommend a conservative fluid strategy for patients with established sepsis-induced ARDS who do not have evidence of tissue hypoperfusion (strong recommendation, moderate quality of evidence).</p> <p>10. We recommend against the use of <math>\beta</math>-2 agonists for the treatment of patients with sepsis-induced ARDS without bronchospasm (strong recommendation, moderate quality of evidence).</p> <p>11. We recommend against the routine use of the pulmonary artery catheter for patients with sepsis-induced ARDS (strong recommendation, high quality of evidence).</p> <p>12. We suggest using lower tidal volumes over higher tidal volumes in adult patients with sepsis-induced respiratory failure without ARDS (weak recommendation, low quality of evidence).</p>

(Continued)



**APPENDIX 2. (Continued). Comparison of Recommendations From 2012 to 2016**

2012 RECOMMENDATIONS	2016 RECOMMENDATIONS
	<ol style="list-style-type: none"> <li>13. We recommend that mechanically ventilated sepsis patients be maintained with the head of the bed elevated between 30 and 45 degrees to limit aspiration risk and to prevent the development of ventilator-associated pneumonia (strong recommendation, low quality of evidence).</li> <li>14. We recommend using spontaneous breathing trials in mechanically ventilated patients with sepsis who are ready for weaning (strong recommendation, high quality of evidence).</li> <li>15. We recommend using a weaning protocol in mechanically ventilated patients with sepsis-induced respiratory failure who can tolerate weaning (strong recommendation, moderate quality of evidence).</li> </ol>
<p><b>N. SEDATION AND ANALGESIA</b></p> <ol style="list-style-type: none"> <li>1. Continuous or intermittent sedation be minimized in mechanically ventilated sepsis patients, targeting specific titration end points (grade 1B).</li> <li>2. Neuromuscular blocking agents (NMBAs) be avoided if possible in septic patients without ARDS due to the risk of prolonged neuromuscular blockade following discontinuation. If NMBAs must be maintained, either intermittent bolus as required or continuous infusion with train-of-four monitoring of the depth of blockade should be used (grade 1C).</li> <li>3. A short course of NMBA of not greater than 48 hours for patients with early sepsis-induced ARDS and a <math>P_{aO_2}/F_{iO_2}</math> ratio &lt; 150 mm Hg (grade 2C).</li> </ol>	<p><b>N. SEDATION AND ANALGESIA</b></p> <ol style="list-style-type: none"> <li>1. We recommend that continuous or intermittent sedation be minimized in mechanically ventilated sepsis patients, targeting specific titration endpoints (BPS).</li> </ol>
<p><b>O. GLUCOSE CONTROL</b></p> <ol style="list-style-type: none"> <li>1. A protocolized approach to blood glucose management in ICU patients with severe sepsis commencing insulin dosing when consecutive blood glucose levels are &gt; 180 mg/dL. This protocolized approach should target an upper blood glucose level ≤ 180 mg/dL rather than an upper target blood glucose level ≤ 110 mg/dL (grade 1A).</li> <li>2. Blood glucose values be monitored every 1 to 2 hours until glucose values and insulin infusion rates are stable and then every 4 hours thereafter (grade 1C).</li> <li>3. Glucose levels obtained with point-of-care testing of capillary blood be interpreted with caution because such measurements may not accurately estimate arterial blood or plasma glucose values (UG).</li> </ol>	<p><b>O. GLUCOSE CONTROL</b></p> <ol style="list-style-type: none"> <li>1. We recommend a protocolized approach to blood glucose management in ICU patients with sepsis, commencing insulin dosing when two consecutive blood glucose levels are &gt; 180 mg/dL. This approach should target an upper blood glucose level ≤ 180 mg/dL rather than an upper target blood glucose level ≤ 110 mg/dL (strong recommendation, high quality of evidence).</li> <li>2. We recommend that blood glucose values be monitored every 1 to 2 hours until glucose values and insulin infusion rates are stable, then every 4 hours thereafter in patients receiving insulin infusions (BPS).</li> <li>3. We recommend that glucose levels obtained with point-of-care testing of capillary blood be interpreted with caution because such measurements may not accurately estimate arterial blood or plasma glucose values (BPS).</li> <li>4. We suggest the use of arterial blood rather than capillary blood for point-of-care testing using glucose meters if patients have arterial catheters (weak recommendation, low quality of evidence).</li> </ol>
<p><b>P. RENAL REPLACEMENT THERAPY</b></p> <ol style="list-style-type: none"> <li>1. Continuous renal replacement therapies and intermittent hemodialysis are equivalent in patients with severe sepsis and acute renal failure (grade 2B).</li> <li>2. Use continuous therapies to facilitate management of fluid balance in hemodynamically unstable septic patients (grade 2D).</li> </ol>	<p><b>P. RENAL REPLACEMENT THERAPY</b></p> <ol style="list-style-type: none"> <li>1. We suggest that either continuous or intermittent renal replacement therapy (RRT) be used in patients with sepsis and acute kidney injury (weak recommendation, moderate quality of evidence).</li> <li>2. We suggest using continuous therapies to facilitate management of fluid balance in hemodynamically unstable septic patients (weak recommendation, very low quality of evidence).</li> <li>3. We suggest against the use of RRT in patients with sepsis and acute kidney injury for increase in creatinine or oliguria without other definitive indications for dialysis (weak recommendation, low quality of evidence).</li> </ol>

(Continued)

**APPENDIX 2. (Continued). Comparison of Recommendations From 2012 to 2016**

2012 RECOMMENDATIONS	2016 RECOMMENDATIONS
<p><b>Q. BICARBONATE THERAPY</b></p> <ol style="list-style-type: none"> <li>1. Not using sodium bicarbonate therapy for the purpose of improving hemodynamics or reducing vasopressor requirements in patients with hypoperfusion-induced lactic acidemia with pH <math>\geq</math> 7.15 (grade 2B).</li> </ol>	<p><b>Q. BICARBONATE THERAPY</b></p> <ol style="list-style-type: none"> <li>1. We suggest against the use of sodium bicarbonate therapy to improve hemodynamics or to reduce vasopressor requirements in patients with hypoperfusion-induced lactic acidemia with pH <math>\geq</math> 7.15 (weak recommendation, moderate quality of evidence).</li> </ol>
<p><b>R. VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS</b></p> <ol style="list-style-type: none"> <li>1. Patients with severe sepsis receive daily pharmacoprophylaxis against venous thromboembolism (VTE) (grade 1B). This should be accomplished with daily subcutaneous low-molecular-weight heparin (LMWH) (grade 1B versus twice daily unfractionated heparin [UFH], grade 2C versus three times daily UFH). If creatinine clearance is <math>&lt;</math> 30 mL/min, use dalteparin (grade 1A) or another form of LMWH that has a low degree of renal metabolism (grade 2C) or UFH (grade 1A).</li> <li>2. Patients with severe sepsis be treated with a combination of pharmacologic therapy and intermittent pneumatic compression devices whenever possible (grade 2C).</li> <li>3. Septic patients who have a contraindication for heparin use (e.g., thrombocytopenia, severe coagulopathy, active bleeding, recent intracerebral hemorrhage) not receive pharmacoprophylaxis (grade 1B), but receive mechanical prophylactic treatment, such as graduated compression stockings or intermittent compression devices (grade 2C), unless contraindicated. When the risk decreases, start pharmacoprophylaxis (grade 2C).</li> </ol>	<p><b>R. VENOUS THROMBOEMBOLISM PROPHYLAXIS</b></p> <ol style="list-style-type: none"> <li>1. We recommend pharmacologic prophylaxis (unfractionated heparin [UFH] or low-molecular-weight heparin [LMWH]) against venous thromboembolism (VTE) in the absence of contraindications to the use of these agents (strong recommendation, moderate quality of evidence).</li> <li>2. We recommend LMWH rather than UFH for VTE prophylaxis in the absence of contraindications to the use of LMWH (strong recommendation, moderate quality of evidence).</li> <li>3. We suggest combination pharmacologic VTE prophylaxis and mechanical prophylaxis, whenever possible (weak recommendation, low quality of evidence).</li> <li>4. We suggest mechanical VTE prophylaxis when pharmacologic VTE is contraindicated (weak recommendation, low quality of evidence).</li> </ol>
<p><b>S. STRESS ULCER PROPHYLAXIS</b></p> <ol style="list-style-type: none"> <li>1. Stress ulcer prophylaxis using histamine-2 blocker or proton pump inhibitor be given to patients with severe sepsis or septic shock who have bleeding risk factors (grade 1B).</li> <li>2. When stress ulcer prophylaxis is used, proton pump inhibitors rather than histamine-2 receptor antagonists (grade 2D).</li> <li>3. Patients without risk factors do not receive prophylaxis (grade 2B).</li> </ol>	<p><b>S. STRESS ULCER PROPHYLAXIS</b></p> <ol style="list-style-type: none"> <li>1. We recommend that stress ulcer prophylaxis be given to patients with sepsis or septic shock who have risk factors for gastrointestinal (GI) bleeding (strong recommendation, low quality of evidence).</li> <li>2. We suggest using either proton pump inhibitors or histamine-2 receptor antagonists when stress ulcer prophylaxis is indicated (weak recommendation, low quality of evidence).</li> <li>3. We recommend against stress ulcer prophylaxis in patients without risk factors for GI bleeding (BPS).</li> </ol>
<p><b>T. NUTRITION</b></p> <ol style="list-style-type: none"> <li>1. Administer oral or enteral (if necessary) feedings, as tolerated, rather than either complete fasting or provision of only IV glucose within the first 48 hours after a diagnosis of severe sepsis or septic shock (grade 2C).</li> <li>2. Avoid mandatory full caloric feeding in the first week but rather suggest low-dose feeding (e.g., up to 500 calories per day), advancing only as tolerated (grade 2B).</li> <li>3. Use IV glucose and enteral nutrition rather than total parenteral nutrition alone or parenteral nutrition in conjunction with enteral feeding in the first 7 days after a diagnosis of severe sepsis or septic shock (grade 2B).</li> <li>4. Use nutrition with no specific immunomodulating supplementation rather than nutrition providing specific immunomodulating supplementation in patients with severe sepsis (grade 2C).</li> <li>5. Not using IV selenium for the treatment of severe sepsis (grade 2C).</li> </ol>	<p><b>T. NUTRITION</b></p> <ol style="list-style-type: none"> <li>1. We recommend against the administration of early parenteral nutrition alone or parenteral nutrition in combination with enteral feedings (but rather initiate early enteral nutrition) in critically ill patients with sepsis or septic shock who can be fed enterally (strong recommendation, moderate quality of evidence).</li> <li>2. We recommend against the administration of parenteral nutrition alone or in combination with enteral feeds (but rather to initiate IV glucose and advance enteral feeds as tolerated) over the first 7 days in critically ill patients with sepsis or septic shock for whom early enteral feeding is not feasible (strong recommendation, moderate quality of evidence).</li> <li>3. We suggest the early initiation of enteral feeding rather than a complete fast or only IV glucose in critically ill patients with sepsis or septic shock who can be fed enterally (weak recommendation, low quality of evidence).</li> <li>4. We suggest either early trophic/hypocaloric or early full enteral feeding in critically ill patients with sepsis or septic shock; if trophic/hypocaloric feeding is the initial strategy, then feeds should be advanced according to patient tolerance (weak recommendation, moderate quality of evidence).</li> </ol>

(Continued)

**APPENDIX 2. (Continued). Comparison of Recommendations From 2012 to 2016**

2012 RECOMMENDATIONS	2016 RECOMMENDATIONS
	<p>5. We recommend against the use of omega-3 fatty acids as an immune supplement in critically ill patients with sepsis or septic shock (strong recommendation, low quality of evidence).</p> <p>6. We suggest against routinely monitoring gastric residual volumes in critically ill patients with sepsis or septic shock (weak recommendation, low quality of evidence). However, we suggest measurement of gastric residuals in patients with feeding intolerance or who are considered to be at high risk of aspiration (weak recommendation, very low quality of evidence).</p> <p>Remarks: This recommendation refers to nonsurgical critically ill patients with sepsis or septic shock.</p> <p>7. We suggest the use of prokinetic agents in critically ill patients with sepsis or septic shock and feeding intolerance (weak recommendation, low quality of evidence).</p> <p>8. We suggest placement of post-pyloric feeding tubes in critically ill patients with sepsis or septic shock with feeding intolerance or who are considered to be at high risk of aspiration (weak recommendation, low quality of evidence).</p> <p>9. We recommend against the use of IV selenium to treat sepsis and septic shock (strong recommendation, moderate quality of evidence).</p> <p>10. We suggest against the use of arginine to treat sepsis and septic shock (weak recommendation, low quality of evidence).</p> <p>11. We recommend against the use of glutamine to treat sepsis and septic shock (strong recommendation, moderate quality of evidence).</p> <p>12. We make no recommendation about the use of carnitine for sepsis and septic shock.</p>
<p><b>U. SETTING GOALS OF CARE</b></p> <p>1. Discuss goals of care and prognosis with patients and families (grade 1B).</p> <p>2. Incorporate goals of care into treatment and end-of-life care planning, utilizing palliative care principles where appropriate (grade 1B).</p> <p>3. Address goals of care as early as feasible, but no later than within 72 hours of ICU admission (grade 2C).</p>	<p><b>U. SETTING GOALS OF CARE</b></p> <p>1. We recommend that goals of care and prognosis be discussed with patients and families (BPS).</p> <p>2. We recommend that goals of care be incorporated into treatment and end-of-life care planning, utilizing palliative care principles where appropriate (strong recommendation, moderate quality of evidence).</p> <p>3. We suggest that goals of care be addressed as early as feasible, but no later than within 72 hours of ICU admission (weak recommendation, low quality of evidence).</p>